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Abstract 
There is a significant need for research and development into paediatric medicines. The 
absence of suitable medicines or critical safety and efficacy information, poses significant 
risks to a particularly vulnerable patient population. The paediatric population is made up 
of a wide range of individuals of substantially varied physical size, weight and stage of 
physiological development. Some commonly used excipients may be unsuitable for use in 
children; and some dosage forms may be undesirable to the paediatric population. There is 
a need for a dosage form platform that is designed to meet the needs of the paediatric 
patient. The dosage form should offer dose flexibility, dose accuracy, afford acceptable 
taste of undesirable tasting drug substances and be suitable for administration to all 
paediatric sub groups. To ensure affordability and thus enhance access to medicines for 
children in developing countries or emerging markets, the dosage form should be simple to 
manufacture without the need for specialised equipment.  
Spray-drying was investigated to co-process a functional polymer, hypromellose, with a 
model drug substance, paracetamol, to enhance the functionality of the polymer and to 
taste mask the paracetamol. Though hypromellose was successfully spray-dried it was not 
possible to spray-dry hypromellose with paracetamol. The viscosity of aqueous solutions of 
hypromellose played a key role in determining the grade and concentration of 
hypromellose that could be successfully spray-dried. Temperature was used to reduce 
viscosity of hypromellose solutions but careful temperature control is required to avoid 
reaching the gelation temperature of the hypromellose. 
The effect of temperature on aqueous hydroxyl propylcellulose (HPC) solutions showed 
that heating causes a reduction in solubility of HPC in water which results in its 
precipitation and the formation of liquid crystals. Consequently, the aqueous HPC solutions 
appear ‘cloudy’ and their viscosity decreases. The temperature at which these changes 
occur is referred to as the ‘cloud-point’. The effect of temperature on aqueous HPC 
solutions containing drug is dependent on the properties of the drug. Paracetamol 
decreased the temperatures of dehydration and onset of precipitation and ranitidine 
hydrochloride increased the temperatures of dehydration and precipitation. This is 
probably associated with a salting in effect.  
HPC was used to form films which disintegrate in <30 seconds but are able to retard 
dissolution rate of paracetamol. HPC may be used to form films which meet the 
pharmacopoeial content uniformity criteria typically applied to oral dosage forms. HPC 
films have application for administering drugs to paediatric or geriatric patients by 
disintegrating in the mouth and so overcoming swallowing difficulties; potentially providing 
taste masking and aiding absorption across the oral cavity.  
HPC films offer significant benefits to the paediatric population. The manufacturing process 
is simple and transportation is easy as secondary packs are likely to be less bulky than 
currently used for tablets. The films may also be suitable for administering combinations of 
drugs in the same dosage form by layering or by combining the drugs at the HPC solution 
stage. For these reasons the HPC films may have particular application for diseases in the 
developing world and meet many requirements associated with WHO and other global 
regulatory guidelines.
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but also believe.” 
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1  INTRODUCTION  
1.1  General Introduction 
One in five children (3 million) within the United Kingdom has a long standing illness 
or disability (Martin 2004).  Many, if not most, of these disadvantaged children will 
use medication on a long term basis that is either unlicensed for paediatric use or 
has not been scientifically studied within this patient population.  Around 90 % of 
babies in neonatal intensive care, 70 % of patients in paediatric intensive care, and 
almost 70 % of children in hospital in Europe receive at least one unlicensed or off-
label medicine during a hospital stay (Conroy 2003). 
The majority of marketed drugs are either not labelled, or inadequately labelled, for 
intended use in paediatric patients. Approximately, 80 % of listed product 
information labels (PILs) in the US either disclaimed usage or lacked specific dosing 
information for paediatric use.  Less than 30 % of drugs approved by the Food and 
Drugs Administration (FDA) were authorised for paediatric use. Additionally, only 38 
% of new medicinal products, which were potentially of benefit in paediatric 
therapy, were initially labelled for paediatric use (Goldkind 2004). 
A lack of vital, supporting information often prompts conservatism from 
paediatricians who often choose to prescribe existing, established medications 
(Standing and Tuleu 2005). Though these products may have well established safety 
profiles, their efficacy may be marginal, and be potentially less effective than the 
newer drugs, which lack relevant safety data. 
Children are not young adults and due to many physiological, regulatory, ethical and 
practical reasons, effective adult doses of newly approved medicinal products 
cannot necessarily be reduced based on a simplistic, relative mg/kg body weight 
basis alone (Cella et al 2010) 
In an attempt to encourage pharmaceutical companies to invest in the research and 
development of paediatric medicines, regulatory agencies such as the European 
Medicines Agency (EMA) and the Food and Drug Administration (FDA) in the US, 
2 
published regulations forcing companies to consider the development of medicines 
for children (EMA 2006 and FDA 2003). 
Paediatric formulations must provide dose flexibility, accurate dosing, have 
acceptable taste and be designed to enhance patient compliance. Further 
investigation into the development of ‘Paediatric Friendly’ formulations is required. 
  
3 
1.2  Challenges Associated with Developing Paediatric 
Medicines 
There are many aspects to be considered when developing paediatric medicines. 
Due to the complexity of this patient population, it is critical that the patient is 
considered at the outset of the development of the dosage form.  
1.2.1 Physiological and pharmacological challenges 
Children are not just small adults; either from a biological or pharmacological 
development perspective (Bowles et al 2010). However, it is often overlooked that 
the paediatric patient population is not a homogenous sub-group either, and can be 
sub-classified, based on very real physiological (size, and developmental biology) 
and pharmacological differences (RCPCH 1999) as follows: 
 Pre-term new-born infants i.e. born before gestation date 
 Full term new-born infants (0-27 days where day ‘0’ is day of birth) 
 Infants and toddlers (28 days to 23 months) 
 Children (2 to 11 years) 
 Adolescents (12-16/18 years, but dependent on region) 
1.2.1.1 Pre-term new-born infants 
It is not possible (except in rare cases e.g. vaccines, antidotes, Baker 2007) to 
extrapolate the efficacy of medicinal products from studies in adults to predict 
efficacy in paediatrics.  However, even studies in older paediatric patients can be 
difficult to meaningfully extrapolate to preterm new-born infants (ICH 2000). 
Clinical study design considerations that need to be evaluated include:  
(1) difficulties in assessing study outcomes 
(2) small patient numbers at each centre and very real centre differences 
(based on care, experience and infrastructure) 
4 
(3) small pharmacokinetic sampling (the total blood volume of a 0.5 kg 
preterm infant is 40ml) necessitating enhanced sampling and preparation 
techniques and more sensitive analytical methodologies 
(4) weight and age (gestational and postnatal)   
More worryingly, this sub-category of the paediatric population is also not 
homogenous, as there are huge developmental differences between a 25-week 
gestation new-born (0.5 kg) from the much heavier 30-week gestation newborn (1.5 
kg) (Kearns et al 2003 and Rakhmanina and van den Anker 2006). Important 
developmental, biological and pharmacological features that need to be considered 
when administering medicines to preterm paediatric patients include:  
(1) rapid changes of pharmacology and physiology necessitating unique 
dosing regimens  
(2) the immaturity of the renal and hepatic clearance mechanisms, and of 
the blood-brain barrier (this has the potential for all administered drugs to 
penetrate into the central nervous system (CNS), not just those that are 
reported to have high CNS permeability in adults) 
(3) protein binding and displacement issues (in particular, bilirubin) 
(4) opportunities (often inadvertent) for transdermal absorption of drugs 
(5) unique neonatal susceptibilities, e.g. retinopathy and unique neonatal 
disease states, e.g. respiratory distress syndrome.  
1.2.1.2 Full-term new-born infants 
Although more mature, ’full term newborn infants’ is a similar sub-class to preterm 
newborn infants in terms of relative maturity to an adult.  Drugs that demonstrate 
high protein binding in adults are often more freely available in neonates due to the 
competitive binding seen between albumin and bilirubin (elevated in neonates). 
The displacement of bilirubin can cause CNS toxicity as the blood-brain barrier is still 
not fully mature. This is a particular problem with sulphonamides (Choonara 2009).  
5 
The hepatic and renal clearance mechanisms are rapidly developing during the first 
month after birth and consequently, hepatically-cleared drugs are extracted more 
slowly, so drug doses and resultant efficacy need to be carefully monitored and 
potentially altered on a daily (or near daily) basis, e.g. phenytoin, phenobarbitone.  
The body water, fat content and high surface area to weight ratio of new-born 
paediatric patients indicate that the volumes of distribution of drugs may be 
significantly different to older paediatric or adult patients  (Duke and Urquhart 
1997). As a consequence water soluble drugs are diluted to a greater extent in 
neonates resulting in the potential requirement to increase dose to produce the 
desired plasma concentration. 
One of the most important differences between paediatric and adult patients is 
oxygen consumption which, in infants may exceed 6 ml/kg/min, twice that of adults 
(Rusy and Usaleva 1998). There are physiological adaptations in paediatric cardiac 
and respiratory systems to meet this increased demand. Both induction and 
emergence from anesthesia are more rapid in children than in adults. This is 
probably because of a smaller lung functional residual capacity per unit body weight 
and a greater tissue blood flow, especially to the key organs (brain, heart, liver and 
kidney). These organs in adults account for 10 % of body weight versus 22 % in 
neonates (Rusy and Usaleva 1998).  
Similarly, oral absorption is less predictable than in older paediatric or adult 
patients.  In the early days after birth, neonates are achlorohydric, with gastric pHs 
being much higher than in the majority of Caucasian adults.  As a consequence, the 
absorption of acid labile drugs may be enhanced, e.g. proton-pump inhibitors 
whereas, the absorption of fat soluble drugs may be reduced, for example fat 
soluble vitamins (Duke and Urquhart 1997).  Additionally, the selection of delayed 
release formulations, which rely on pH sensitive enteric coated formulations, should 
be cautiously considered for use in neonates.  There are many examples in the 
literature of unanticipated toxic effects from limited clearance and resultant 
accumulation of drugs in this class of infants; for example, chloramphenicol grey 
baby syndrome (Mulhall et al 1983). In contrast, established toxicology profiles may 
be less applicable to this patient sub-set; for example, aminoglycosides are safe and 
effective in neonates (Nestaas et al 2005), whereas nephrotoxicity is commonly 
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encountered from these drugs in older patient sub-sets (Giacoia and Schentag 
1986). 
1.2.1.3 Infants and toddlers (28 days to 23 months) 
This is a period of very rapid growth and maturation.  Oral absorption becomes 
much more reliable, adult gastric pH is achieved by 23 months, and clearance 
mechanisms are maturing rapidly (but with significant intra-subject variability); and 
with clearance (based on a mg/kg basis) often exceeding that seen in adults. This is 
a result of the liver being up to 50 % greater (as a percentage of total body weight) 
than in adults.  As a consequence the administered doses for hepatically-cleared 
drugs may need to be higher than in adults. The rates of gastric emptying and 
general gut motility fall during infancy and early childhood.  Although, the extent of 
drug absorption is usually not impacted, the rate may be i.e. the maximum blood 
plasma concentration (Cmax) increases, but the area under the blood plasma 
concentration versus time curve (AUC) remains the same. Consequently, sustained 
release formulations should be used with caution during childhood (Duke and 
Urquhart 1997).  
1.2.1.4 Children (2-11 years) 
The clearance pathways of most drugs have matured in this sub-class; however, 
clearance values again often exceed adult values, and are often dependent on the 
maturation of specific metabolic pathways.  Neonates and children have greater 
surface area to weight ratios and thinner stratum cornea than adults (Werfel et al 
1998). Consequently, there is a greater potential for high systemic exposure and 
subsequent adverse events from topical application of drugs. Of particular 
importance to the study of drugs in this sub-class is the impact on growth and 
development. Drugs that are CNS-active can adversely affect psychomotor skills in 
pre-school/school age groups and impact on the efficacy end-points.  The impact of 
the drug on the child can be monitored using developmental end points, such as 
growth, weight gain or school performance.  
Though rectally administered drugs can produce variable and erratic systemic 
absorption, administration of drugs via the rectal route can be especially useful to 
treat the very young, who can experience difficulties swallowing solid oral dosage 
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forms, and which, thereby avoids the need for injections or in emergency use, such 
as prolonged fitting, e.g. rectal diazepam (EMA 2013).  
Puberty can impact on the efficacy of metabolising enzymes, which significantly 
impacts on the administered dose on a mg/kg basis, of certain drugs, for example, 
theophyline (Conroy 2003).  Puberty is highly variable and is different in the sexes; 
girls maturing earlier (as young as 9 years) and more rapidly.  
Children often benefit from drugs with intrinsically long half-lives or modified 
release dosage forms as they can be administered once-daily. For example, the 
compliance and ethical issues of teachers and carers administering certain 
medicinal products should not be under-estimated, e.g. Ritalin (Drug and Alcohol 
Education and Prevention Team 2005).  
1.2.1.5 Adolescents 
The impact of any medicinal product on the physical, mental or sexual maturation 
of this paediatric sub-class should be considered.  As with late-phase infants, the 
impact on puberty is important.  In particular, the impact on hormones (especially 
sex hormones), sexual activity and the need for contraception or pregnancy testing 
can be important factors in clinical trial design.  Several disease states are 
influenced by hormonal changes, for example, changes of frequency and severity of 
asthma and migraine (Salam et al 2006).  However, non-compliance is particularly 
acute in this age range and recreational drug use, for example, of alcohol, tobacco, 
cocaine, ecstasy, etc., is unfortunately, becoming more prevalent (Williams et al 
2002).   
 
1.2.2 Ethical challenges 
There is a growing body of opinion within the world-wide community that children 
(and their parents) have the right to properly researched and regulated medicines 
(Davies 2004).  Unfortunately, there is an equally strong lobby that considers 
experimentation on children (particularly, placebo-controlled study designs) to be 
unethical; and for this to be ultimately a potentially profitable exercise, to be 
morally indefensible.  Consequently, the availability of financial incentives, in terms 
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of patent life extensions and exclusivity, for industry to develop paediatric 
medicines in the US and EU is viewed by some as setting an unwanted precedent.   
Before undertaking any paediatric research, an investigator needs to ensure that 
such research cannot be done in adults, with the results being extrapolated to 
children.  The overarching purpose of paediatric research is to obtain knowledge, 
applicable to the wider needs of the paediatric community.   
Paediatrics are a particularly vulnerable patient group.  As such, special measures 
and precautions are required to protect the participants (or their parents, if they 
are of an age where informed consent is not practicable) from undue risks.  Some of 
the issues perceived by parents (Martin 2004) include: 
(1) risks (both known and unknown) 
(2) discomfort to the child, especially from invasive treatments 
(3) disruption to routine and  to family schedules 
(4) financial impact 
(5) incentive to change (if current regimen is working well) 
(6) poor communication, both in terms of on-going issues and feedback on trial 
results 
(7) scepticism on the real goals of the researchers (more focussed on the 
research, rather than the treatment and care of the child).   
However, rights and duties are ‘two sides of the same coin’.  If there is a strong 
lobby for accessibility to paediatric medicines via well designed and controlled, 
clinical studies, is there an associated duty for families to become involved in such 
trials? Unfortunately, even world-renowned ethics advisors are at a loss to answer 
this key question (Davies 2004).   
However, participation in any clinical trial involves the issue of risk/benefit, which 
needs to be carefully evaluated by the overseeing Independent Ethics Committee 
and Institutional Review Boards.  These organisations should ensure that 
participation in such studies is free from inappropriate inducements, and any 
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reimbursement and subsistence costs are appropriate. Since in the majority of 
cases, participants in paediatric studies are unable to provide informed consent, 
this must be obtained from parents or guardians.  However, in all cases participants 
should be made aware of their rights to withdraw from the trial at any time; except 
in those very rare instances where the welfare of the participant would be placed in 
jeopardy by failing to participate, or continuing to participate in the clinical 
programme (FDA 2001a).  
Minimising the risk to the participants should be the principal objective, even if the 
whole community benefits; and every effort should be made to anticipate or reduce 
known risks.  There should be full awareness of the known pharmacology, 
toxicology, safety and efficacy of the medicinal product prior to the initiation of the 
study. In addition, studies should be conducted by trained paediatricians, with 
knowledge of, and experience of dealing with adverse events in paediatrics.  The 
number of participants should be as low as is commensurate with appropriate study 
designs, and processes for ensuring rapid termination of a study should be in place, 
should additional, unanticipated risks emerge.   Approaches to reduce invasive 
procedures and minimise the number and volume of samples for subsequent 
pharmacokinetic evaluation, should form part of the study protocol (EMA 2005).  
The various regulatory agencies also evaluate the risk to the child of participating in 
the paediatric clinical trial.  In the UK, the Royal College of Paediatrics and Child 
Health (RCPCH) define the perceived risk as minimal, low and high risk (McIntosh et 
al 2000). However, in the latter two categories the RCPCH argue that such research 
deserves serious ethical consideration, but provide no further guidance.  In 
contrast, in the US, the control of risk is divided into four categories;  
(1) minimal risk 
(2) minor increase over minimal risk 
(3) no direct benefit 
(4) direct benefit  
The whole area of paediatric medicine is more extensively regulated in the US (FDA 
2001b).   
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The US Food and Drug Administration (FDA) under the auspices of the Pediatric 
Advisory Subcommittee (PAS) have taken steps to reassure the general public that 
the safety of participating children is of paramount concern (Woodcock 2001).  The 
PAS have addressed several of ethical issues, including:  
(1) children as volunteers, versus paediatric patient studies 
(2) placebo controlled trials  
(3) clinical trial design and data analysis.  
To provide specific additional safeguards for children, to ensure compliance with 
the Children’s Health Act of 2000, and to coordinate these regulations with Health 
and Human Services regulations, the FDA introduced Additional Safeguards for 
Children in Clinical Investigations of FDA Regulated Products (FDA 2001b). 
The factors affecting the need for paediatric investigation of either an established 
drug, or a newly developed drug, and the nature of this clinical programme are 
varied (Richey et al 2012).  They include: 
(1) the seriousness of the condition requiring treatment 
(2) the prevalence of that condition in the paediatric sub-set 
(3) whether the medicine is ‘first in its class’, or another representative of an 
established class of compounds 
(4) the availability and suitability of alternative treatments especially the 
safety and efficacy of these alternative treatments 
(5) the need to develop paediatric specific end-points in the therapeutic 
disorder 
(6) unique safety concerns 
(7) research that indicates that there could be unique paediatric applications 
for this medicinal product 
(8) the likely age ranges of the paediatric population 
(9) the need for paediatric formulation development  
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Pharmaceutical companies developing medicinal products in new therapeutic 
indications are often viewed from the outside as considering clinical studies in 
children to be an unattractive, non-viable or non-profitable option (Conroy et al 
2000). However, industry has long recognised the need for paediatric medicines and 
for nearly a decade has been calling for medicines to be licensed to children of 
specific age ranges, for the publishing of paediatric clinical research guidelines and 
for regulatory guidance in this area (The Association of British Pharmaceutical 
Industry (ABPI) 1996). 
Unfortunately, there are issues for the pharmaceutical industry in this area.  Despite 
the numbers of children affected in the developed world the paediatric market is 
still comparatively small.  It has been estimated that the cost of a paediatric 
development plan for a new medicinal product is in the order of $20 million, and for 
an existing product, that could equate to a poor, or even negative, return on 
investment (Tiner 2004).  The objectives of the proposed regulations in the EU and 
US are to improve the overall health and welfare of children, by increasing research, 
development and approval of paediatric medicinal products.  However, it is not 
clear that the existing incentives will lead to more paediatric research in the EU, as 
the EU patent extension period is no improvement on the current US position.  
Although there are some incentives to encourage the generic industry to carry out 
more research, or develop new paediatric dosage forms on older established 
products, the generic industry has no record of innovative research to fall back on, 
which may hamper future development.  This is obviously unfortunate as there are 
often large knowledge gaps with the existing products as many of them have been 
used ‘off-label’ and there is no incentive to publish this information, particularly 
when there is often no obvious advancement in the particular field of research.  
In the US, the paediatric exclusivity provision has been highly effective, with 
industry responding positively, and with resultant extensive paediatric health 
benefits.  In the 3-year period covering implementation of the guidance to 2001, 
there were 218 paediatric proposals from industry 188 Written Requests from FDA, 
77 incomplete letters issued in place of a Written Request, and 95 amendments to 
Written Requests after negotiations between FDA and industry.  This resulted in the 
submission of 34 products (which included paediatric studies as part of the NDA 
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submission), of which 28 products (82 %) were granted paediatric exclusivity.  The 
complete list can be found on an FDA website (FDA 2013) and include drugs for the 
treatment of HIV, diabetes, hypertension, obsessive compulsive disorders, allergies, 
juvenile rheumatoid arthritis and seizures. It has been estimated that industry had 
completed 80 % of the paediatric studies requested by FDA, which is in contrast to 
the 15 % completion rate in the 6-year period before the initiation of the paediatric 
exclusivity provision (Woodcock 2001).  
 
1.2.3 Formulation challenges 
1.2.3.1 Toxicity issues of some common excipients in paediatric formulations 
One of the greatest medicinal tragedies of the last century (diethylene glycol 
poisoning) was prompted in many ways by the need to develop ‘child-friendly’ 
dosage forms (Geiling and Cannon 1938).  At that time clinical safety of new 
medicines and new formulations was not required; nor was there an extensive 
safety data base on existing or novel excipients.  In the resulting tragedy 107 
patients died of diethylene glycol poisoning, many of them children (Steinbrook 
2002) and hence the Best Pharmaceuticals for Children Act (BPCA) became public 
law in the US in 2002 (FDA 2002).   
A safety database exists for established excipients commonly used in 
pharmaceutical products intended for adults, and new excipients are required to 
undergo extensive animal safety testing before they can be used in clinical studies.  
However, the toxicity of some common excipients, like lactose, may differ across 
the various paediatric sub-groups and between paediatrics and adult patient groups 
(Edge et al 2005).   
One of the direct consequences of the need for oral liquid preparations (that 
children typically find easiest to swallow), is that taste-masking which often relies 
on sweeteners, is essential. Aspartame is used as an intense sweetener in 
beverages, food products, and in pharmaceutical preparations.  It enhances flavour 
systems and can be used to taste-mask unpleasantly bitter tasting characteristics of 
common drugs.  A number of adverse events, e.g. headaches and seizures, has been 
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reported following the consumption of large quantities of aspartame in beverages 
(Golightly et al 1988; Butchko and Kotsonis 1989).  Although, aspartame has been 
blamed for hyperactivity in children; a double-blind study of 48 pre-school children 
who were dosed with diets containing 38 ± 13 mg/kg body weight of aspartame for 
three weeks, showed no appreciable adverse behaviour or impact on cognitive 
function (Wolraich et al 1994).   
The development of multi-dose oral liquid and parenteral preparations also 
necessitates the requirement for preservative(s) to prevent microbial 
contamination.    
Benzyl alcohol is an antimicrobial preservative used in cosmetics, food, and in a 
wide range of pharmaceutical preparations including oral liquid and parenteral 
preparations.  Although widely utilised, its use has been associated with some fatal 
adverse reactions when given to neonates (Gershanik et al 1981).  It is now 
recommended that its use as a parenteral preservative for new born infants is 
discontinued.  The fatal toxic syndrome in low birth weight premature children was 
attributed to the use of benzyl alcohol as a preservative in solutions used to flush-
out umbilical catheters (Brown et al 1982; Gershanik et al 1982; McCloskey et al 
1986).  The FDA subsequently recommended discontinuation of this practice and of 
the use of medicinal products containing preservatives in neonates (FDA 1982; 
Belson 1982).   
Sodium benzoate is an antimicrobial preservative used in cosmetics, food, and in a 
wide range of pharmaceutical preparations.  It has been shown to elicit non-
immunological contact reactions, including urticaria and this should be taken into 
account when formulating paediatric products (Nair 2001).  In addition, it is 
recommended that parenteral combinations of caffeine and sodium benzoate 
should not be used in neonates (Edwards and Voegeli 1984).   
Thiomersal is an antimicrobial preservative used in cosmetics, soft contact lens 
solutions, and in some pharmaceutical preparations.  However, its use is declining 
owing to its toxicity and there are suggestions for discontinuing its use in eye drops 
(Ford et al 1985) and vaccines (Cox and Forysth 1988; Seal et al 1991; Noel et al 
1991).  In both the US and EU, regulatory bodies have recommended that its use in 
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vaccines, particularly paediatric vaccines is discontinued (APA 1999; EMEA 1999).   
In recent years public pressure groups have tried to link thimerosal in paediatric 
vaccines with autism but this claim was unsubstantiated and repudiated by 
regulatory agencies (Department of Health 2001).  
Propyl gallate is a widely used antioxidant in cosmetics, foods, and in a wide range 
of pharmaceutical preparations.  Although, propyl gallate has strong sensitising 
potential in animals, there are few reports of adverse events in humans but these 
include methemoglobinemia in neonates (Nitzan et al 1979).   
Oral Liquid formulations are often complementarily coloured and flavoured to aid in 
paediatric patient acceptance and long term compliance.  For instance, a paediatric 
formulation might be taste-masked using banana flavour (a particular favourite of 
many young children), which would be complemented by the addition of a yellow 
colorant.  One such colorant (FD&C Yellow No. 5 or tartrazine) has long been the 
subject of much controversy centred around its safety profile, and its possible link 
with hives (reported incidences of 0.001 %) and hyperactivity in children (Ward et al 
1990).  In the US, any prescription drug containing tartrazine, is labelled: “This 
product contains FD&C Yellow No. 5 (tartrazine) which may cause allergic reactions 
(including bronchial asthma) in certain susceptible persons.” (Mroz 2003) 
Generally, concerns over the safety profile of colorants in pharmaceuticals and 
foods are associated with hypersensitivity and hyperactivity (Bell 1991; Lévesque et 
al 1991; Dietemann-Molard et al 1991), especially in children (Pollock et al 1989).  
Poorly soluble drugs are often prepared as oral suspensions, and are frequently co-
formulated with surfactants to aid in the wetting of the drug, and in its subsequent 
dissolution.  Docusate sodium, an anionic surfactant, is widely used in 
pharmaceutical preparations as a wetting agent, dissolution aid and as laxative and 
faecal softeners.  However, the levels of docusate sodium should be strictly 
controlled in medicinal products to prevent unwanted incidences of diarrhoea, 
especially in infants.  The adult dose (500 mg) is over six times the amount 
administered to children of 6-months (75 mg) and older (Guidott 1996).  
Polyoxyethylene sorbitan fatty acid esters (Polysorbates 20, 40 and 60) are used as 
emulsifying agents, non-ionic surfactants, solubilising agents, wetting, dispersing 
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and as suspending agents.   Polysorbates are generally regarded as non-toxic and 
non-irritant materials; however, they have been associated with serious adverse 
events, including some deaths, in neonates who were administrated with vitamin E 
intravenous preparations (Alade et al 1986; Balistreri et al 1986).     
Carrageenan is a naturally occurring gel base or suspending agent derived from 
seaweed extracts.  Carrageenan is generally considered to be non-toxic and non-
irritating, except in parenteral preparations.  However, because of its ability to 
induce inflammatory responses in animals, the UK Food Advisory Committee did 
recommend the removal of carrageenan as an additive in infant food formulas 
(Ministry of Agriculture, Fisheries and Food (MAFF) 1992).  
Lactic acid is used in beverages, food, cosmetics and pharmaceuticals.  In topical 
cosmetics it is used as a skin softener.  In food and beverages it is used as a 
preservative.  It is usually present as the racemate (RS); but in some cases the S 
isomer predominates.  Lactic acid is the naturally occurring endpoint of anaerobic 
metabolism of carbohydrates so is usually viewed as being non-toxic at the levels 
used in typical formulations.  However, there is evidence that neonates have 
difficulty in metabolising the R isomer; and hence this isomer and the racemate 
should not be used in infant formulas for children less than 3 months old (World 
Health Organisation (WHO) 1974). 
Almond oil is used as an emollient in infant skin-care preparations  Although, 
typically regarded as non-toxic and non-irritant there has been one case reported in 
the literature of a 5-month old child developing contact dermatitis, which was 
attributed to the topical application for a 2 month period to the cheeks and 
buttocks (Guillet and Guillet 2000).   
Mineral oil is used as an emollient, lubricant or oleaginous vehicle.  The most 
serious adverse event caused by this excipient is lipoid pneumonia caused by 
inhalation of the oil as it does not elicit the cough reflex.  With the reduction in the 
use of this excipient in intra-nasal formulations the incidence of lipoid pneumonia 
has decreased (Owen 2005). However, this condition has been associated with the 
use of mineral oil in cosmetics in an adolescent (Becton et al 1984) and in 
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ophthalmic formulations (Prakesh and Rosenow 1990).   It is recommended that this 
excipient is not used in paediatric formulations.   
Peanut oil is used as a food additive and as a solvent in intra-muscular injections.  
Some workers have suggested that the use of peanut oil in childhood (infant 
formula and topical preparations) can lead to later episodes of hypersensitivity, and 
therefore should be discontinued (Monerat-Vautrin et al 1991; Brown 1991; De 
Montis et al 1993; Lever 1996; Wistow and Bassan 1999).  
Propylene glycol is a general solvent and antimicrobial preservative used in a wide 
range of pharmaceutical preparations including oral liquid, topical and parenteral 
preparations.  Its use in large volumes in children is discouraged, and it has been 
associated with CNS adverse events, especially in neonates (Martin and Finberg 
1970; Arulanantham and Genel 1978; MacDonald et al 1987). 
Lactose occurs widely in dairy products and is used in infant feed formulas.  In 
pharmaceutical preparations it is widely used as a diluent in tablets and capsules, in 
lyophilised powders, and as a carrier in dry powder inhalation products.  Lactose 
intolerance occurs when there is a deficiency in the intestinal enzyme lactase.  This 
enzyme is normally present at high levels at birth, declining rapidly in early 
childhood.  Hypolactasia (malabsorption of lactose) can thus occur at an early age 
(4-8 years) and varies among different ethnic groups (Suarez and Saviano 1997). It is 
unlikely that severe gastrointestinal adverse events could result from ingestion of 
medicinal products in adults, but it is less clear if this is equally applicable in infants.   
Talc is commonly used as a dusting powder and historically has been used as both a 
glidant and lubricant.  Although, generally regarded as non-toxic when orally 
ingested, inhalation of talc causes irritation and severe respiratory distress in 
children (Pairaudeau et al 1991).   
1.2.3.2 Palatability challenges 
Taste is the most important parameter governing paediatric patient compliance. 
Unfortunately, undesirable palatability is one of the most important formulation 
challenges encountered with the majority of drug substances (Tuleu 2009, Cram et 
al 2009).  Several approaches have been utilised to overcome this issue including 
17 
the use of flavours, sweeteners, amino acids, polymer coating, conventional 
granulation, lipids; including lipid emulsions and liposomes, lecithins, complexes 
with cyclodextrins and ion-exchange resins, salts, and polymeric materials. 
The use of flavours, generally in combination with artificial sweeteners, is by far the 
most commonly utilised approach in paediatric formulations; but is not the most 
successful for highly soluble or very bitter drugs.  Artificial flavours (grape, cherry, 
raspberry, etc.) have been used to mask the taste of some saline drugs (Lankford 
and Becker 1951).   The combination of an effervescent citrate couple in 
combination with cream and orange flavours was used to mask the bitter taste of 
chlorpheniramine and phenylpropylamine (Brideau 1995), lemon flavour was used 
to mask the taste of famotidine (Wehling and Schuehle 1993a); whilst cherry flavour 
was used to mask the flavour of paracetamol (Wehling and Schuehle 1993b).  
Vitamin B oral solutions, inosinate and fruit flavours (particularly, orange) are 
reported to have been used to have improved taste (Kobayashi et al 1992).   
Monosodium glyceryrrhizinate, an artificial sweetener with a longer acting 
sweetness, and flavours has been utilised to improve the bitter taste of guaifenesin 
(Fawzy et al 1998).  Low levels of ammonium glyceryrrhizinate are used to mask the 
bitter tastes of chewable multivitamin and analgesic tablet formulations, cough and 
cold syrups, and oral antibiotics (Kurtz and Fuller 1993).  Sorbitol, sodium saccharin, 
sodium glutamate and vanilla flavours have been used to produce palatable 
solutions of theophylline (Maegaki et al 1993).  
Lipids can be used to coat the buccal cavity (including the taste buds) and reduce 
the flavour threshold of bitter tasting molecules.  Cimitedine can be taste-masked 
by granulation with the lipid lubricant, glyceryl monostearate (Gottwald et al 1991).  
Similarly, gabapentin can be mixed with gelatine, partially hydrogenated soybean oil 
and glyceryl monostearate (Chau and Cherukuri 1991).  Palatable syrups of 
carbetapentanecitratem, diphenylhydramine, paracetamol and noscapine can be 
prepared using glycerine, polygylcerine fatty acid esters and triglycerides (Miura et 
al 1992).  
Formulations using lecithin, or related compounds can improve the taste of bitter 
drugs.  Soybean lecithin has been used to mask the unpleasant taste of the 
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antibiotic, talampicillin (Kinoshita and Shibuya 1987).  Similarly, suspensions of 
phosphatidic acid and β-lactoglobulin, suppress the bitter tastes of caffeine, quinine 
and papaverine (Kasturagi and Kurihara 1993). 
Coating of bitter tasting drugs with hydrophilic agents provides one of the most 
straightforward approaches to taste masking.  The unpleasant taste of ibuprofen in 
a suspension formulation, can be taste masked (Motola et al 1995) using a mixture 
of sodium carboxymethyl cellulose and sweeteners (sucrose, sorbitol and glycerine).  
The bitter tasting antibiotic, amoxicillin, can be taste-masked by granulating with 
microcrystalline cellulose, and then mixing with hydroxypropylcellulose (Olthoff et 
al 1988).  Tripolidine, can be taste-masked using hydroxypropylcellulose, 
sweeteners and flavours (McCabe et al 1992).  
A variety of proteinaceous excipients has been utilised to improve palatability.  
Various analgesics, hormones, enzymes, antibiotics, vitamins and dietary fibres have 
been taste-masked using prolamine coatings; without impacting on bioavailability.  
Amprilose was taste-masked by coating with calcium gluconate and sodium 
alginate; the latter forming a gel on contact with water and effectively masking 
unpleasant tastes (Nanda et al 2002).  A gel-based sweet was developed to improve 
the taste of paediatric paracetamol (Toraishi et al 1988).  Sodium alginate mixed 
with ibuprofen and added drop-wise to a calcium chloride solution gives a 
colourless and tasteless gel (Andou et al 1998).  The bitter taste of the antibiotic 
clairithrsomycin can be taste masked by granulation with carbopol and polyvinyl 
pyrrolidone (Saleki and Keski 1997).  
Complexation is a well-documented approach to taste masking. Complexes of 
ibuprofen, hydroxypropyl-β-cyclodextrin and sweeteners improved the palatability 
of ibuprofen solutions (Motola et al 1991).  The strong bitter taste of 
carbetapentane was decreased significantly following complexation (1:1) with 
cyclodextrins (Kurasumi et al 1991).  Similarly, bitter tasting drugs can be complexed 
with ion exchange resins (Elder 2005).  Polystyrene based cationic exchange resins 
(Indion CRP-244 and 254) have been utilised to complex bitter tasting drugs; 
diphenhydramine, chlorpheniramine, ephedrine, noscapine, and amphetamine 
(Manek and Kamat 1981). The strong cationic exchange resin Amberlite IRP-69 can 
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be used to mask the taste of the bitter tasting drugs like paroxetine (Elder et al 
2000).  
Low solubility salts (dibenzylethylenediamine and bis-ethylenediamine) of penicillin 
and the magnesium salt of aspirin are tasteless (Nanda et al 2002).  Similarly, the 
magnesium salts of dihydrocodeine, methylephedrine and chlorphenniramine, 
together with sweeteners are palatable (Nishikawa and Hyashi 1993). 
1.2.3.3 Dysphagia challenges 
The anatomy of the buccal cavity within a paediatric patient is not a scaled down 
version of that of an adult and differences exist between neonates and older 
children, as well as between children and adults.  The differences include (Evans-
Morris 1998):  
(1) the oral cavity is small in a neonate and is completely filled by the tongue 
(2) neonates have a set of sucking pads in the cheeks 
(3) the soft palate and epiglottis are in contact at rest, providing an 
additional valve at the back of the oral cavity 
(4) the larynx and hyoid cartilage are both higher in the neck and closer to 
the back of the epiglottis, providing additional protection to the airway 
(5) the eustachian tube runs horizontally from the middle ear to the 
nasopharynx (rather than the vertical angle found in older children and 
adults).    
Although, most medicinal products are developed as solid oral dosage forms, 
typically tablets and capsules (Rubinstein 1988) more than 25 % of adult patients 
have difficulty in swallowing (dysphagia) these type of medicinal products, and for 
paediatric and geriatric populations the percentages are much higher.  Children 
over the age of five years can usually swallow a tablet and those as young as three 
years can be taught, particularly where they suffer from chronic illnesses.  Standard 
tablets (without functional film coats) may be halved (if there is a break-line) or 
crushed (Richey et al 2012).  However, due to difficulties encountered by children 
with swallowing, alternative formulations, such as oral liquids, oral suspensions, 
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elixirs, drops, dispersible and chewable tablets are often required.  Injectable 
solutions can be dosed orally, e.g. phytomenadione injection (Duke and Urquhart 
1997).  
1.2.3.4 Examples of paediatric formulations 
Customised paediatric drug products must be carefully designed to overcome the 
challenges described. As for adults, the most commonly used route of 
administration is the oral route, but other routes that may be considered are 
topical, rectal, nasal, inhaled or intravenous. Some of these routes may offer 
specific advantages for the paediatric population for example, the rectal and topical 
routes both overcome issues associated with dysphagia and palatability. 
Traditionally, liquid oral products have been used to treat children as these offer 
dose flexibility and avoid swallowing difficulties but these product types also pose 
many formulation challenges including potential chemical, physical and 
microbiological stability and taste issues (Nunn and Williams 2005) 
As described, unfortunately in many cases, there is a need to manipulate adult 
medicines when a paediatric product is unavailable. Examples of manipulation 
include the crushing or splitting of tablets, opening capsules, cutting suppositories, 
or administering products designed for intravenous routes via alternative routes. 
Such practical solutions have been used to influence the design of customised oral 
paediatric formulations where oral liquid formulations are undesirable or non-
developable (Richey et al 2012). 
For example, a novel fixed dose combination tablet containing zidovudine and 
lamivudine has been developed as rectangular tablets with multiple fraction bars 
enabling the units to be split into 8 subunits enabling dose flexibility by weight 
(Kayitare et al 2009).  
Additionally, the concept of emptying capsules has driven the development of 
granules for dispersion. Instead of being filled into capsules for single unit dosing, 
the granules are filled into sachets and designed to be dispersed immediately prior 
to administration e.g. Singulair®.  
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The use of mini-tablets to overcome swallowing difficulties associated with children 
has also been explored. Tablets of 3mm diameter were dosed to pre-school children 
(2 to 6 years) with some success (Thomson et al 2009). Such formulations could be 
used to dose immediate release or modified release formulations and could be 
directly associated with the adult formulation. 
Other types of solid oral formulations that may enhance compliance within the 
paediatric population are oral dispersible tablets, films, and melt formulations. 
Examples of commercially available paediatric products and the associated dosage 
form type are provided in Table 1.1.   
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Table 1.1   Examples of commercially available paediatric dosage forms 
designed for oral delivery.  
Product/ Brand Drug substance Dosage format 
Route of 
Administration 
 Nurofen Meltlets Ibuprofen 
Rapidly 
disintegrating 
Tablets 
Oral 
 Diclofenac 
Effervescent 
Tablets, Hermes 
(diclofenac) 
Diclofenac 
Effervescent 
Tablets 
Oral 
 Aspirin 
QuickMelts 
(aspirin) 
Aspirin 
Orally Dissolving 
Tablets 
Oral 
 Paracetamol 
Chewable Tablets, 
CLL 
(acetaminophen) 
Acetaminophen Chewable Tablets Oral 
 LipiGesic 
HPuraMed 
Tension Headache 
(USA) 
Aspirin Sublingual gel Sublingual 
Junior Strength 
Motrin 
 Ibuprofen Chewable Tablets Oral 
 Advil PM 
Diphenhydramine 
Citrate, Ibuprofen 
Caplets, Liquid 
filled capsules 
Oral 
Childrens Advil 
SuspensionChildre
n's Advil-
Flavored(USA) 
Ibuprofen Suspension Oral 
Nexcede Ketoprofen Oral soluble film Oral 
Nurofen for 
Children - 
Strawberry 
Flavoured Fever & 
Pain Relief  
Ibuprofen Liquid Oral 
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1.3 Aims and Objectives 
The aim of this study is to develop a simple polymeric paediatric dosage form 
offering dose accuracy, dose flexibility whilst also addressing challenges associated 
with swallowing difficulties.  
This work evaluates the spray drying of hypromellose and paracetamol to 
determine if spray drying of these materials is feasible and if co-processed material 
may offer advantages over the binary mixing of polymer with drug substance.  
The effect of temperature on aqueous solutions of hypromellose and hydroxyl 
propylcellulose is evaluated to determine if temperature may be used to reduce 
viscosity of polymer solutions. The effect of temperature on aqueous solutions of 
HPC and HPC solutions containing paracetamol and ranitidine hydrochloride 
(ranitidine hydrochloride will be referred to as ‘ranitidine’ throughout this thesis) is 
investigated using UV transmission and viscosity testing. 
These data are then used to develop HPC polymer films containing paracetamol and 
ranitidine. HPC films are characterised to assess the potential use of polymer films 
as a paediatric dosage form platform.  
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2.  MATERIALS AND THEORETICAL BACKGROUND TO 
ANALYTICAL TECHNIQUES USED 
A list of the materials, suppliers and theoretical background to analytical techniques 
used throughout the project is provided below. Where appropriate, specific details 
associated with materials or methods used are provided in the relevant Chapters. 
2.1  Materials 
Details of the materials used throughout the project are provided in Table 2.1.  
Table 2.1  Materials used in investigation 
Material Grade Supplier 
Batch 
Number 
Paracetamol - 
GlaxoSmithKline, 
UK 
0709000128 
Ranitidine Hydrochloride - 
GlaxoSmithKline, 
UK 
K076008 
Hypromellose 
E5LV 
Dow Chemical 
Company, US  
TA24012409 
E15LV UC27012408 
E50LV UI14012401 
HydroxyPropyl Cellulose 
(HPC) 
EXF 
Ashland Inc., US 
65645 
GXF 66643 
HXF 68745 
JXF 76799 
LXF 77019 
MF 74311 
Polyethylene Glycol  400 
Dow Chemical 
Company, US 
XE1901AAKC 
  
2.1.1 Drug substances 
Two drug substances were considered for this project; paracetamol and ranitidine. 
The rationale for selection of these drugs together with a summary of their 
pharmacological application and batch details are provided here. As the data in 
Table 2.4 and Table 2.6 illustrate each drug has a ‘slightly bitter’ taste and therefore 
pose palatability challenges in the development of a paediatric dosage form. These 
data also show that the two drugs have different solubilities, enabling the impact of 
drug solubility to be assessed in the experiments conducted in this investigation.  
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2.1.1.1 Paracetamol 
 
Figure 2.1  Chemical structure of paracetamol  
Paracetamol (Figure 2.1) a para-aminophenol derivative, has analgesic and 
antipyretic properties and weak anti-inflammatory activity. It is given orally or as a 
rectal suppository for mild to moderate pain and for fever. It may also be given by 
intravenous infusion for the short-term treatment of moderate pain, particularly 
after surgery, and of fever. Paracetamol is often the analgesic or antipyretic of 
choice, especially in the elderly and in patients in whom salicylates or other NSAIDs 
(non steroidal anti-inflammatory drugs) are contra-indicated. For example, 
asthmatics, patients with a history of peptic ulcer, and children (Brayfield 2013). 
Potential advantages of paracetamol over other NSAIDs are a much lower incidence 
of commonly encountered gastro-intestinal and renal side effects (Wilson 2000). 
Though commonly used to treat fever and pain in children, paracetamol is also 
recognised by the European Medicines Agency (EMA) as an drug substance for 
which greater research in paediatrics is required. In particular, research into the 
‘safety and efficacy in pre-terms’ and ‘the efficacy and safety of a loading dose’ is 
identified as being required. 
Paracetamol is widely available in a range of formulations including suspensions, 
tablets, and melt formulations. The usual oral and rectal dose is 0.5 to 1 g every 4 to 
6 hrs up to a maximum of 4 g daily in adults (or children over 12 years). In the UK, 
the licensed doses of paracetamol for pain and fever in children, given according to 
age, are shown in Table 2.2. 
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Table 2.2   Recommended paracetamol dose ranges according to age (Brayfield 
 2013). 
Route 
Age 
28 to 32 wks >32 wks 
1 to 3 
months 
3 to 12 
months 
1 to 5 
years 
6 to 12 
years 
Oral 
20 mg/kg as a 
single dose then 
10 to 15 mg/kg 
every 8 to 12 
hrs if necessary 
up to a 
maximum of 30 
mg/kg daily 
20 mg/kg as a 
single dose 
then 10 to 15 
mg/kg every 6 
to 8 hrs if 
necessary up 
to a maximum 
of 60 mg/kg 
daily 
30 to 60 
mg every 
8 hrs 
60 to 
120 mg 
120 to 
250 mg 
250 to 
500 mg 
Rectal 
20 mg/kg as a 
single dose then 
15 mg/kg every 
12 hrs if 
necessary to a 
maximum of 30 
mg/kg daily 
30 mg/kg as a 
single dose 
then 20 mg/kg 
every 8 hrs if 
necessary to a 
maximum of 
60 mg/kg daily 
30 to 60 
mg every 
8 hrs 
60 to 
125 mg 
125 to 
250 mg 
250 to 
500 mg 
 
These doses may be given every 4 to 6 hrs if necessary up to a maximum of 4 doses 
in 24 hrs.  
Doses by intravenous infusion in children are calculated according to body-weight 
and shown in Table 2.3. Doses are usually administered over 15 minutes (Brayfield 
2013):  
Table 2.3   Recommended IV paracetamol dose ranges according to weight 
 (Brayfield 2013). 
Route 
Weight 
<10kg 10 to 33kg 33 to 50kg >50kg 
IV 
Single doses of 7.5 
mg/kg every 4 or 
more hrs to a 
maximum of 30 
mg/kg daily. IV 
paracetamol has not 
been studied in 
premature neonates 
Single doses of 15 
mg/kg every 4 or 
more hrs to a 
maximum of 60 
mg/kg or 2g daily 
(whichever is less). 
Single doses of 15 
mg/kg every 4 or 
more hrs to a 
maximum of 60 
mg/kg or 3g daily 
(whichever is 
less). 
Adult 
doses 
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The recommended doses of paracetamol for children may result in sub-therapeutic 
blood concentrations, and that an initial loading dose should be given, followed by 
regular doses up to the recommended maximum daily dose. However, the 
appropriate maximum daily dose remains controversial, and there is obvious 
concern given the risks of overdosage.  
Paracetamol was sourced from GSK and has the physico-chemical properties given 
in Table 2.4: 
Table 2.4  Physico-chemical properties of Paracetamol (El-Obeid and A-Badr 
  1985) 
Attribute Value 
Alternative generic names Acetaminophen 
pKa 9.5 
Molecular weight 151.16 
Appearance White, crystalline powder 
Odour Odourless 
Colour White 
Taste Slightly bitter 
Melting point 169 to 170.5 °C 
Solubility 
Sparingly soluble in water (30 to 100 parts 
solvent for one part soluble by weight) 
Freely soluble in alcohol (1 to 10 parts 
solvent for one part soluble by weight) 
A saturated aqueous solution has a pH of 
about 6 
 
2.1.1.2 Ranitidine hydrochloride 
 
Figure 2.2  Chemical structure of ranitidine hydrochloride 
Ranitidine (Figure 2.2) is a histamine H2-antagonist which may be given orally or 
parenterally by the intravenous or intramuscular routes to inhibit gastric acid 
secretion. Ranitidine may be used to treat benign gastric and duodenal ulceration, 
duodenal ulcers associated with Helicobacter pylori infection, gastro-oesophageal 
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reflux disease, and stress ulceration of the upper gastrointestinal tract (Brayfield 
2013). Ranitidine hydrochloride is the most commonly used salt form of ranitidine. 
Dosing is dependent upon disease type but in adults oral dosing is generally 150 mg 
to 300 mg twice a day (Brayfield 2013). 
Ranitidine is used in children to heal duodenal and gastric ulcers and to prevent 
stress ulceration in critically ill patients. It is licensed in children, although 
indications, age ranges, and doses may vary from country to country (Table 2.5). 
When given orally, ranitidine is licensed from ages 3 to 11 years and over 30kg 
body-weight in the UK, and from 1 month to 16 years in the USA.  
Table 2.5  Recommended ranitidine dose ranges according to age (Brayfield 
  2013)  
Route 
Age 
Neonates 
1 to 6 
months 
6 months 
to 3 year 
3 to 11 years (UK) 
1 month to 16 years 
(US) 
12 to 18 
years 
Oral 
2 mg/kg 
three times 
a day (max 3 
mg/kg). 
1 mg/kg 
three 
times a 
day (max 
3 
mg/kg). 
2 to 4 
mg/kg 
twice a 
day 
4 to 8 mg/kg daily as 2 
doses, up to a max of 
300 mg daily for 4 to 8 
weeks for duodenal 
and gastric ulcers. 
5 to 10 mg/kg daily in 
2 doses to a maximum 
of 600 mg daily for 
gastro-oesophageal 
reflux disease. 
Adult 
doses 
IV 
0.5 to 1 
mg/kg every 
6 to 8 hrs 
OR 
30 to 60 
µg/kg/hrs 
(up to 3 
mg/kg/day) 
1 mg/kg (to a max of 50 mg) every 6 to 8 hrs by slow IV 
injection or intermittent infusion at 25 mg/hrs 
OR 
125 to 250 µg/kg/hrs by infusion. 
 
Though commonly used to treat reflux oesophagitis, benign gastric and duodenal 
ulceration, and prophylaxis of duodenal ulceration in children, ranitidine is also 
recognised by the European Medicines Agency (EMA) as an drug substance for 
which greater research in paediatrics is required. In particular, the EMA indicate 
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that research into the ‘the development of an age appropriate alcohol free 
formulation for use in neonates’ is required which suggests that an age appropriate 
dosage form containing ranitidine is not currently available.  
Ranitidine was sourced from GSK and has the physico-chemical properties given in 
Table 2.6: 
Table 2.6  Physico-chemical properties of ranitidine (Hohnjec et al 1986) 
Attribute Value 
Alternative generic names Ranitidine Hydrochloride 
pKa 2.7 and 8.2 
Molecular weight 350.9 (HCl) 314.4 (Base) 
Salt conversion factor 
1 part of free base equivalent to 1.116 of 
HCl salt 
Appearance White or pale yellow, crystalline powder 
Odour Practically odourless 
Colour White or pale yellow 
Taste Slightly bitter 
Melting point 140 °C 
Solubility 
Freely soluble in water (1 to 10 parts 
solvent for one part soluble by weight) 
Sparingly soluble in alcohol (30 to 100 
parts solvent for one part soluble by 
weight) 
A 1 % solution in water has a pH of 4.5 to 
6 
 
2.1.2 Polymers 
Hydrophilic polymers are used routinely in pharmaceutical dosage forms as they are 
safe and well tolerated and offer excellent functionality. Polymers can be used as 
suspending agents in oral suspensions; as controlled release polymers in oral 
sustained release matrix tablets and as film formers in film coatings.  
Two hydrophilic polymer types were considered for this project; Hypromellose and 
HydroxyPropylCellulose (HPC). The rationale for selection of these polymers 
together with a summary of their pharmaceutical application, chemical properties 
and relevant details of the specific grades of hypromellose and HPC investigated in 
this project are provided here. 
2.1.2.1 Hypromellose 
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Hypromellose is one of the most commonly researched and frequently utilised 
polymers in pharmaceutical product development, having many applications 
including; modified release matrix tablets, binder in granulation processes, viscosity 
enhancing in suspension products and as a film forming agent in coatings. 
Hypromellose is a polypropylene ether of methyl cellulose derived from cotton or 
wood pulp and contains a basic repeating structure of anhydroglucose units. It is a 
non-ionic, hydrophilic, swellable polymer with a pH of 5 to 8 (1 %w/v). The chemical 
structure of hypromellose is shown Figure 2.3. 
 
Figure 2.3:  Chemical structure of hypromellose 
The physicochemical properties of hypromellose are affected by i) its methoxyl 
group content ii) its hydroxypropoxyl group content and iii) its molecular weight or 
degree of polymerisation (Dow 2013). A number of grades of hypromellose are 
available based upon these three characteristics of its chemistry. The United States 
Pharmacopoeia (USP) recognises 4 different types of hypromellose based upon the 
methoxyl and hydroxypropoxyl substitution of the molecule. These different types 
are classified as hypromellose 1828, hypromellose 2208, hypromellose 2906 and 
hypromellose 2910. The first two digits indicate the percentage number of methoxyl 
groups and the last two digits indicate the percentage number of hydroxypropoxyl 
groups e.g. hypromellose 2208 contains 22 % of methoxyl groups and 8 % 
hydroxypropoxyl groups.  
Hypromellose may be further characterised according to the viscosity of a 2 %w/v at 
25°C aqueous solution of the particular polymer. The viscosity serves as a measure 
for the average chain length of the polymer, the degree of polymerisation and 
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provides a relative indication of the molecular weight (Jumel et al 1995). A range of 
viscosity grades of hypromellose 2208 and 2910 is available and provides good 
flexibility for achieving desired function within the dosage form. Some 
manufacturers are also able to supply ‘fine grade’ material. Due to their finer 
polymer particle size, the polymer particles are able to hydrate and solubilise more 
readily (Mitchell and Balwinski 2007). Finer grade material may offer advantages to 
its function within dosage forms, e.g. a more rapidly hydrating gel layer in matrix 
tablets.  
Hypromellose (Methocel®) supplied by The Dow Chemical Company (Midland, 
Michigan, USA) was used in this investigation. The particular grades of Methocel® 
chosen for this investigation are shown in Table 2.7. The Methocel grades are 
categorised according to viscosity of the polymers at 2 % aqueous solution (Table 
2.7). 
Table 2.7  Details of Methocel®grades selected (Dow 2013) 
Methocel®Grade 
Viscosity 
 (as 2 % w/w aqueous 
solution) 
Particle Size1 
E5LV 5cP (4cP to 6cP) 100 % pass through 30 
mesh screen; 
99 % pass through 40 mesh 
screen 
E15LV 15cP (12cP to 16cP) 
E50LV 50cP (40cP to 60cP) 
 
Note 
1. Particle size of polymer is presented as provided by The Dow Chemical Company. 
30 mesh screen is equivalent to 595 µm and 40 mesh is equivalent to 400 µm. 99 
% by mass of the polymer will pass through a 400 µm screen.  
 
2.1.2.2 HPC 
HPC is a non-ionic, water soluble, partially substituted poly(hydroxypropyl) cellulose 
ether, available in a range of molecular weights, viscosities and particle sizes. HPC is 
manufactured by reacting alkali cellulose with propylene oxide at elevated 
temperatures and pressures. The propylene oxide can be substituted on the 
cellulose through an ether linkage at the three reactive hydroxyls present on each 
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anhydroglucose monomer unit of the cellulose chain (Fulzele and Hamed 2013). The 
chemical structure of HPC is shown in Figure 2.4. 
 
 
Figure 2.4:  Chemical structure of HPC 
Similar to hypromellose, the physicochemical properties of HPC are attributable to 
i) the degree of hydroxypropyl substitution and ii) the molecular weight or degree 
of polymerisation of the molecule (Hercules 2001). However, unlike hypromellose, 
HPC is not generally available in a range of different levels of substitution. Only two 
types of HPC are commercially available; one has a molar substitution of 3.5 to 4.5 
of hydroxypropyl groups (approx 60 % substitution), and the other, termed ‘low 
substituted HPC’, has a molar substitution of 0.11 to 0.39 of hydroxypropyl groups, 
and is available from some manufacturers. Low substituted HPC has very different 
properties to the standard type and is generally used as a disintegrant in solid 
dosage forms (Kawashima et al 1993).  
HPC is available in a range of molecular weights and viscosities, and has various 
applications based on their characteristics.  
Five grades of HPC (Klucel®) supplied by Aqualon (a division of Hercules 
Incorporated, Wilmington, USA) were used in this investigation: MXF Pharm, EXF 
Pharm, GXF Pharm, JXF Pharm and LF Pharm. The viscosity, molecular weight and 
particle size of these polymer grades are shown in Table 2.8.   
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Table 2.8  Klucel grade material properties (Aqualon 2004) 
Klucel Grade 
Viscosity 
(cP)/Aqueous 
Solution ( %w/w) 
Typical 
Molecular 
weight 
Particle Size (by 
weight) 
HXF Pharm 
1,500 to 3000 
1 % w/w 
1,150,000 99.9 %<60 Mesh 
MXF Pharm 
4000 to 6500cP 
2 %w/w 
850,000 99.9 %<60 Mesh 
GXF Pharm 
150 to 400cP 
2 %w/w 
370,000 99.9 %<60 Mesh 
JXF Pharm 
150 to 400cP 
5 %w/w 
140,000 99.9 %<60 Mesh 
LF Pharm 
75 to 150cP 
5 %w/w 
95,000 99.9 %<20 Mesh 
EXF Pharm 
300 to 600cP 
10 %w/w 
80,000 99.9 %<60 Mesh 
 
HPC grades are categorised according to the polymer molecular weight and 
viscosity is determined varies dependent upon the molecular weight of the 
polymer. All grades of HPC are available as ‘fine grade’ (Denoted by an ‘X’ in the 
grade name, e.g. EXF) except for the ‘L-grade’. The definition of fine grade polymers 
are based on 99.9 % by mass of the polymer passing through a 60 mesh (equivalent 
to 250µm). The particle size of LF Pharm is described as 99.9 % by mass of the 
polymer passing through a 20 mesh (equivalent to 841µm). 
2.1.3 Other materials 
In addition to the drug substances and polymers considered in this investigation, 
purified water was also used.   
2.1.3.1 Purified water 
Purified water meeting USP monograph was sourced from GlaxoSmithKline.  
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2.2 Analytical Techniques 
A range of analytical methods was used throughout the investigation to 
characterise the spray-dried material, film solutions and films. The analytical 
methods are summarised here and further details are provided in the relevant 
Chapters. 
2.2.1 Determination of viscosity 
The viscosity of the solutions was used in the characterisation of polymers. The 
viscosity of a polymer solution is a key physical parameter for spray-drying and may 
affect the characteristics of the spray-dried product produced (Cal and Sollohub 
2010; Sollohub and Cal 2010). Viscosity testing was used extensively to characterise 
the impact of temperature on aqueous solutions of both hypromellose and HPC. 
The viscosity of a fluid describes its resistance to flow or movement. It is a measure 
of the internal friction of a fluid. Therefore, viscosity is often used to describe the 
flow properties of materials. Friction within a fluid becomes apparent when a layer 
of fluid is made to move in relation to another. The greater the friction, the greater 
the amount of force required to cause this movement, which is called shear 
(Viswanath et al 2007). Viscosity (η) is a function of shear stress (F) and shear rate 
(S) as shown in Equation 2.1. 
η = F/S    (Equation 2.1) 
Based on its rheological behaviour, a fluid may be considered ‘Newtonian’ or Non 
Newtonian’. Newtonian fluids demonstrate the relationships shown in Figure 2.6 
between these three factors. 
 
 
 
 
Figure 2.5  The behaviour of Newtonian fluids 
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An increase in shear stress results in a linear increase in shear rate (as shown in Fig. 
2.6A but viscosity remains constant with an increase in shear rate (as shown Fig 
2.6B) for Newtonian fluids. 
Non-Newtonian fluids do not follow these principles. The relationship between 
shear stress and shear rate is non-linear and not constant. A change in shear rate 
will not necessarily result in a similar change in shear stress and consequently the 
viscosity of a non-Newtonian fluid will change with a change in shear rate.  
Depending upon the change to viscosity caused by shear rate or time, there are 
different types of non-Newtonian fluids (Viswanath et al 2007): 
i) pseudoplastic (decrease in viscosity with an increase in shear rate) 
ii) dilatant (increase in viscosity with an increase in shear rate) 
iii) plastic (behaves as a solid until a specific amount of shear is applied and 
 then shear thins) 
iv) thixotropic (decrease in viscosity at constant shear with increase in time) 
v) rheopectic (increase in viscosity at constant shear with increase in time). 
Brookfield viscometers were used to measure polymer viscosity. A RVDV-I 
viscometer (Brookfield UK) was used to measure polymer solution viscosity (see 
Chapters 5 and 6) and a LVDV-II viscometer (Brookfield UK) with small sample 
adaptor was used as described in Chapter 7. More details about the viscometer 
model and test parameters are found in those Chapters. 
2.2.2 Ultraviolet spectrometry 
Ultraviolet spectrometry is the measurement and interpretation of ultraviolet 
radiation absorbed, scattered or emitted by atoms, molecules or other chemical 
species. Ultraviolet light has a wavelength of 200 nm to 400 nm (Willard et al 1988). 
UV transmission was used in this work to characterise the polymer solutions and to 
investigate the potential formation of liquid crystals in aqueous HPC solutions 
(Maugey and Navard 2002). UV absorbance was used in this work to measure drug 
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content and dissolution rate of drug for polymer films produced and characterised 
in Chapter 8. 
UV transmission analysis is a form of UV spectroscopy measuring the amount of 
light at a particular wavelength that is transmitted through a sample and is the 
opposite to UV absorption spectroscopy that measures the amount of light 
absorbed of a particular wavelength by a particular species within a sample (Willard 
et al 1988). 
The radiant power of a beam of radiation is proportional to the number of photons 
per unit time. Absorbance occurs when a photon collides with a molecule and raises 
that molecule to its excited state. The number of photon collisions with a molecule 
will depend upon the wavelength selected. The number of photon collisions will be 
increased by increasing the path length that the light beam passes through the 
sample or the concentration of the absorbing species. Increasing the beam power 
will also increase the number of photon collisions. Absorbance may be defined by 
the Beer-Lambert law (Equation 2.2).  
A = log P0/P = abC   (Equation 2.2)  
Where: 
A is absorbance 
 P0 is radiant power at source 
 P is radiant power of the transmitted radiation that emerges from absorbing 
medium (unabsorbed power) 
 a is proportionality constant (absorptivity) 
 b is path length 
 C is concentration of test solution 
The absorbance (A) is proportional to the concentration (C) of the solution and the 
length (b) of the layer of solution through which the light passes. Calculated on the 
basis that b is 1 cm and c is 1 % w/v solution, the absorbance is called specific 
absorbance (A1 %1cm )  
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Per-cent transmission, T, is defined by Equation 2.3 
%T = P/P0 x 100   (Equation 2.3) 
Meaning that absorbance is the inverse log of transmission (Equation 2.4). 
A = log 1/T = -log T   (Equation 2.4) 
Application of UV transmission and absorbance is provided in Chapter 4. 
2.2.3 Hot stage microscopy 
Hot-stage microscopy combines microscopy and thermal analysis to enable the 
characterization of the physical properties of materials as a function of temperature 
(Vitez et al 1998). More recently, hot stage microscopes have been integrated with 
high resolution cameras, data capture software and image manipulation software to 
enable thermal images to be reliably collected over time as the sample is heated at 
a pre-determined rate or for a pre-determined period of time. The use of data 
capture software prevents the need for the analyst to constantly observe the 
sample for extended periods of time. Sample holders may be programmed to 
control temperature changes over time so that carefully prepared programmes may 
be developed to monitor changes to the sample over a predetermined range of 
temperatures or at a predetermined rate in change of temperature (Vitez et al 
1998). Temperature cycling may also be considered if applicable. 
A schematic diagram of a typical hot stage microscope sample holder is shown in 
Figure 2.7. The diagram shows a silver heating block element held between the 
stage lid and base plate. Both the stage lid and base plate have a window to allow 
light to pass through the sample. A sample is prepared as normal using a glass cover 
slip and inserted above the silver heating block element. All other aspects of the 
microscope are comparable to a conventional light microscope e.g. condenser lens 
and objective lens. 
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Figure 2.7  Schematic diagram of hot stage microscope sample holder (Mirjalili 
 et al 2012) 
Hot-stage microscopy is used in a variety of ways to confirm transitions observed 
using other techniques. Hot-stage microscopy may be used for the solid-state 
characterization of bulk drugs, evaluation of crystal forms and hydrates, and other 
physico-chemical properties (Shur and Price 2012). 
Hot stage microscopy was used in this work to complement UV transmission to 
monitor the potential liquid crystal formation in aqueous polymer solutions. A hot 
stage microscope integrated with a high-resolution camera, real time video 
capability and computer software was used to observe changes in aqueous polymer 
solutions at increasing temperature. (Vitez et al 1998). Details of the hot stage 
microscopy method used in the work may be found in Chapter 7. 
2.2.4 Dissolution testing 
Dissolution testing is a commonly applied characterisation technique for oral 
dosage forms. The principle aim of the technique is to determine the dissolution 
rate of the active substance from the dosage form. A number of dissolution 
techniques are described by pharmacopeia such as the British Pharmacopoeia, the 
US Pharmacopeia and the European Pharmacopoeia. These pharmacopoeias specify 
the apparatus requirements including dimensions of each of the techniques (British 
Pharmacopoeia 2013; United States Pharmacopeia 35/National Formulary 30; and 
European Pharmacopoeia 7th edition). The US Pharmacopeia for example describes 
four types of dissolution apparatus i) baskets (USP I); paddles (USPII); reciprocating 
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cylinder (USPIII) and flow-through cell (USPIV) (United States Pharmacopeia 
34/National Formulary Chapter 711, General Dissolution). 
Dissolution using paddles is the most commonly used technique for immediate 
release dosage forms. Dissolution using USPII (paddles) with UV absorbance is used 
(see Chapter 9) in this investigation to measure paracetamol release from the 
polymer films. 
Selection of the dissolution media is critical to determining the in-vivo relevance of 
the dissolution data obtained. For example, most immediate release solid oral 
dosage forms will be presented intact to the stomach following administration so a 
dissolution medium representative of the stomach contents provides greater insight 
to the impact of the stomach contents on the dissolution of the dosage form 
(Juenemann et al 2011, Wagner et al 2012). For this investigation purified water 
was selected as the dissolution media. Further details of the dissolution technique 
applied to characterise the polymer films is provided in Chapter 8. 
2.2.5 Disintegration testing 
Disintegration testing is a commonly applied characterisation technique for oral 
dosage forms. The principle aim of the technique is to determine the time taken for 
the dosage form to disintegrate. Pharmacopoeia such as the British Pharmacopoeia, 
the US Pharmacopeia and the European Pharmacopoeia, describe disintegration 
methods and apparatus applicable to the testing of tablets and capsules but they do 
not describe a method or apparatus specific for oral films (British Pharmacopoeia 
2013; United States Pharmacopeia 35/National Formulary 30; and European 
Pharmacopoeia 7th edition). 
A disintegration technique described by Chen 2006 was used in this investigation 
and details are provided in Chapter 8. 
Dissolution testing and disintegration testing techniques are often used together to 
predict in-vivo behaviour of the dosage form. Disintegration testing indicates how 
quickly the dosage form will be reduced to component particles in-vivo thus 
enabling the drug substances to be dissolved in the dissolution media (gastro 
intestinal fluid). In this investigation, the disintegration technique employed is 
40 
designed to mimic disintegration of the polymer film on the tongue in the mouth 
cavity. The dissolution technique is designed to predict how quickly the drug would 
dissolve in the mouth following disintegration of the film. 
2.2.6 Scanning Electron Microscopy (SEM) 
Scanning Electron Microscopy is an alternative microscopic technique to light 
microscopy. Scanning Electron Microscopy offers a much greater depth of field 
compared with light microscopy and therefore is able to generate three-
dimensional images. Scanning Electron Microscopy is also able to measure smaller 
particles compared with light microscopy (Egerton 2005) 
Scanning Electron Microscopy uses a focused beam of high-energy electrons to 
generate a variety of signals at the surface of solid specimens. The signals that 
derive from electron sample interactions reveal information about the sample 
including particle shape and topography. Sizes ranging from approximately 5 
microns to 1 cm in width can be imaged using conventional SEM techniques. 
Magnifications from 20x to 30,000x with spatial resolution of 50 to 100 µm are 
possible (McMullan 1995). 
The principle of SEM is that a significant amount of the kinetic energy carried by the 
accelerated electrons is dissipated as a variety of signals produced by electron-
sample interactions when the incident electrons are decelerated in the solid 
sample. These signals include secondary electrons that produce SEM images but 
may also include backscattered electrons, diffracted back scattered electrons, 
photons, visible light and heat. Secondary electrons and backscattered electrons are 
commonly used for imaging samples; secondary electrons showing morphology and 
topography and back scattered electrons for illustrating contrast in composition in 
multiphase sample (Egerton 2005). SEM analysis is typically ‘non destructive’ so it is 
possible to analyse the same materials repeatedly (Wells and Joy 2006).  
Scanning Electron Microscopy is routinely used to generate high resolution images 
of shapes of objects; to show spatial variations in chemical composition; and to 
identify phases based on qualitative chemical analysis and crystalline structure 
(Clarke and Eberhadt 2002).  
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Though SEM has vast application in the study of solid materials, the technique does 
have limitations. For example, the samples must be solid and fit into the microscope 
chamber. Typically the maximum size is 10cm x 0.4cm and the sample must be 
stable under vacuum (Egerton 2005). 
Details of the scanning electron microscope used in these investigations may be 
found in Chapter 4. 
2.2.7 Differential Scanning Calorimetry (DSC) 
DSC measures the amount of energy required to keep a sample at the same 
temperature as a reference. It measures the enthalpy of transition. When there is 
no physical or chemical change within the sample there is no change in temperature 
of the sample nor need to input energy to maintain an isotherm. When a phase 
change occurs latent heat suppresses the temperature increase or decrease and the 
change in temperature or isothermal energy required is determined (Wendlandt 
1986). DSC can be used to measure a variety of physical changes including, changes 
in crystalline state and determining melting point or glass transition temperature 
(Griffin and Laye 1992) 
DSC was used in this investigation to determine if polymer films have a glass 
transition temperature. Details of the DSC method employed may be found in 
Chapter 4.  
2.2.8 Thermal Gravimetric Analysis (TGA) 
TGA can be used to measure loss in weight as a function of time and under 
isothermal conditions where transitions involve dehydration or decomposition 
(Honda 1911). The rate of such thermally induced changes is a function of molecular 
structure. Changes in weight result from physical and chemical bonds forming and 
breaking at elevated temperatures.TGA data can be used to characterise materials 
as well as investigating the thermodynamics and kinetics of the reactions and 
transitions that result from the application of heat to the sample (Dollimore 1992).  
TGA may be used in isolation or with differential thermal analysis as all weight 
change processes absorb or release energy (so are measureable by DSC) but not all 
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energy change processes are accompanied by changes in weight (Charsley and 
Warrington 1992). 
TGA was used in this investigation to complement the DSC analysis (2.2.7) and to 
gain an insight into the stability of the polymer films produced. Details of the TGA 
method and apparatus used may be found in Chapter 8. 
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3  PREPARATION OF POLYMER SOLUTIONS FOR 
CHARACTERISATION, SPRAY-DRYING AND FILM 
FORMATION 
Polymer solution preparation is fundamental to this investigation as it is required 
for all aspects of this thesis. Spray drying of polymer solutions is considered in 
Chapter 4 to investigate the potential to co-process hypromellose with drug 
substance; the impact of temperature on polymer solution characteristics is 
considered in Chapters 5, 6 and 7; and  film formation from a polymer solution is 
investigated in Chapter 9 to prepare an age appropriate oral dosage form.  
This Chapter provides preparation details for aqueous solutions of hypromellose or 
HPC; with or without paracetamol or ranitidine.    
3.1  Preparation of Polymer Solutions 
Aqueous polymer solutions were used throughout this investigation. Aqueous 
solutions containing i) hypromellose E5, E15 and E50LV were considered for spray-
drying; ii) HPC grades EXF, GXF, JXF, LXF and MXF were considered to understand 
the impact of temperature on the polymer solution and iii) HPC EXF was considered 
for film formation and characterisation. The method of preparation of aqueous 
polymer solutions using hypromellose and HPC is described below. 
3.1.1 Preparation of hypromellose solutions 
Formulation details for each aqueous hypromellose solution prepared may be 
found in Chapters 4 and 5. 
Aqueous solutions of hypromellose were prepared by slowly heating the required 
quantity of purified water to 75°C to 85°C in a tared glass beaker using a hot plate 
(IKA magnetic stirrer and hotplate, Germany) with calibrated temperature probe 
thermostat (IKA, Germany) whilst gently stirring using a magnetic bar (Fisher, UK). 
Once within the required temperature range the required quantity of hypromellose 
was dispensed and slowly added to the water whilst continually stirring. It was 
44 
important not to add the hypromellose too quickly as the polymer tended to 
hydrate and swell, becoming difficult to dissolve. After dispersing the hypromellose 
powder at 75°C to 85 °C, the dispersion was allowed to cool to ambient 
temperature with constant stirring using the magnetic stirrer. The hypromellose 
hydrated and dissolved as the solution cooled. The dispersion was mixed at room 
temperature until all hypromellose had fully dissolved. Where necessary, the 
hypromellose solution was made to weight with purified water. Each aqueous 
hypromellose solution was transferred to a clear glass bottle ready for use or stored 
at ambient temperature.  
3.1.2 Preparation of HPC solutions 
Formulation details for each aqueous HPC solution prepared may be found in 
Chapters 6, 7 and 8. 
HPC solutions were prepared using a similar method to that used for hypromellose 
however, it was not necessary to heat the purified water prior to dispersion of the 
HPC. The required quantity of the appropriate grade of HPC was dispensed and 
slowly added to the required quantity of purified water in a tared glass beaker at 
ambient temperature whilst continually stirring using a magnetic stirrer without 
heating (IKA magnetic stirrer and hotplate, Germany).  The HPC dispersion was 
mixed until the HPC was completely dissolved and a clear solution achieved. Larger 
molecular weight grades of HPC took longer to dissolve and in some cases it was 
necessary to leave the solution mixing overnight to fully solubilise the HPC. Where 
necessary, the HPC solution was made to weight with purified water. Each aqueous 
HPC solution was transferred to a clear glass bottle ready for use or stored at 
ambient temperature.  
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3.2  Preparation of Drug Polymer Solutions/Dispersions 
Drug polymer solutions or dispersions were prepared using hypromellose or HPC 
and ranitidine or paracetamol. Drug polymer solutions or dispersions are used 
throughout this investigation. Formulation details may be found in the relevant 
Chapters. 
3.2.1 Preparation of hypromellose drug solutions/dispersions 
Drug polymer solutions or dispersions using hypromellose were prepared using a 
similar method to that described in Section 3.1.1. The hypromellose was dissolved 
in half of the required quantity of water. After dispersing the hypromellose at 75°C 
to 85°C and solubilising whilst cooling to ambient temperature as previously 
described, the drug solution/dispersion was prepared. To the other half of the 
required quantity of water, the paracetamol or ranitidine powder was slowly added 
at ambient temperature and dispersed using the magnetic stirrer (IKA, Germany). 
After dispersing the paracetamol or ranitidine, the dispersion was added to the 
hypromellose solution and mixed using a high shear Silverson L4RT mixer (Silverson, 
UK) with homogeniser head fitted at 1800rpm (1600 to 2000rpm). Care was taken 
to avoid excessive entrapment of air during homogenisation. The dispersion was 
homogenised until a clear solution or a smooth, lump-free homogeneous dispersion 
(for higher concentrations of paracetamol) formed. A stainless steel spatula was 
used to examine the dispersion for lumps and consistency. The drug polymer 
dispersion or solution was made to weight with purified water. The aqueous drug 
polymer hypromellose solution/dispersion was transferred to a clear glass bottle 
ready for use or stored at ambient temperature.  
3.2.2 Preparation of HPC drug solutions/dispersions 
Drug polymer solutions or dispersions using hypromellose were prepared using a 
similar method to that described in Section 3.1.2 above. The HPC was dissolved in 
half of the required quantity of water. After solubilising the HPC in half of the 
required quantity of purified water the paracetamol or ranitidine powder was 
added (at ambient temperature) to the remaining quantity required of purified 
water and dispersed or dissolved using the magnetic stirrer (IKA, Germany). After 
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dispersing the paracetamol or ranitidine, the dispersion or solution was added to 
the HPC solution and mixed using a high shear Silverson mixer L4RT (Silverson, UK) 
at 1800 rpm (1600 to 2000 rpm) with homogeniser head fitted. Care was taken to 
avoid excessive entrapment of air during homogenisation. The dispersion was 
homogenised until a clear solution or a smooth, lump-free homogeneous dispersion 
(for higher concentrations of paracetamol) formed. A stainless steel spatula was 
used to examine the dispersion for lumps and consistency. The drug polymer 
solution/dispersion was made to weight with purified water. The aqueous drug 
polymer HPC solution/dispersion was transferred to a clear glass bottle ready for 
use or stored at ambient temperature.  
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4 FEASIBILITY OF SPRAY-DRYING AQUEOUS 
HYPROMELLOSE SOLUTIONS 
4.1 Introduction  
As discussed in Chapter 1, the use of excipients, particularly in paediatric patients 
should be minimised. The draft EMA guideline ‘'Guideline on pharmaceutical 
development of medicines for paediatric use' (EMA 2013) requires the use of 
excipients in pediatric patients to be justified and minimized to avoid safety 
concerns that may be associated with the excipient. Reducing the level of excipients 
will also help minimize the size of the dosage form which is particularly important 
for oral solid dosage forms.  
Chapter 5 of this investigation considers the potential to co-process an drug 
substance (paracetamol), with a hydrophilic polymer (hypromellose) by spray-
drying to investigate if the co-processed material offers advantages over a binary 
mix of the two materials. This Chapter considers the feasibility of spray-drying 
aqueous solutions of hypromellose before considering the addition of the drug 
substance as discussed in Chapter 5. 
As described by Paudel et al (2012), hypromellose is commonly used to stabilise 
suspensions for spray-drying but very little work has been conducted to investigate 
the aqueous spray-drying of hypromellose to produce spray-dried hypromellose 
powder. Alanazi et al (2006) described a solvent spray-drying technique using 
indomethacin and hypromellose. The applicability of the processing parameters 
determined will be considered here, for an aqueous based system. 
Within this Chapter the preparation of polymer solutions; the influence of 
temperature on polymer solution viscosity, the development of a suitable spray-
drying process and the comparison of spray-dried and non spray-dried materials are 
considered. 
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4.2 Materials and Methods 
The following hypromellose, Methocel® grades were used for this investigation:  
•  E5LV  Premium 
•  E15LV Premium 
•  E50LV Premium 
Details associated with these polymer grades may be found in Chapter 1. In this 
investigation a range of aqueous polymer concentrations (5 %w/w to 30 %w/w) 
were considered. Table 4.1 shows the polymer solutions considered in this Chapter 
and the respective formula of each solution based on polymer concentration is 
provided in Table 4.2. 
Table 4.1 Aqueous hypromellose solutions considered 
Polymer Grade 
Polymer Concentration 
(%w/w) 
Methocel® E5LV 
5 
20 
30 
Methocel® E15LV 
5 
30 
Methocel® E50LV 
5 
30 
 
Table 4.2  Quantitative composition of aqueous hypromellose solutions (per 
500g of solution) 
 Polymer Concentration 
5 %w/w 10 %w/w 20 %w/w 30 %w/w 
Excipient 
Content 
(% w/w) 
Quantity 
(g) 
Content 
(% w/w) 
Quantity 
(g)  
Content 
(% w/w) 
Quantity 
(g) 
Content 
(% w/w) 
Quantity 
(g) 
Polymer 5.0 25.0 10.0 50.0 20.0 100.0 30.0 150.0 
Purified 
Water 
95.0 475.0 90.0 450.0 80.0 400.0 70.0 350.0 
Total 100.0 500.0 100.0 500.0 100.0 500.0 100.0 500.0 
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4.2.1 Preparation of aqueous hypromellose solutions  
Details of the method used to prepare the aqueous hypromellose solutions are 
provided in Section 3.1.1.  
4.2.2 Physical appearance of aqueous hypromellose solutions 
Once prepared, the solutions were examined to determine their flow properties by 
gently stirring the sample using a spatula to determine how easily the solution could 
be agitated. If the solution was difficult to stir using the spatula, i.e. ‘gel-like’, it was 
considered to have poor flow and therefore would not be initially considered for 
spray-drying. High viscosity polymer solutions would only be considered for spray-
drying if similar low viscosity solutions could be successfully spray-dried or if an 
increase in temperature of the polymer solutions reduced polymer solution 
viscosity.  
The flow of the solution determined by stirring using a spatula was described as 
follows: 
 ‘Good’ – the solution could be easily agitated/stirred using a spatula. 
 ‘Fair’ – the solution could be agitated but the surface of the solution took 
slightly longer to settle following agitation. 
 ‘Poor’ – it was very difficult to agitate/stir the solution. 
4.2.3 Viscosity determination of aqueous hypromellose solutions 
The theoretical aspects associated with the measurement of viscosity are described 
in Section 2.2.1. 
The viscosity of a spray-drying solution is critical to the spray-drying process. High 
viscosity solutions may be difficult to transfer to the atomising nozzle and 
consequently spray rates may be very slow, ultimately affecting the spray-dried 
material produced (Maltesen et al 2008).  
The viscosities of those solutions shown in Table 4.1 were measured to assess their 
suitability for spray-drying. Based on visual observations highly viscous solutions 
were not considered for spray-drying. Solutions which formed a gel were eliminated 
50 
from further investigation as these were considered unsuitable for spray-drying. 
Solutions which did not form a gel were considered for spray-drying. For the 
purposes of this work a gel is defined as a solution of hypromellose which forms a 
semi-solid.  
The viscosity of each solution selected for spray-drying was determined using a 
RVDT I Viscometer (Brookfield, UK). Spindle speed and spindle number were 
selected as appropriate (refer to Table 4.5). 650mL of polymer solution measured 
using an 800mL measuring cylinder, was used per viscosity determination in a 1L 
beaker. Viscosity was initially determined at ambient temperature with the 
viscometer guard leg in place to aid reproducible location of the spindle in the test 
solution for each test conducted and to ensure that the spindle height was 
reproducible between samples. The viscosity reading in % torque was recorded 
every minute for 5 minutes, timed using a calibrated stop watch, and the mean 
viscosity in centipoises over 5 minutes was calculated after applying the appropriate 
‘viscosity factor’ according to Brookfield literature (Brookfield 2005).  
The impact of temperature on viscosity was also determined. A 2L glass beaker was 
filled with 500 mL of purified water and heated to the target temperature using an 
IKA magnetic stirrer/hotplate (IKA, Germany). The test temperature was controlled 
to ± 5°C during testing using a IKA calibrated thermostat temperature probe (IKA, 
Germany). The test solution was placed in a 1 L beaker and the beaker suspended in 
the heated water using a clamp during viscosity testing. This method prevented 
significant and localised heating of the test solution caused by the hot plate. 
Viscosity was determined at ambient temperature, 40°C (± 5 °C) and 60°C (± 5 °C). 
Once the test solution had reached the required temperature the viscosity was 
determined every minute for five mins. Viscosity of each solution was measured in 
duplicate and the mean of ten viscosity measurements was determined. 
4.2.4 Spray-drying of aqueous hypromellose solutions 
Spray-drying was used to investigate the influence of co-processing the cellulosic 
polymer, hypromellose with the drug substance paracetamol. 
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4.2.4.1 Process overview 
Spray-drying is a processing technique which dates back to the 19th century and is 
used today in a number of industries including the food and pharmaceutical 
industry. Typical spray-dried products are dry milk powder, detergents, and dyes. 
Spray-drying can also be used to preserve food (Masters 1991). Within the 
pharmaceutical industry, the technique may be used to co-process two or more 
materials to optimise their combined functionality, to change the physical 
properties of a powder to improve flow or change the particle size to improve 
bioavailability (Okuyama et al 2006, Alanazi et al 2006). 
The basic principle of the technique is to remove the solvent from a liquid feed e.g. 
suspension, solution, dispersion or emulsion by spraying the feed into a hot drying 
medium. The dried product usually takes the form of powder or granules and its 
properties may be controlled by the processing parameters used (Shabde 2006).  
 
 
Figure 4.1   Principle components of a spray-drying process (after: Aghbashlo et 
 al 2012). 
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Spray-drying involves evaporation of moisture from an atomised feed by mixing the 
spray and the drying medium. Typically, the drying medium is air. Drying continues 
until the desired moisture content of the particles is reached and they are then 
separated from the air (Aghbashlo et al 2012).   
A spray-drying process typically consists of four sequential processes: 
1. Atomisation of the liquid feed, 
2. The mixing of the atomised liquid feed with the drying air resulting in 
 heating and subsequent mass transfer, 
3. The constant flow of heated air through the system, and 
4. The drying of the spray and the separation of the product from the air 
A typical fluid bed drier comprises a feed system which is used to transfer the liquid 
product into the drying chamber via an atomising nozzle (Figure 4.1). A heater heats 
the intake air and passes it into the drying chamber where the product is dried. A 
cyclone separates the product from the air flow and the spray-dried material is 
captured in a container. The air may then be recycled or exhausted depending upon 
the design of the spray drier. A temperature sensor at the inlet and outlet is used to 
maintain the drying conditions (Shabde 2006, Maltesen et al 2008).   
The critical process parameters associated with spray-drying are a) the solids 
content of the solution (or liquid feed), b) the feed rate, c) the air volume, d) the 
atomising air pressure, and e) the inlet temperature. The humidity of the inlet air is 
also critical but may not be able to be controlled (Tewa-Tagne et al 2007, Vehring 
2007). 
These process parameters interact to affect the process and/or physical properties 
of the spray-dried material. For example, an increase in solids content of the spray 
solution could result in an increase in particle size of the spray-dried material and 
also increase the rate of production of spray-dried material. Feed rate also 
influences the rate of production but it also influences particle size; a faster feed 
rate usually results in smaller particles (Cal and Solluhub 2010). As the feed rate 
becomes faster, more energy is required to dry the particles and consequently the 
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outlet temperature decreases and the residual moisture content increases 
(Maltesen et al 2008). 
The inlet temperature is generally regarded as that of the heated drying air (Paudel 
et al 2013). The moisture gradient between the wet surface of the atomised droplet 
and the dry air leads to evaporation at temperatures that may be below the boiling 
point of water (Vehrsing 2007). The outlet temperature is generally regarded as the 
temperature of the air with the solid particles just prior to the cyclone (Paudel et al 
2013). The outlet temperature in most cases is likely to be the maximum product 
temperature due to the heat, mass transfer and low humidity at this particular 
stage of the spray-drying process. A minimal temperature difference between inlet 
and outlet temperature results in a very small quantity of residual moisture in the 
spray-dried material. An increase in this temperature difference increases the 
residual moisture content of the spray-dried material (Vehrsing 2007).  
The air volume used during spray-drying determines the amount of energy available 
for vaporisation and as a consequence has a significant effect on the drying process 
(Cal and Sollohub 2010). A high air volume results in a high degree of separation in 
the cyclone improving yield,  whilst a low air volume results in the spray-dried 
material having a low residual moisture content which may influence the physical 
properties of the spray-dried material (Billon et al 2000).  
4.2.4.2 Development of a spray-drying process for aqueous solutions of 
 hypromellose 
Aqueous solutions of hypromellose E5LV and E50LV were spray-dried using a 
Labplant SD-05 Spray Drier (Labplant UK) using the process parameters given in 
Table 4.3, fitted with a 0.5 mm spray nozzle. Similar parameters were previously 
used by Alanazi et al (2006) who attempted to spray dry hypromellose and were 
applied to this investigation. Each solution (1000 mL) was spray-dried.  
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Table 4.3  Spray-drying process parameters used 
Process Parameter Setting 
Product 
temperature 
Ambient ( °C) 
Air Flow Rate  50 m3/hrs 
Inlet temperature 160 °C 
Pump rate 7 mL/min (max) 
Exhaust 
Temperature  
90°C to 110 °C 
Nozzle  0.5 mm 
Atomising air 1 bar 
 
Figure 4.1 demonstrates aspects of the spray-drying process that these parameters 
refer to. The ‘Product Temperature’ is the temperature of the hypromellose 
solution immediately prior to spray-drying; ‘Air Flow Rate’ is the set point for the 
drying air volume; ‘Inlet temperature’ is the temperature of the drying air; ‘Pump 
rate’ is the spray rate at which the hypromellose solution is provided to the 
atomiser; ‘Exhaust Temperature’ is the temperature range of the air leaving the 
spraying chamber and is controlled by modifying the inlet temperature or air flow 
rate; the ‘nozzle’ is the diameter of the spray nozzle used; and the ‘atomising air’ is 
the pressure used to generate atomisation of the hypromellose solution.  
Spray-dried hypromellose was obtained from the collection vessel and 
characterised as described in section 4.2.4. 
4.2.5 Characterisation of spray-dried hypromellose 
Spray-dried hypromellose was characterised using SEM and compared with non 
spray-dried hypromellose. The viscosity of polymer solutions prepared using spray-
dried and non spray-dried hypromellose was also compared to determine if the 
functional attributes of the hypromellose had been affected by the spray-drying 
process.  
4.2.5.1 Physical appearance by Scanning Electron Microscopy 
Scanning Electron Microscopy (SEM) at x50, x100, x500, x1000 and x2000 
magnification using a Philips XL30 SEM (Philips, Netherlands) was used to compare 
the physical appearance of spray-dried hypromellose and non spray-dried 
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hypromellose. Samples of non spray-dried and spray-dried hypromellose powder 
were applied by brush to an adhesive carbon disk on a specimen stub. Excess 
powder was removed by a compressed air jet. The samples were sputter-coated 
with platinum for 45s (Agar Scientific Coater US), then imaged. 
The particle size and shape of spray-dried and non spray-dried material were 
compared at each magnification.  
4.2.5.2 Viscosity testing 
Aqueous polymer solutions of spray-dried and non spray-dried hypromellose were 
prepared as described in Section 3.2.1. Aqueous solutions of polymer 
concentrations of 0.5 %w/w and 5 %w/w concentrations were prepared. The 
viscosities of these solutions were measured as described in Section 3.2.3 and 
compared to determine if there was any change in functionality between spray-
dried and non spray-dried polymer. The effect of temperature on viscosity was also 
considered by measuring viscosity at ambient, 40°C (± 5 °C) and 60°C (± 5 °C).  
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4.3 Results and Discussion 
4.3.1 Preparation and physical appearance of aqueous hypromellose 
solutions 
Table 4.4 shows a description of flow for each hypromellose solution. These 
polymer solutions were deselected based on the potential for the feed rate during 
spray-drying to be restricted by the viscosity of the solution and hence the 
appearance of the spray-dried material produced to be directly associated with the 
polymer solution viscosity.  
Table 4.4  Assessment of spray-drying solution suitability based on polymer 
  grades and polymer concentrations 
Polymer 
Grade 
Polymer 
Concentration 
(%w/w) 
Observations 
Methocel® 
E5LV 
5 
Solution has good flow so was considered 
for spray-drying. 
20 
Very viscous but solution has fair flow so 
was considered for spray-drying. 
30 
Very viscous. Solution has poor flow so 
was not considered for spray-drying. 
Methocel® 
E15LV 
5 
Solution has fair flow and was considered 
for spray-drying. 
30 
Very viscous. Solution has poor flow so 
was not considered for spray-drying. 
Methocel® 
E50LV 
5 
Solution has fair flow and was considered 
for spray-drying. 
30 
Very viscous. Solution has poor flow so 
was not considered for spray-drying. 
Methocel® 
K100LV  
10 
Very viscous. Solution has poor flow so 
was not considered for spray-drying. 
 
Note 
Shading indicates which of the polymers were considered unsuitable for spray-drying in this 
investigation.  
Aqueous solutions containing polymer concentrations of 30 %w/w hypromellose 
were very viscous for all polymer grades selected. These solutions could only be 
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considered for spray-drying if their viscosity could be reduced by increasing the 
temperature of the solution.   
This initial visual assessment to determine flow, indicated that polymer loading was 
critical to the feasibility of spray-drying hypromellose solutions. Furthermore, it also 
indicated that only low molecular weight grades of hypromellose could be 
considered for spray-drying at an appropriate concentration (>5 %w/w). 
 
4.3.2 Viscosity determination of aqueous hypromellose solutions 
Viscosity data were obtained for those formulations considered suitable for spray-
drying 
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Table 4.5 – Viscosity method parameters and mean viscosity data 
 
Note: 
Mean values are determined from 5 viscosity readings for each test condition. 
Polymer Grade and 
Concentration 
Product Temperature 
5 % HPMC E5LV 25 °C 40 °C 60 °C 
Sample A 
Mean Viscosity (cP)  66.0 49.6 75.0 
Standard Deviation (±) 0.0 0.5 2.1 
Sample B 
Mean Viscosity (cP) 67.0 50.0 75.0 
Standard Deviation (±) 0.0 0.0 0.0 
Method Details 
 
Spindle Number 1 1 1 
Speed 100rpm 100rpm 100rpm 
20 % HPMC E5LV 25 °C 40 °C 60 °C 
Sample A 
Mean Viscosity (cP) 187.1 135.0 1297.0 
Standard Deviation (±) 1.4 4.3 120.3 
Sample B 
Mean Viscosity (cP) 188.3 136.6 1204.4 
Standard Deviation (±) 1.0 1.2 56.8 
Method Details 
 Spindle Number 2 2 2 
Speed 10rpm 100rpm 2.5rpm 
5 % HPMC E15LV 25 °C 40 °C 60 °C 
Sample A 
Mean Viscosity (cP) 221.2 118.6 263.4 
Standard Deviation (±) 6.4 1.0 8.0 
Sample B 
Mean Viscosity (cP) 224.0 117.6 257.2 
Standard Deviation (±) 3.6 1.5 1.6 
Method Details 
 Spindle Number 1 1 1 
Speed 20rpm 20rpm 20rpm 
5 % HPMC E50LV 25 °C 40 °C 60 °C 
Sample A 
Mean Viscosity (cP) 892.8 433.6 679.2 
Standard Deviation (±) 1.6 6.1 22.6 
Sample B 
Mean Viscosity (cP) 888.8 435.2 680.4 
Standard Deviation (±) 1.6 2.0 17.5 
Method Details 
 Spindle Number 1 1 1 
Speed 5rpm 5rpm 5rpm 
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As described in Section 4.2.2, viscosity of polymer solution was determined at 
ambient temperature, 40°C and 60 °C. If temperature could be used as a potential 
means to reduce the viscosity of the hypromellose solutions, spray-drying solutions 
could be held at an appropriate temperature during spray-drying using a water bath 
or jacketed vessel with thermostat control to enable the spray-drying of solutions 
either having higher polymer concentration or containing higher molecular weight 
polymer.  
The viscosity data and viscosity method parameters used are shown in Table 4.5. 
The viscosity data are illustrated in Figures 4.2a, 4.2b, 4.2c and 4.2d. 
It was noted during the viscosity testing that at 60°C all hypromellose solutions 
tested became cloudy. This is due to the cloudpoint of the hypromellose being 
reached as described by Sarker (1979). Sarker described the cloudpoint as the 
temperature at which the hypromellose polymer molecules precipitate out of 
solution. Cloud point is the temperature at which the light transmission of a gel is 
reduced by 50 % of the initial value. Cloudpoint is often referred to as the lowest 
temperature at which turbidity of solution first occurs (Klug 1971, Fagan et al 1989). 
Figures 4.2a, 4.2b, 4.2c and 4.2d show the mean viscosity measurements (n=5) 
determined for solutions containing 5 % w/w E5, E15 or E50LV and 20 %w/w E5LV 
at ambient, 40°C and 60°C (Data for ‘Solution A’ is plotted. Data for ‘Solution B’ 
follows similar trends as shown in table 4.5). 
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The viscosity data show that hypromellose solution viscosity reduced at 40°C but 
increased at 60 °C. For both the E5 and E15 hypromellose the viscosity at 60°C was 
greater than that at 25 °C. This effect was most pronounced for 20 % w/w E5 LV 
solutions. At 60°C this solution was observed to completely gel during viscosity 
testing. The viscosity of 5 %w/w E50LV at 60°C did not exceed the viscosity of the 
same solution at ambient temperature. This temperature effect on viscosity is 
associated with the gelation temperature (Sarker 1979) and the concentration of E 
grade hypromellose polymers. As the temperature begins to increase the polymer 
molecules are dehydrated thus reducing viscosity before, at higher temperatures 
(the gelation temperature), continued dehydration enables greater polymer-
polymer interaction to take place, thus increasing viscosity (Sarker 1979). This effect 
is more significant at higher polymer concentrations due to the potential for greater 
polymer-polymer interaction. The relatively high molecular weight of the E50LV 
polymer probably prevented similar entanglement as observed for E5 and E15 
polymer solutions at 60°C and therefore the viscosity at this temperature did not 
exceed the viscosity measured at ambient temperature.   
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4.3.3 Spray-drying of aqueous hypromellose solutions 
4.3.3.1 Development of a spray-drying process for aqueous solutions of 
hypromellose 
A solution of 5 % w/w hypromellose E5LV solution was spray-dried according to the 
conditions described in Section 4.2.4. 200mL of the hypromellose solution was 
spray-dried in 30 min and 7.68 g of spray-dried hypromellose was yielded from the 
spray-drying process. This equated to a yield of 76.8 %. 
Alanazi et al (2006) described a spray-drying process for hypromellose with 
indomethacin. The hypromellose was solubilised in purified water as described here 
but the indomethacin was solubilised in ethanol. The ethanolic solution of 
indomethacin was added to the aqueous hypromellose solution prior to spray-
drying. Alanazi et al (2006) was able to achieve a flow rate of 16 mL/min. In this 
investigation a maximum flow rate of 7 mL/min could be achieved. Based on 
observations in this study the spray rate was limited due to the viscosity of the 
hypromellose solution. The ethanolic solution used by Alanazi et al (2006) may have 
been less viscous due to the hydration of the hypromellose being retarded by the 
use of ethanol (Roberts et al 2007) upon mixing the ethanolic solution of 
indomethacin with the aqueous solution of hypromellose. The presence of ethanol 
may have caused dehydration of the hypromellose in aqueous solution reducing the 
solution viscosity. 
However, the spray rate used in this investigation achieved a similar target exhaust 
temperature to that achieved by Alanazi of 90 to 110°C but also an excellent 
process yield of 76.8 %. Billon et al (2000) achieved an optimised spray-drying yield 
of approximately 80 %w/w using paracetamol following experimental design 
indicating that a yield of 76.8 % is acceptable.  
Spray solution viscosity is critical to the spray-drying process. If the spray solution 
viscosity is too high, the spray rate will be impacted and ultimately the spray-drying 
process will be rate limited by the solution viscosity. Consequently, as polymer 
concentration and polymer molecular weight both directly impact solution viscosity 
only low concentrations of low molecular weight polymers may be considered for 
aqueous spray-drying. 
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The viscosity of aqueous hypromellose solutions limits the solids content if spray-
drying solutions and also restricts the molecular weight of the hypromellose that 
may be selected for spray-drying. Only low molecular weight hypromellose grades 
at concentrations of 5 %w/w are feasible due to the viscosity of the aqueous 
solutions formed. This constraint will limit the applicability of spray-drying 
hypromellose. 
It may be possible to use temperature to reduce the viscosity of hypromellose 
solutions. However, due to the non-linear impact of temperature on viscosity; very 
careful temperature control would be required to avoid excessively dehydrating the 
polymer and consequently significantly increasing viscosity of the polymer solution. 
A greater understanding of polymer viscosity at temperatures close to the polymer 
cloud point is required to determine the optimum temperature for spray-drying by 
reducing the polymer viscosity to enable transfer from a source to the spray nozzle 
by transfer tubing. This approach may also enable higher molecular weight 
polymers or higher polymer concentrations to be considered but would require 
significant modifications to standard spray dryer units. For example, the entire 
transfer tube from a heated source to the spray nozzle prior to atomisation, would 
require insulation and precise temperature control. This may be feasible using 
temperature control based on re-circulating hot and cold water. 
An alternative method to incorporate an drug substance in the polymer solution is 
to use a solvent such as ethanol as used by Alanazi et al (2006). The use of a solvent 
system, however, may pose challenges for commercial manufacturability over 
aqueous spray-drying due to the need to dispose or clean the solvent waste. 
4.3.3.2 Characterisation of spray-dried hypromellose 
4.3.3.2.1 Physical appearance by Scanning Electron Microscopy 
The SEM images associated with the spray-dried material showed a significant 
change in physical appearance of the spray-dried hypromellose compared with non 
spray-dried hypromellose (Figures 4.4 to 4.12). Based on the SEM images, the mean 
particle size of the spray-dried material was estimated as 20 µm whilst the mean 
particle size of the non spray-dried material was estimated as 200 µm. In addition, 
as can be seen in Figure 4.8, the spray-dried material was uniform in shape and size 
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and spherical whilst Figure 4.4 shows the non spray-dried material was long and 
thin. Figures 4.3 and 4.4 show the non spray-dried material to be non uniform in 
terms of shape and size whilst Figures 4.8 and 4.9 show the spray-dried material to 
be far more uniform. Figures 4.13, 4.14 and 4.15 show that some of the spherical 
spray-dried particles appear to have collapsed. This is likely to be due to the vacuum 
applied during SEM analysis. This indicates that the particles may be hollow.  
 
 
Figure 4.3   SEM of E5LV Non Spray-dried Hypromellose Powder (Scale bar  
  indicates 500µm) 
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Figure 4.4   SEM of E5LV Non Spray-dried Hypromellose Powder (Scale bar 
 indicates 200µm) 
 
Figure 4.5   SEM of E5LV Non Spray-dried Hypromellose Powder (Scale bar 
 indicates 50µm) 
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Figure 4.6   SEM of E5LV Non Spray-dried Hypromellose Powder (Scale bar 
 indicates 20µm) 
 
 
Figure 4.7   SEM of E5LV Non Spray-dried Hypromellose Powder (Scale bar 
 indicates 10µm) 
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Figure 4.8   SEM of E5LV Spray-dried Hypromellose Powder (Scale bar indicates 
 500µm) 
 
 
Figure 4.9  SEM of E5LV Spray-dried Hypromellose Powder (Scale bar indicates 
 200µm) 
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Figure 4.10   SEM of E5LV Spray-dried Hypromellose Powder (Scale bar indicates 
 50µm) 
 
 
Figure 4.11  SEM of E5LV Spray-dried Hypromellose Powder (Scale bar indicates 
 20µm) 
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Figure 4.12  SEM of E5LV Spray-dried Hypromellose Powder (Scale bar indicates 
 10µm) 
4.3.3.2.2 Viscosity testing 
Spray-dried and non-spray-dried hypromellose E5LV was used to prepare 0.5 % and 
5 % w/w solutions and their viscosities determined. Upon preparing the solution, 
the spray-dried material was very difficult to ‘wet’ and had increased cohesion 
properties compared with non spray-dried hypromellose. The fine particle size of 
the spray-dried hypromellose was highly cohesive and difficult to disperse in the 
purified water. However, once dispersed using a Silverson mixer, the spray-dried 
material performed similar to the non spray-dried material. Table 4.6 shows the 
viscosity data and viscosity method parameters used. 
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Table 4.6  Viscosity method parameters and mean viscosity data of polymer 
solutions prepared using non spray-dried and non spray-dried 
hypromellose 
 
Note: 
Mean values are determined from 5 viscosity readings for each test condition. 
Polymer Grade and 
Concentration 
Product Temperature 
5 % HPMC E5LV 25 °C 40 °C 60 °C 
Sample A 
Mean Viscosity (cP)  66.0 49.6 75.0 
Standard Deviation (±) 0.0 0.5 2.1 
Sample B 
Mean Viscosity (cP) 67.0 50.0 75.0 
Standard Deviation (±) 0.0 0.0 0.0 
Method Details 
 
Spindle Number 1 1 1 
Speed 100rpm 100rpm 100rpm 
Spray Dried 5 % HPMC E5LV 25 °C 40 °C 60 °C 
Sample A 
Mean Viscosity (cP) 66.0 50.8 73.4 
Standard Deviation (±) 0.0 1.6 0.9 
Sample B 
Mean Viscosity (cP) 66.0 50.8 72.8 
Standard Deviation (±) 0.0 1.1 0.8 
Method Details 
 Spindle Number 1 1 1 
Speed 100rpm 100rpm 100rpm 
0.5 % HPMC E5LV 25 °C 40 °C 60 °C 
Sample A 
Mean Viscosity (cP) 14.8 13.5 12.0 
Standard Deviation (±) 0.2 0.7 0.0 
Sample B 
Mean Viscosity (cP) 15.5 14.3 12.0 
Standard Deviation (±) 0.4 0.4 0.0 
Method Details 
 Spindle Number 1 1 1 
Speed 100rpm 100rpm 100rpm 
Spray Dried 0.5 % HPMC 
E5LV 
25 °C 40 °C 60 °C 
Sample A 
Mean Viscosity (cP) 14.8 11.9 11.8 
Standard Deviation (±) 0.2 0.2 0.2 
Sample B 
Mean Viscosity (cP) 14.8 11.8 11.7 
Standard Deviation (±) 0.2 0.2 0.1 
Method Details 
 Spindle Number 1 1 1 
Speed 100rpm 100rpm 100rpm 
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Table 4.6 shows that spray-dried and non spray-dried E5 LV hypromellose solutions 
have similar viscosities at 0.5 % w/w and 5 % w/w polymer concentration 
demonstrating the functionality of polymer is not impacted by the spray-drying 
process. However, the viscosity data also show that the 0.5 % w/w polymer solution 
behaves differently to the 5 % w/w polymer solution at increased temperature. The 
data demonstrate that 0.5 % w/w polymer solution does not exhibit a gelation 
temperature. This may be due to minimal polymer-polymer interaction at this 
concentration and the sensitivity of the viscosity method employed being 
insufficient to determine any change in viscosity caused by polymer dehydration 
and polymer-polymer interaction as previously described in Section 4.3.1.  
Spray-drying hypromellose significantly changed the physical shape of the 
hypromellose but did not alter its functionality. The viscosities of solutions 
containing similar concentrations of spray-dried and non spray-dried materials were 
similar. 
Based on the viscosity data obtained for spray-dried and non spray-dried 
hypromellose, spray-drying does not appear to improve the overall function of the 
polymer. By drastically changing the physical appearance of the polymer powder 
however, the reduced particle size and spherical shape associated with the spray-
dried material may offer some advantages. For example, a reduced particle size is 
likely to increase the rate of hydration of the polymer which may offer advantages 
to modified release matrices by improving the formation of the controlling gel layer.  
The spherical shape of the spray-dried hypromellose is likely to have an increased 
surface area than the non-spray-dried material. This may offer advantages for 
modified release matrix tablets as more uniform gel layers may be possible to form. 
In addition the spherical particles are likely to hydrate more quickly than the non 
spray-dried material due to the increased surface area. The spherical particles may 
also offer improved tabletting properties in terms of compression and flow. The 
physical appearance of the spray-dried hypromellose is distinctly different to that of 
non spray-dried hypromellose and the potential benefits of spray-dried 
hypromellose could be further explored.   
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4.4 Conclusion 
Only low molecular weight hypromellose grades at concentrations of 5 %w/w are 
feasible due to the viscosity of the aqueous solutions formed. This constraint limits 
the applicability of spray-drying aqueous solutions of hypromellose. 
It may be possible to use temperature to reduce the viscosity of hypromellose 
solutions. A greater understanding of polymer viscosity at temperatures close to the 
polymer cloud point is required to determine the optimum temperature for spray-
drying by reducing the polymer viscosity to enable transfer from a source to the 
spray nozzle by transfer tubing.  
Spray-drying significantly changed the physical structure of hypromellose powder. 
The physical appearance of the spray-dried hypromellose is distinctly different to 
that of non spray-dried hypromellose and the potential benefits of spray-dried 
hypromellose could be further explored.   
A suitable spray-drying process for an aqueous solution of 5 % hypromellose E5LV 
has been developed. The potential to spray-dry an aqueous solution of 
hypromellose to optimise the physical properties of the material without 
compromising its ability to hydrate and swell, could offer significant advantages in 
the manufacture pharmaceutical products.  
Spray-drying will be used to investigate the potential to co-process paracetamol 
with hypromellose E5LV by spray-drying in Chapter 5, to determine if the 
functionality of the hypromellose may be enhanced by preparing a polymer:drug 
particle. 
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5 PREPARATION AND VISCOSITY DETERMINATION OF 
AQUEOUS HYPROMELLOSE DISPERSIONS CONTAINING 
PARACETAMOL 
5.1 Introduction 
It was determined in Chapter 4 that it is possible to spray dry aqueous solutions of 
hypromellose but that polymer solution viscosity restricts the grade and 
concentration of polymer that may be spray-dried. As previously discussed in 
Chapter 1 the potential to co-process polymer and drug substance may present 
significant advantages for dosage form design. 
Based on the findings in Chapter 4, prior to assessing the feasibility of spray-drying 
aqueous hypromellose solutions containing paracetamol, the impact of 
paracetamol on the viscosity of hypromellose solutions was investigated. Within 
this Chapter the preparation of polymer solutions containing paracetamol and the 
influence of temperature on polymer solution viscosity are considered.  
A 5 % w/w hypromellose E5LV solution was successfully spray-dried (see Chapter 4) 
and for process efficiency, a target minimum solid concentration of 20 %w/w is 
desired (Billon 2000). A spray-drying dispersion containing 5 % w/w hypromellose 
E5LV and 15 % w/w paracetamol was therefore considered for this investigation. 
 
5.2 Materials and Methods 
5.2.1  Preparation of aqueous hypromellose dispersions containing 
 paracetamol 
A dispersion containing 5 %w/w hypromellose E5LV and 15 %w/w paracetamol (to 
be known as ‘drug-polymer dispersion’ from here on in this chapter) was prepared 
as described in Section 3.2.1. Table 5.1 shows the formulation that was prepared.  
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Table 5.1 Quantitative composition of drug-polymer dispersion (per 500g of 
dispersion) 
 Formulation 
Excipient Content ( % w/w) 
Quantity (g) per 500g 
Solution 
Hypromellose E5LV 5.0 25.0 
Paracetamol 15.0 75.0 
Purified Water 80.0 400.0 
Total 100.0 % 500.0g 
 
5.2.2 Physical appearance of aqueous hypromellose dispersions 
 containing paracetamol 
Once prepared, the drug-polymer dispersion was examined to determine its flow 
properties by gently stirring the sample using a spatula to determine how easy the 
solution could be agitated as described in Section 4.2.1. The appearance of the 
dispersion was recorded. 
5.2.3  Viscosity determination of aqueous hypromellose dispersions 
 containing paracetamol 
The viscosity of the drug polymer dispersion was determined at ambient 
temperature and at 40°C and 60°C according to the viscosity method described in 
Section 4.2.2.  
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5.3 Results and Discussion 
5.3.1 Preparation and physical appearance of aqueous hypromellose 
 dispersions containing paracetamol 
A smooth, white paracetamol dispersion which was free of lumps was produced and 
combined with a clear hypromellose solution. After adding the paracetamol 
dispersion to the hypromellose solution and subsequent mixing, a smooth white 
dispersion was produced. 
5.3.2  Viscosity determination of aqueous hypromellose dispersions 
 containing paracetamol 
Table 5.2 shows viscosity data obtained for the dispersion containing 5 % 
hypromellose E5LV and 15 %w/w paracetamol.  
Table 5.2   Viscosity method parameters and mean viscosity data for 5 %w/w 
HPMC E5LV containing 15 %w/w paracetamol at 25°C and 40 °C. 
 
The drug-polymer dispersion has a greater viscosity at ambient temperature than 
the 5 % hypromellose E5LV solution prepared in Chapter 4 (103 cP versus 66 cP 
respectively, refer to Tables 5.2 and 4.4). During viscosity testing it was noted that 
at 40°C the dispersion began to flocculate and sediment resulting in the viscosity 
readings obtained over 5 mins showing a decrease in viscosity. Large standard 
deviations are calculated for these samples. At 60 °C, the dispersion flocculated and 
Polymer Grade and 
Concentration 
Product Temperature 
5 % HPMC E5LV 25 °C 40 °C 
Sample A 
Mean Viscosity (cP)  103.0 166.2 
Standard Deviation (±) 0.0 19.8 
Sample B 
Mean Viscosity (cP) 105.0 167.1 
Standard Deviation (±) 0.0 24.9 
Method Details 
 
Spindle Number 1 1 
Speed 20rpm 20rpm 
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then caked. The cake could not be resuspended by agitation. The viscosity at 60°C 
was consequently not determined as the dispersion was not uniform.  
The inclusion of 15 %w/w paracetamol in the 5 %w/w hypromellose E5LV solution 
increased the viscosity at ambient temperature. The increase in viscosity is likely to 
be due to the presence of dispersed undissolved paracetamol forming physical 
bridges with each other and the hydrated hypromellose molecules. 
The viscosity of the drug-polymer dispersion was higher at 40°C than at 25°C prior 
to the dispersion eventually flocculating. The viscosity data obtained show that at 
40°C the dispersion was non-homogeneous as the viscosity decreased over the 5 
minutes testing period. As the paracetamol flocculated, the dispersion became non-
homogeneous, and consequently, the composition of the dispersion in the micro 
environment around the viscometer spindle is continually changing and hence 
reducing viscosity data recorded. As described in Chapter 4, the viscosity of the 5 
%w/w hypromellose E5LV solution without paracetamol decreased at 40°C and the 
solution remained clear (refer to Table 5.4). As the temperature was increased to 
60°C the viscosity increased, indicating that the gelation temperature was reached 
between 40°C and 60 °C. The viscosity of 5 %w/w hypromellose E5LV solutions 
containing paracetamol increased between 25°C and 40°C suggesting that the 
gelation temperature was reached at a temperature <40 °C. This may be due to the 
dispersed paracetamol providing opportunity for polymer-paracetamol interaction 
in addition to typical polymer-polymer interaction as dehydration occurs at 
increasing temperature (Mitchel et al 1990). The gelation temperature of a 
dispersion containing 5 %w/w E5LV hypromellose and 15 %w/w paracetamol is 
between ambient temperature and 40 °C. The gelation temperature of an aqueous 
solution containing 5 %w/w E5LV hypromellose is between 40°C and 60 °C.  
It was not possible to assess the effect of paracetamol on the cloudpoint of the 
hypromellose in the drug-polymer dispersion by visual assessment, as the drug-
dispersion was white in appearance. As discussed in Chapter 4, the cloudpoint may 
be described as the temperature at which the hypromellose polymer molecules 
precipitate out of solution (Sarker 1979). Paracetamol may also reduce the 
cloudpoint of the hypromellose solution and hence the precipitation of the 
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hypromellose molecules may have caused flocculation of the dispersed paracetamol 
as observed at 40 °C. 
Hypromellose solutions containing dispersed drug particles have a reduced 
cloudpoint and gelation temperature (Mitchell et al 1990). This results in 
flocculation of the drug particles and physical instability of the drug-polymer 
dispersion when heated above 40 °C. In Chapter 4, it was demonstrated that 
heating to 40°C could be used to reduce polymer solution viscosity. It was not 
possible to use heat to reduce the viscosity of a drug-polymer dispersion without 
affecting the physical stability of the dispersion.  
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5.4 Conclusion 
The presence of paracetamol at 15 %w/w in a 5 % w/w hypromellose E5LV solution 
affects the gelation temperature and cloudpoint of hypromellose. 
These data indicate that preparing a dispersion containing hypromellose and 
paracetamol is possible but that heating to reduce viscosity, as previously 
considered for aqueous hypromellose solutions without paracetamol in Chapter 4, 
has a detrimental impact on the physical stability of the dispersion. It may therefore 
not be possible for this drug-polymer dispersion to be spray-dried as the viscosity 
may be too high to enable appropriate feed rate. 
The drug-polymer dispersion has a gelation temperature lower than that observed 
for an aqueous hypromellose solution using the same polymer at the same 
concentration. Based on the increase in viscosity observed between 25°C and 40°C 
in the presence of paracetamol, the gelation temperature of a dispersion containing 
5 %w/w E5LV hypromellose and 15 %w/w paracetamol is between ambient 
temperature and 40 °C. The gelation temperature of an aqueous solution containing 
5 %w/w E5LV hypromellose is between 40°C and 60 °C.  
The drug-polymer dispersion has a cloudpoint temperature lower than that 
observed for an aqueous hypromellose solution using the same polymer. The 
cloudpoint of a dispersion containing 5 %w/w E5LV hypromellose and 15 %w/w 
paracetamol is between ambient temperature and 40 °C. The cloudpoint of an 
aqueous solution containing 5 %w/w E5LV hypromellose is between 40°C and 60 °C.  
Spray drying of hypromellose solutions containing paracetamol was not performed 
due to the flocculation of the dispersion obtain at temperatures >25°C. Further 
work associated to optimise the physical stability of the 5 % hypromellose E5LV 
solution containing paracetamol will not be conducted at this stage. The use of HPC 
as an alternative aqueous soluble polymer will be considered in Chapter 6. 
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6 INVESTIGATING THE INFLUENCE OF TEMPERATURE ON 
PHYSICAL PROPERTIES OF AQUEOUS SOLUTIONS OF 
HPC 
6.1  Introduction 
Chapters 4 and 5 demonstrated the influence of temperature and the presence of 
paracetamol on the viscosity of hypromellose solutions and the associated 
implications for spray-drying aqueous hypromellose solutions. This Chapter 
investigates if aqueous solutions of HPC are influenced by temperature in a similar 
way to hypromellose. Aqueous solutions of HPC are known to undergo phase 
transformations at elevated temperatures (Vshivkov and Rusinova 2007). In this 
investigation a range of Klucel® HPC polymer grades (molecular weights 80,000 to 
370,000 Daltons), at a range of concentrations were considered. 
Aqueous solutions were prepared and changes in physical structure at increasing 
temperature determined using viscosity and UV transmission testing. Based on 
these properties, an application using HPC to develop a paediatric dosage form is 
proposed.  
6.2 Materials and Methods 
The following Klucel® HPC grades were used for this investigation:  
i. EXF Pharm 
ii. LF PHarm 
iii. JXF Pharm 
iv. GXF PHarm 
v. MXF Pharm 
vi. HXF Pharm 
Details associated with these polymer grades may be found in Section 2.1.2.2 of this 
thesis. In this Chapter a range of aqueous polymer concentrations (5 %w/w 10 
%w/w and 20 %w/w) was considered.  
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Table 6.1 shows the polymer solutions considered and the respective composition 
of each solution based on polymer concentration. 
Table 6.1  Quantitative composition of aqueous HPC solutions (per 500g of 
solution) 
 Polymer Concentration 
5 %w/w 10 %w/w 20 %w/w 
Excipient 
Content  
( % w/w) 
Quantit
y (g) 
Content  
( % w/w) 
Quantity 
(g)  
Content 
 ( % w/w) 
Quantity 
(g) 
Polymer 5.0 25.0 10.0 50.0 20.0 100.0 
Purified 
Water 
95.0 475.0 90.0 450.0 80.0 400.0 
Total 100.0 % 500.0g 100.0 % 500.0g 100.0 % 500.0g 
 
6.2.1 Preparation of aqueous HPC solutions 
Aqueous solutions of HPC were prepared as described in Section 3.1.2.  
6.2.2 UV transmission measurement of aqueous HPC solutions 
The theory of UV spectroscopy is described in Section 2.2.2 of this investigation. UV 
transmission is used here to determine how HPC solutions physically change with an 
increase in temperature. The per-cent UV transmission decreased as the test 
samples became more cloudy.  
UV transmission was measured using a spectrophotometer (Hewlett Packard Model 
8453, UK) with jacketed cuvette holder (Agilent, US). A water bath (Thermo 
Scientific, UK) set at 65°C was used to circulate warm water around the jacketed 
cuvette holder (Agilent US) and a temperature probe (RS Components UK) was used 
to measure the temperature of the test sample within the cuvette. The 
temperature probe was held using a clamp inside the top of the cuvette to monitor 
the temperature of the test solution during UV transmission measurement. Purified 
water was used as a blank to generate a UV transmission baseline at 540 nm. Per-
cent UV transmission at 540 nm was measured across the sample at ambient 
temperature and at 1 to 2°C sample temperature intervals up to 50°C or until a 
constant transmittance reading was reached. Software (UV Vis Chemstation, Agilent 
Technologies, US) was used to analyse the data obtained by the 
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spectrophotometer. The per-cent UV transmission reading was plotted against 
temperature. A change in physical appearance of the test solution was indicated by 
a change in per-cent UV transmittance.  
6.2.3 Viscosity determination of aqueous HPC solutions 
The viscosities of the aqueous HPC solutions were measured using a different 
method to that used previously in Chapter 4. To acquire more data points to 
investigate the effect of temperature on viscosity of aqueous HPC solutions an 
alternative method to enable greater control of sample temperature increase was 
implemented. This method enabled viscosity to be determined at 5°C temperature 
intervals from ambient temperature to 60°C  
6.2.3.1 Viscosity determination using small sample adaptor 
The viscosity of each solution was determined using a Brookfield LVDV III 
viscometer and jacketed small sample adaptor (Brookfield, UK) with integrated 
sample temperature measurement. The viscosity of each solution was measured 
from ambient temperature to 60°C at 5°C intervals. A water bath (Thermo Scientific, 
UK) was used to control the temperature of the small sample adaptor and is set at 
65 °C. The parameters shown in Table 6.2 were used to determine solution viscosity 
at increasing temperature.   
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Table 6.2  Viscometer spindle type and speed Used for viscosity testing 
Viscosity (cP) ≤50 50 to 120 120 to 400 400 to 1500 1500 to 
7000 
Spindle SC4-18 SC4-18 SC4-18 SC4-18 SC4-34 
Spindle Speed 
(rpm) 
30 12 6 1.5 6 
 
Note:  
Sample size used 8mL 
 
The test sample volume (8 mL) was extracted from the stock polymer solution and 
transferred to the small sample adaptor using a 10 mL polypropylene syringe (BD 
Plastipak, US). Having connected the small sample adaptor to the viscometer the 
water bath pump was started and the sample was heated. Viscosity measurement 
commenced and viscometer torque; viscosity in centipoises and sample 
temperature were recorded. The viscosity of each HPC solution in centipoises was 
determined as a function of temperature for each sample.  
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6.3 Results and Discussion 
6.3.1 Preparation of aqueous HPC solutions 
Upon addition to purified water the HPC particles hydrate and swell prior to 
solubilisation. Consequently the higher molecular weight grades of HPC took longer 
to solubilise as the gel layer which formed at the surfaces of the HPC particles was 
very viscous and caused the HPC particles to be difficult to solubilise. In association 
with this observation, it was not possible to form HPC solutions using MXF and HXF 
Pharm grades at 5 %w/w concentration as a viscous gel formed quickly after HPC 
addition preventing agitation by the magnetic stirrer and solubilisation of the HPC 
particles (shown shaded in Table 6.3). This was also the case for EXF, LXF, JXF and 
GXF grades at concentrations of 20 %w/w and at GXF at a concentration of 10 
%w/w as shown in Table 6.3. Table 6.3 also shows the molecular weight and 
nominal viscosity associated with each HPC polymer grade considered. 
The difficulty to solubilise high molecular weight HPC grades (>370,000 Daltons) and 
high polymer concentrations restricted the grades of and the maximum 
concentration of HPC that could be used to form a true HPC solution. The maximum 
viscosity of HPC solution considered for this work was 6900 cP as determined for 5 
%w/w GXF.  
Preparation of the HPC aqueous solutions demonstrated that HPC powder is best 
dispersed and dissolved at room temperature whilst hypromellose is best dispersed 
at high temperature prior to solubilising at reduced temperature. The need to heat 
purified water prior to dispersion of hypromellose is a manufacturability 
disadvantage of hypromellose compared to HPC, due to the energy and time 
required to reach 70°C to 85 °C.  
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Table 6.3  HPC polymer grades, concentrations considered and occurrence of 
  gelling 
HPC Polymer 
Grade 
Molecular 
Weight 
(Daltons) 
Nominal Viscosity 
(cP) 
Polymer 
Concentration ( 
%w/w) 
EXF Pharm 80,000 
300 to 600 (10 % 
w/w) 
5 % 10 % 20 % 
   
LF Pharm 95,000 75 to 150 (5 % w/w) 5 % 10 % 20 % 
   
JXF Pharm 140,000 150 to 400 (5 % w/w) 5 % 10 % 20 % 
   
GXF Pharm 370,000 150 to 400 (2 % w/w) 5 % 10 % 20 % 
   
MXF Pharm 850,000 4,000 to 6,500 (2 % 
w/w) 
5 % 10 % 20 % 
   
HXF Pharm 1,150,000 1,500 to 3000 (1 % 
w/w) 
5 % 10 % 20 % 
   
 
Note 
The ‘’ indicates those polymer solutions which were successfully prepared and 
further characterised. The ‘’ indicate those polymer solutions that were 
successfully prepared but formed a gel and were not considered for further 
characterisation. 
 
As illustrated in Table 6.3, based on viscosity, only low molecular weight HPC grade 
(≤ 370,000 Daltons) was suitable for spray-drying. High molecular weight polymer 
grades (> 370,000 Daltons) formed a gel at solutions of ≥ 5 %w/w which would 
restrict flow rate to the atomising nozzle of the spray drier. Concentrations of >10 % 
w/w were also unsuitable for low molecular weight HPC grade polymers due to the 
formation of a gel. The viscosity of aqueous HPC solutions limits the solids content 
of spray-drying solutions and also restricts the molecular weight of the HPC that 
may be selected for spray-drying. This limitation was also observed for 
hypromellose as described in Chapter 4. 
6.3.2 UV Transmission data for aqueous HPC solutions 
UV transmission was successfully applied to identify physical changes in the visual 
appearance of the solution caused by temperature increase. In all cases the HPC 
solution changed from clear to cloudy upon heating. Being controlled at 65 °C, the 
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water bath could not control the lower temperatures of the samples (below 30 °C). 
The lower temperature was determined by ambient temperature within the 
laboratory. The method could have been improved by conditioning the samples and 
holding them at a defined temperature prior to testing, for example 20°C using a 
second water bath. This limitation is not considered to have compromised the data 
collected for this part of the investigation.  
 
Figure 6.1 The effect of temperature on % transmission for aqueous solutions 
  of HPC. 
Per-cent UV transmission data were collected for those HPC solutions prepared as 
detailed in Table 6.3. Figure 6.1 shows the influence of temperature on the per-cent 
UV transmission of HPC solutions of various HPC polymer grades at various polymer 
concentrations. In all cases as the sample temperature increased the percent UV 
transmission of the HPC solution decreased. The onset of this change occurred 
slowly initially up to 30°C but changed significantly between 30°C and 35°C before 
rapidly reaching the minimum percent UV transmission at 35°C to 38 °C. 
Solutions containing 10 % polymer reached their minimum per-cent UV 
transmission at a slightly lower temperature than solutions containing 5 % polymer. 
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The molecular weight of HPC appeared to have little impact on the trends observed 
in percent UV transmission.  
HPC solutions containing 10 %w/w EXF and JXF HPC gave the lowest percent UV 
transmission at 25 °C. This may be due to the onset of change in physical 
appearance occurring at a temperature below 25°C and although these solutions 
appeared clear and particulate free to the naked eye, prior to testing, there were 
some changes already occurring that the percent UV transmission method was able 
to detect.  
An increase in HPC concentration results in a more significant effect of temperature 
on per-cent UV transmission. These physical changes are the result of either HPC 
dehydration and precipitation or the formation of liquid crystals within the solution.  
6.3.3 Viscosity data for aqueous HPC solutions 
Viscosity testing was successfully performed as described in Section 6.2.2.  
 
Figure 6.2  The effect of temperature on viscosity of solutions containing 5  
  %w/w or 10 %w/w HPC EXF 
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Figure 6.3  The effect of temperature on viscosity of solutions containing 5  
 %w/w or 10 %w/w HPC LXF 
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Figure 6.4 The effect of temperature on viscosity of solutions containing 5  
  %w/w or 10 %w/w HPC JXF 
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Figure 6.5  The effect of temperature on viscosity of solutions containing 5  
  %w/w HPC GXF 
Viscosity determination was successfully performed using the Brookfield LVDV III 
viscometer with small sample adaptor and appropriate spindle and spindle speed. 
Being controlled at 65 °C, the water bath could not control the lower temperatures 
of the samples (below 30 °C). These were controlled only by ambient temperature 
within the laboratory. Similar to the per-cent UV transmission data reported 
previously, the method could have been improved by conditioning the samples and 
holding them at a defined temperature prior to testing, for example 20°C using a 
second water bath. This limitation is not considered to have compromised the data 
collected for this part of the investigation.  
Figure 6.5 shows that at 30°C the viscosity of solutions containing 10 % w/w EXF 
was approximately 7 times that of solutions containing 5 % w/w EXF. The viscosity 
of 10 % w/w LXF is approximately 11 times that of 5 %w/w LXF and the viscosity of 
10 % w/w JXF was approximately 12 times that of 5 % w/w JXF demonstrating that 
the effect of polymer concentration on solution viscosity was different for each 
polymer grade.  The larger molecular weight polymers exhibited the highest 
viscosity. However, the impact of molecular weight on solution viscosity was also 
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non linear. EXF and LXF were more similar in molecular weight (80,000 compared to 
90,000) than LXF and JXF (90,000 compared to 140,000) yet the difference in 
viscosity at 5 % and 10 %w/w was greater between EXF and LXF than LXF and JXF. 
All HPC solutions investigated showed a reduction in viscosity with an increase in 
temperature. In all cases a near sigmoidal shape was evident for viscosity versus 
temperature plots. The change in viscosity appeared to occur in 3 phases; i) initially 
a linear reduction in viscosity ii) at 40°C the rate of change in viscosity was more 
significant and at phase iii) at 50°C the rate of change reached a minimum and 
minimum viscosity was reached. These phase changes occur at similar temperatures 
to the phase changes also observed in Section 6.3.2.  
HPC polymer solutions did not exhibit the same viscosity behaviour as hypromellose 
solutions. HPC polymer solutions did not exhibit a gelation temperature like 
hypromellose solutions and consequently an increase in temperature resulted in a 
decrease in viscosity. 
HPC solutions containing 10 %w/w HPC exhibited the greatest change in viscosity 
with increasing temperature. Solutions containing high concentrations of HPC 
exhibited the greatest change in viscosity.  For all grades of HPC, the viscosity of 10 
% w/w solutions at 60°C approached the viscosity of 5 % w/w solutions at 30 °C. The 
higher molecular grades of HPC also demonstrated the greatest change in viscosity.  
Plots of percent UV transmission versus temperature and viscosity versus 
temperature exhibited a similar sigmoidal shape and indicated that change with 
temperature occurred in distinct phases. The effect of increase in temperature on 
HPC solution viscosity and per-cent UV transmission indicated that the HPC 
solutions investigated undergo phase transition changes (Guido 1995). All grades of 
HPC and concentrations considered demonstrated similar phase changes in viscosity 
and approached a minimal viscosity at approximately 60 °C indicating that the 
solutions were being changed to a similar ‘end point’ or ‘completion stage’ with 
increasing temperature. These data also indicate that aqueous solutions of HPC did 
not exhibit a gelation temperature as observed for aqueous solutions of 
hypromellose in Chapter 4. 
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The temperature at which these phase changes occur were similar for per-cent UV 
transmission and viscosity (see Figure 6.1 and Figure 6.6). These data suggest that 
the effect of temperature on percent UV transmission and the effect of 
temperature on viscosity are directly linked. The physical change which resulted in a 
change per-cent UV transmission is also attributable to the change in viscosity. 
These physical changes could be associated with the formation of liquid crystals at 
elevated temperatures. Liquid crystal defines a physical state at which the material 
exhibits both liquid and solid crystal properties. Liquids crystals are capable of 
flowing like liquids but are optically anisotropic. Such a state may also be termed 
mesomorphic state. There are three distinct categories of mesomorphic state; 
smectic, nematic and cholesteric (Gray 1962). For the purposes of this work, the 
terms ‘liquid crystal’ is used to describe material exhibiting both liquid and solid 
crystal properties. 
This HPC is a semi-rigid macromolecule capable of exhibiting liquid crystallinity both 
at elevated temperatures and in a variety of organic solvents as well as in water. 
Similar observations to those presented here were first reported by Werbowyj and 
Gray (1980), who showed that HPC is soluble in cold water but when aqueous 
solutions of HPC are warmed to about 40 °C, a phase separation occurs with a sharp 
increase in turbidity and a decrease in viscosity. The temperature at which this 
phase separation occurs may be known as the cloud point or lower critical solution 
temperature (LCST) (Nishio et al 2002). Nishio’s work suggested that the scattering 
of light was due to the separation of a polymer rich phase which with further 
heating coagulated to form a white gel. Nishio et al (2002) defined cloud-point as 
the temperature at which the light scattered at a 90°angle to the incident beam 
(Nishio 2002). Nishio measured the cloudpoint upon heating at 0.2 °C/min as 44°C 
for HPC grades E, L, and G and as 41°C for J grade HPC for solutions containing ≤40 
% w/w HPC. An anisotropic phase, which shows birefringence under crossed polars, 
was also observed in concentrated HPC solutions (>40 %w/w) and the appearance 
of cholesteric colours was observed in HPC solutions containing >60 %w/w HPC 
(Nishio et al 2002). The liquid crystalline structure of these concentrated aqueous 
HPC solutions has been characterised by Werbowyj and Gray (1976; 1980). 
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A phase diagram may be used to describe these phase changes i)isotropic ii) 
anisotropic and iii) biphasic (Werbowyj and Gray 1980 ; Guido and Grizutti 1995, 
Vshivkov and Rusinova 2006) for HPC concentration versus temperature.  
 
Figure 6.7  Phase diagram for HPC solutions proposed by Werbowyj and Gray 
  1980. 
Fortin and Charlet (1989) explored this phase diagram further using carefully 
fractionated samples of HPC with different degrees of substitution and concluded 
that the reduced aqueous solubility of HPC at high temperature originates from the 
melting of the enhanced water structure built around the hydrophobic regions of 
the polymer molecule.  This could also be considered as the dehydration of the 
polymer at high temperatures. 
Aqueous solutions of HPC at concentrations of 20 %w/w are considered isotropic at 
room temperature but form precipitating spherical droplets at 40°C turning white 
and turbid. Under the microscope these droplets look anisotropic with the presence 
of maltese crosses. The precipitation of these droplets coincides with a sharp 
increase in turbidity (Guido and Grizzuti 1995).  
The reduction in viscosity may be explained due to the dehydration of the HPC 
molecules and the resulting chain flexibility. Chain rigidity is associated with strong 
hydrogen bonding; between HPC molecules and with water molecules (Guido and 
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Grizzuti 1995). As these hydrogen bonds are broken by temperature increase the 
HPC molecules become more flexible and able to form spherical droplets which 
eventually precipitate. 
This investigation considered HPC concentrations lower than those considered in 
previous work Werbowyj and Gray (1980), Guido and Grizzuti (1995) and Nishio et 
al (2002) considered HPC concentrations of ≥10 % w/w). However, the impact of 
polymer concentration on cloudpoint is consistent with observations previously 
reported. An increase in polymer concentration reduces the cloudpoint 
temperature for isotropic HPC solutions due to the formation of liquid crystals or 
HPC spheres which form with an increase in temperature. HPC molecules are 
dehydrated with heating and the hydrogen bonds between the HPC molecules and 
water molecule are broken resulting precipitation of the liquid crystals and 
consequently a reduction in viscosity.  
The phases of change observed here are similar to those described by Werbowyj 
and Gray (1980) and Guido and Grizzuti (1995). In phase i) the HPC solutions are 
isotropic; in phase ii) the solutions reach cloudpoint and transition to the completed 
biphasic phase (phase iii). At the concentrations considered here it is not possible 
for the HPC solutions to reach the anisoptropic phase typically observed for HPC 
concentrations >40 % w/w with an appropriate increase in temperature. The data 
reported here may be used to further expand the phase diagrams proposed for <20 
% w/w  HPC concentrations. 
Based on these observations HPC polymer solutions may be suitable for spray-
drying at an increased temperature, as previously described for hypromellose. 
Temperature control may not be as critical as a gelation temperature is not present. 
However, the liquid crystal phenomenon observed could impact both the spray-
drying process and characteristics of the spray-dried material produced. 
The physical changes observed which occur at temperatures close to 37°C are likely 
to have significant application for drug development due to the association with 
body temperature. An application of these physical changes will be discussed 
further in Chapter 8. 
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6.4 Conclusion 
These data presented in this chapter illustrated that an increase in temperature 
causes reduction in solubility of HPC in water resulting in precipitation of HPC and 
consequently a reduction in solution viscosity. Precipitation of the HPC also caused 
the aqueous HPC solutions to appear cloudy at increased temperature. This 
temperature is referred to as the ‘cloud-point’ temperature. Changes in viscosity 
may occur at temperatures below the cloud-point temperature and at the 
cloudpoint temperature the viscosity of the HPC solution is significantly decreased. 
Aqueous HPC solutions do not exhibit a gelation temperature as aqueous 
hypromellose solutions do.  
Due to the precipitation of HPC in aqueous HPC solutions at an increased 
temperature, these solutions will not be considered for spray drying The impact of 
temperature on HPC hydration shown here will be further explored in the presence 
of paracetamol and ranitidine.  
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7 INVESTIGATING THE INFLUENCE OF TEMPERATURE 
AND DRUG SUBSTANCE ON AQUEOUS SOLUTIONS OF 
HPC 
7.1  Introduction 
The data in Chapter 6 demonstrated the changes in physical structure of aqueous 
HPC solutions at increasing temperature determined using viscosity and UV 
transmission testing. Based on these properties, applications using HPC to develop a 
paediatric dosage form were examined. Prior to evaluating these applications the 
impact of drug substances paracetamol and ranitidine on the effects previously 
observed in Chapter 6 will be considered in this Chapter.  
The effects of concentration of these two commonly prescribed paediatric drugs 
which have different solubilities were considered by solubilising them in various 
aqueous concentrations of HPC Klucel®EXF Grade solutions and comparing the 
effect of temperature on viscosity and UV transmission of these solutions with data 
obtained in Chapter 6 for HPC solutions without drug substance. 
7.2 Materials and Methods 
Klucel® HPC EXF Pharm was used for this investigation. Details associated with this 
polymer may be found in Chapters 1 and 2. An aqueous polymer concentration of 5 
%w/w was used. A low concentration of the lowest viscosity polymer was 
considered for this investigation to avoid potential limitations and challenges that 
may be associated with the high viscosity of solutions prepared using higher 
molecular weight polymer grades. Data obtained may be transferable to other 
grades of HPC. 
Details of paracetamol and ranitidine may be found in Chapter 1 and 2. In this 
Chapter a range of concentrations of drug substances were considered.  
Table 7.1 shows the concentrations of the drug substances used and the respective 
composition of each solution are shown in Tables 7.2 and 7.3.  
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Table 7.1  Active polymer solutions considered 
Polymer 
Grade 
Polymer 
Concentration 
(mg/g) 
Drug 
Drug 
Concentration 
(mg/g) 
Drug:Polymer 
Ratio 
EXF 50 
Paracetamol 
5 1:10 
10 1:5 
15 3:10 (1:3.3333) 
20* 1:2.5 
25* 1:2 
Ranitidine 
2.5 1:20 
5 1:10 
50 1:1 
100 2:1 
Note 
* A clear solution could not be achieved so a maximum paracetamol concentration 
of 15 mg/g was considered for this investigation. 
 
Ranitidine hydrochloride is significantly more soluble than paracetamol (>10x) so a 
higher concentration range could be considered for ranitidine. A maximum 
concentration of 15 mg/g was achieved for paracetamol and a highest 
concentration of 100 mg/g was considered for ranitidine. Consequently, a 
drug:polymer ratio range of 1:10 to 3:10 (1:3.333) was considered for paracetamol 
and 1:20 to 2:1 for ranitidine. 
Table 7.2  Quantitative composition of paracetamol aqueous HPC solutions 
(per 500g of solution) 
 Drug substance Concentration (mg/g)* 
5 10 15 20 25 
Excipient 
% 
w/w 
g 
% 
w/w 
G 
% 
w/w 
g 
% 
w/w 
g 
% 
w/w 
g 
Paracetamol 0.5 2.5 1.0 5.0 1.5 7.5 2.0 10.0 2.5 12.5 
Polymer 5.0 25.0 5.0 25.0 5.0 25.0 5.0 25.0 5.0 25.0 
Purified 
Water 
qs qs qs Qs qs qs qs qs qs qs 
Total 100.0 500.0 100.0 500.0g 100.0 500.0 100.0 500.0 100.0 500.0 
Note 
* Concentrations are expressed as mg/g of solution. 
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Table 7.3  Quantitative composition of ranitidine aqueous HPC solutions (per 
500g of solution) 
 Drug substance Concentration (mg/g*) 
2.5 5 50 100 
Excipient % w/w g % w/w g % w/w g % w/w g 
Ranitidine** 0.25 1.25 0.5 2.5 5.0 25.0 10.0 50.0 
Polymer 5.0 25.0 5.0 25.0 5.0 25.0 5.0 25.0 
Purified Water qs qs qs qs qs qs qs qs 
Total 100.0 500.0 100.0 500.0g 100.0 500.0 100.0 500.0 
Note 
* Concentrations are expressed as mg/g of solution. 
** Weighing factor for ranitidine hydrochloride (refer to Table 2.6). 
 
7.2.1 Preparation of aqueous HPC solutions 
Aqueous solutions of HPC were prepared as described in Section 3.2.2.  
7.2.2 UV transmission measurement 
The theory of UV spectroscopy is described in Section 2.2.2 of this investigation. UV 
transmission was used here to determine how HPC solutions physically change with 
an increase in temperature. As the test sample becomes more cloudy, the per-cent 
UV transmission decreases. UV transmission measurements were performed as 
described in Section 6.2.3. 
The per-cent UV transmission was plotted as a function of temperature. A change in 
physical appearance of the test solution was indicated by a change in per-cent UV 
transmittance.  
7.2.3 Viscosity determination of aqueous HPC solutions 
The viscosity of the aqueous HPC solutions was measured using the same method 
described in Section 6.2.2. 
  
97 
7.2.4  Hot stage microscopy 
HPC solutions were characterised using hot stage microscopy. Hot stage microscopy 
is described in Section 2.2.3. HPC solutions were heated using a Mettler hot stage 
plate (Mettler FTP82HT, UK) and images were captured using an Olympus Camera 
and Microscope (BH2 Optical Microscope, UK). A sample of 5 % w/w EXF HPC 
solution containing 15 mg/g of paracetamol was heated from room temperature to 
45°C at a rate of 2 °C/min and then held at 45°C for 2 minutes before cooling back 
to room temperature. Changes in the physical appearance were observed at 100x 
magnification using cross polarised light. 
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7.3 Results and Discussion 
7.3.1 Preparation of aqueous HPC solutions containing drug 
 substance 
Ranitidine formed a yellow solution when dissolved in purified water. 5 % w/w EXF 
HPC solutions containing ranitidine at a concentration of 100 mg/g were distinctly 
more intense in colour than those containing a 2.5 mg/g of ranitidine. Paracetamol 
formed a colourless solution at concentrations up to 15 mg/g. As UV transmission 
was used to investigate the impact of temperature on the physical changes within 
the solution and the potential formation of liquid crystals, it was important that 
clear solutions were used for this investigation. Therefore, only drug concentrations 
that produced a clear solution were considered. Ranitidine has a higher solubility 
than paracetamol so a higher concentration of ranitidine could be used. 
Paracetamol concentrations of 5 mg/g, 10 mg/g and 15 mg/g and ranitidine 
concentrations of 2.5 mg/g, 5 mg/g, 50 mg/g and 100 mg/g were investigated. 
7.3.2 UV transmission data for HPC solutions containing drug 
 substance 
The effect of temperature on percent UV transmission for HPC solutions containing 
paracetamol and ranitidine at various concentrations was successfully determined. 
Similar problems were incurred with consistently controlling the temperature of 
samples at ambient temperatures (<30 °C) as reported in Section 6.3.2.  
UV transmission was successfully used to identify physical changes in the visual 
appearance of the solutions caused by temperature increase. In all cases HPC 
solutions containing paracetamol and ranitidine changed from clear to cloudy upon 
heating.  
Per-cent UV transmission data were collected for 5 %EXF HPC solutions prepared 
containing paracetamol and ranitidine as detailed in Table 7.1. The per-cent UV 
transmission data for these HPC solutions against temperature are shown in Figure 
7.1 and 7.2. 
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Figure 7.1  Effect of temperature on the % transmission for 5 %EXF HPC  
  solution containing different concentrations of paracetamol 
 
Figure 7.2  Effect of temperature on the % transmission for 5 %EXF HPC  
  solution containing different concentrations of ranitidine  
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These data demonstrate that minimum per cent UV transmission is achieved at 
34°C to 36°C for 5 % w/w EXF HPC solutions containing paracetamol at 
concentrations up to 15 mg/g and 42°C to 44°C for 5 % w/w EXF HPC solutions 
containing ranitidine at concentrations up to 100 mg/g.  
Each HPC solution containing paracetamol reached a minimum per cent UV 
transmission at a lower temperature than HPC solutions containing no drug. HPC 
solutions containing paracetamol exhibited a slow onset of physical change initially 
as indicated by per-cent UV transmission measurement, followed by a significant 
change between 30°C and 35°C before rapidly reaching minimum per-cent UV 
transmission at 35°C to 38°C, as previously observed for HPC solutions without drug 
(Section 6.3.2). The concentration of paracetamol appeared to influence the 
temperature at which the onset of change occurred. HPC solutions containing 15 
mg/g paracetamol begin to change at a slightly lower temperature than HPC 
solutions containing 10 mg/g paracetamol solutions which change at a lower 
temperature than HPC solutions containing 5 mg/g paracetamol solutions or HPC 
solutions containing no drug. Thus the onset temperature decreased with increasing 
paracetamol concentrations. 
HPC solutions containing 15 mg/g paracetamol exhibit a lower percent UV 
transmission at ambient temperature (22°C) than HPC solutions containing no 
paracetamol or those containing 5 mg/g and 10 mg/g of paracetamol. This may be 
due to the onset of physical change occurring at a temperature below 22°C or be 
due to the maximum aqueous solubility of the paracetamol being exceeded at 15 
mg/g and the undissolved paracetamol impacting the per cent UV transmission.  
HPC solutions containing ranitidine reached a minimum per cent UV transmission at 
a higher temperature than HPC solutions not containing drug substance or those 
HPC solutions containing paracetamol. The concentration of ranitidine did not 
influence the onset temperature or the temperature at which minimum per cent UV 
transmission occurred. 
The HPC solution containing 100 mg/g ranitidine exhibited more variability in per 
cent UV transmission against temperature between 20°C and 38°C than all other 
samples tested. This may be due to the physical changes at this concentration 
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occurring non-homogeneously within the sample. The process of physical changes 
or phases of transformation occurring within all samples tested may be being 
exaggerated at the 100mg/g concentration due to the higher concentration of drug 
and associated high drug:polymer ratio of 1:5.  
These data indicate that drug concentration (influenced by drug solubility) influence 
the phase transformation exhibited by HPC. Similar effects have also been observed 
by Prevysh et al (1997) and Nishio et al (2002). 
7.3.3 Viscosity data for HPC solutions containing drug substance 
Viscosity testing was performed as described in Section 7.2.2.  
Figure 7.3 illustrates the effect of temperature on the viscosity of HPC solutions 
containing ranitidine.  
 
0
10
20
30
40
50
60
70
80
90
100
20 30 40 50 60 70
V
is
co
si
ty
 c
P
Temperature °C
2.5mg/g Ranitidine
5mg/g Ranitidine
50mg/g Ranitidine
100mg/g Ranitidine
5%E5 Placebo
 
Figure 7.3 Effect of temperature on viscosity of 5 %EXF HPC solutions  
  containing different concentrations of ranitidine 
Each HPC solution containing ranitidine showed a decrease in viscosity with an 
incrase in temperature. Fig 7.3 shows similar sigmoidal shapes to that previously 
102 
observed for HPC solutions not containing drug substance. As previously observed 
and described in Chapter 6, the change in viscosity appeared to occur in 3 phases; i) 
1 linear reduction in viscosity ii) at 45°C the rate of change in viscosity is more 
significant and at phase iii) 50°C the rate of change reaches a minimum and 
minimum viscosity is reached. HPC solutions containing ranitidine reached the 
second phase at a slightly higher temperature than HPC solutions not containing an 
drug substance.  
The HPC solution containing 100 mg/g ranitidine had the highest viscosity; slightly 
higher than the HPC solution not containing drug at 30 °C. HPC solutions containing 
2.5, 5 and 50 mg/g ranitidine have a slightly lower viscosity than the HPC solution 
not containing drug. The impact of ranitidine concentration had minimal impact on 
the viscosity of the solutions and had the least impact at 60°C where all solutions 
had similar viscosities.  
HPC solutions containing 5 %EXF HPC and various concentrations of ranitidine 
exhibited similar change in viscosity with increasing temperature to 5 % EXF HPC 
solutions not containing drug substance. Ranitidine had minimal impact on viscosity 
of the HPC solution.  
Figure 7.4 illustrates the effect of temperature on the viscosity of HPC solutions 
containing paracetamol.  
 
103 
0
10
20
30
40
50
60
70
80
90
100
20 30 40 50 60 70
V
is
co
si
ty
 c
P
Temperature °C
5mg/g Paracetamol
10mg/g Paracetamol
15mg/g Paracetamol
5%E5 HPC
 
Figure 7.4  Effect of temperature on viscosity of 5 %EXF HPC solutions  
  containing different concentrations of paracetamol 
Each HPC solution containing paracetmaol showed a decrease in viscosity with an 
increase in temperature. The plot shown in Fig 7.4 shows a similar sigmoidal shape 
plot to that previously observed for HPC solutions not containing drug substance 
(Section 6.3.3) and those containing ranitidine. At 35°C the viscosity of HPC 
solutions containing 10 mg/g and 15 mg/g paracetamol decreased significantly. 
Viscosity of HPC solutions containing 5 mg/g paracetamol decreases at 40 °C. 
Minimum viscosities were reached at 40°C for 15 mg/g and at 45°C for 5 mg/g and 
10 mg/g paracetamol HPC solutions. HPC solutions containing 10 mg/g and 15 mg/g 
paracetamol exhibited a decrease in viscosity at a slightly lower temperature than 
HPC solutions not containing drug substance, those containing 5 mg/g HPC solutions 
containing paracetamol reached minimum viscosity at a temperature slightly lower 
than HPC solutions not containing drug substance. HPC solutions containing a 
higher concentration of paracetamol exhibit the greatest and fastest change in 
viscosity.  
HPC solutions containing 5 %EXF HPC and various concentrations of paracetamol 
exhibited a similar pattern in change in viscosity with increasing temperature to 5 % 
EXF HPC solutions not containing drug substance. The inclusion of paracetamol 
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increased the viscosity of HPC solutions and reduced the temperature at which 
phase changes occurred in viscosity. 
7.3.4 Hot stage microscopy  
Hot stage microscopy was used to investigate the physical change which occurred 
to HPC polymer solutions upon heating.  
 
Figure 7.5 Still images obtained from the Hot Stage Microscope of HPC  
  polymer solution containing 15 mg/g paracetamol heated at  
  various temperatures. 
The images shown in Figure 7.5, are still shots obtained during video data capture. 
Changes in physical appearance were observed at 100x magnification using cross 
polar light. 
These hot stage microscopy images shows how the liquid solution dehydrates and 
precipitated at increasing temperature. With increasing temperature, greater 
‘texture’ may be observed within the sample. These images are consistent with 
physical changes discriminated using UV transmission and viscosity determination.  
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Plots of percent UV transmission versus temperature and viscosity versus 
temperature for HPC solutions containing drug substance exhibited a similar 
sigmoidal shape and indicate that change with temperature occurred in distinct 
phases as observed in Chapter 6.  
The influence of paracetamol and ranitidine on these changes was also similar for 
both percent UV transmission and viscosity. Ranitidine increases the temperature at 
which these phase changes occurred and paracetamol decreased the temperature 
of change. 
The low solubility of the paracetamol reduces the cloud point of the HPC solutions 
resulting in precipitation of the HPC molecules occurring at a lower temperature 
and hence giving a reduced cloud-point temperature. This is also supported by the 
change in viscosity observed for high concentration paracetamol solutions. 
The effect of ranitidine on HPC solutions may be described by the salting in 
behaviour associated with the hydrochloride salt (Drummond et al 1992, Carlsson 
1990, Prevysh et al 1996, Bonnet-Gonnet et al 2001 and Nishio et al 2002). As the 
hydrochloride salt dissociates upon solubilisation of the rantitidine hydrochloride 
the hydrogen ions are available to repair the hydrogen bonds which break during 
dehydration of the HPC molecules. This results in an increased LCST for solutions 
containing ranitidine and a consequential change to the cloud point temperature 
for these solutions. This effect is not directly associated with the concentration of 
ranitidine as eventually the effect of temperature overcomes the ability for the 
hydrogen bonds to be replaced.  
The effect of ranitidine on HPC solution viscosity did not appear to be related to the 
effect on percent UV transmission. This may be due to the viscosity effects observed 
occurring in the isotropic phase and being independently of the phase transition 
associated with temperature. The viscosity changes observed for HPC solutions 
containing rantidine occurred at temperatures below the cloudpoint and are similar 
to the viscosity changes which occur for HPC solutions not containing drug 
substance. If the cloudpoint can be increased by the addition of drug substance the 
viscosity of the solution will not be impacted and will perform similarly to HPC 
solutions not containing drug substance. Changes in viscosity which occur at 
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temperatures below the cloudpoint are not associated with the phase transition 
and precipitation of the HPC. This is likely to be due to the realignment of the HPC 
molecules at increasing temperature just prior to liquid crystal formation (see 
Section 6.3). The realignment results in a reduction in viscosity but not a change in 
per cent UV transmission as the HPC does not need to precipitate for a change in 
viscosity to be observed.  
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7.4 Conclusion 
HPC solutions containing paracetamol and ranitidine were influenced by 
temperature in a similar way to HPC solutions without drug, as discussed in Chapter 
6. Ranitidine increased the temperature at which these phase changes occur and 
paracetamol decreases the temperature. The ‘sparingly soluble’ drug paracetamol 
(<15 mg/ml) decreased the temperature of dehydration and precipitation onset and 
the ‘freely soluble’ drug ranitidine (>100 mg/ml) increased the temperature of 
dehydration and precipitation. The ‘freely soluble’ drug ranitidine (>100 mg/ml) did 
not influence the viscosity of the HPC solution. Aqueous solutions containing HPC 
do not exhibit a gelation temperature as aqueous solutions containing 
hypromellose do. 
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8 HPC Film Preparation and Characterisation  
8.1 Introduction 
Following the observations made in Chapters 5, 6 and 7 application of these findings 
to develop a paediatric dosage form using HPC are considered in this Chapter. This 
Chapter considered the development of an aqueous based HPC film designed to 
dissolve/melt within the mouth following administration. The dosage form design 
considered dose flexibility, dose accuracy and potential swallowing difficulties 
experienced by this age group. Manufacturability of the dosage form was also 
considered.  
Findings in previous Chapters indicated that that the viscosity of a HPC aqueous 
solution reduced at 35°C to 38 °C; approximately body temperature. This unique 
characteristic was used as the basis to develop the dosage form.  
Based on the data obtained for active HPC solutions in Chapter 7, 5 % Klucel Pharm 
EXF polymer solutions were used. Films were prepared without drug and with 
various concentrations of paracetamol and ranitidine. The effect of drying 
conditions during film manufacture and the inclusion of drug substance on the film 
characteristics were also investigated. 
This Chapter describes the manufacture and characterisation of HPC based films 
manufactured using an aqueous system. 
8.1 Materials and Methods  
Klucel® HPC EXF Pharm was used for this investigation. Details associated with this 
polymer may be found in Chapter 1 and Chapter 2. An aqueous polymer 
concentration of 5 %w/w was used. A low concentration of the lowest viscosity 
polymer was considered for this investigation to avoid potential limitations and 
challenges that may be associated with the high viscosity of solutions prepared 
using higher molecular weight polymer grades (see Sections 4.3.1 and 4.3.2). Data 
obtained may be transferable to other grades of HPC. 
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Paracetamol and ranitidine were used as model drugs. Details of paracetamol and 
ranitidine may be found in Chapter 1 and 2. In this Chapter, a range of drug 
substance concentrations were considered (Table 8.1).  
Table 8.1  Polymer and drug solution concentrations used to produce films 
Polymer 
Grade 
Polymer 
Concentration 
(mg/g) 
Drug 
Drug Concentration 
(mg/g) 
Drug:Polymer 
Ratio 
EXF 50 
None None Polymer only 
Paracetamol 
5 1:10 
15 3:10 (1:3.3333) 
Ranitidine 
2.5 1:20 
5 1:10 
15 3:10 (1:3.3333) 
50 1:1 
100 1:2 
 
8.2.1 Manufacture of HPC Films 
HPC films were prepared from aqueous HPC solution. HPC solutions listed in Table 
8.1 were prepared as described in Section 3.2.2.  
One mL of each solution per film was transferred using a calibrated positive 
displacement pipette (Gilson Microman, US) to a PTFE coated ampoule cap used as 
a casting plate (Fig. 8.1 (Part Number FB67567 Fisherbrand, FisherScientific, UK)).
 
Figure 8.1  PTFE coated ampoule cap used as a casting plate 
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The HPC solution was slowly transferred from the pipette to the casting plate 
avoiding entrapment of air. A number of casting plates were prepared for each 
solution and dried in a Gallenkamp vacuum oven. After drying to a constant weight, 
the films were removed from the casting plate using a scalpel to remove the films 
from the aluminium outer wall and then peeling the film from the saran-faced 
surface. The films were then characterised using a variety of techniques. 
8.2.1.1 Development of drying process 
The required drying time and temperature were determined by drying to a constant 
weight at 40 °C, 60°C and 80°C in the Gallenkamp vacuum oven using a vacuum of 
400 mbar. Having determined the required drying time at each oven temperature at 
a vacuum of 400mbar, the same drying time for each drying temperature was used 
to prepare subsequent films; thus avoiding the need to weigh each subsequent film 
to ensure drying was complete. A 5 % EXF HPC solution containing 15 mg/g 
paracetamol was used to determine the required drying time.  
The tare weights of 9 numbered casting plates were determined and each filled 
with 1mL of 5 % EXF HPC solution containing 15 mg/g paracetamol. The weight of 
the casting plates plus the 1mL solution was determined and recorded. Thrsee of 
the plates were dried at 40 °C, 3 at 60°C and 3 at 80 °C. In all cases the vacuum 
applied was set at 400 mBar. The weights of the samples were recorded at 30 min 
intervals. The films were dried until a constant weight was achieved. These 
respective drying times, 6 hrs at 40 °C, 3 hrs at 60°C and 2 hrs at 80°C were used 
thrsoughout this investigation and films produced at these conditions were 
characterised and compared. 
In addition the impact of vacuum applied during drying was also assessed. Vacuums 
of 400 mBar and 600 mBar were used to dry films and the impact on the physical 
appearance of the films produced was determined. 
8.2.2  Characterisation of films  
Three films of the placebo solution and three films of each concentration of 
paracetamol and ranitidine solutions were cast. Films were cast by drying the 
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solutions at various drying temperatures and times. When dried, the films were 
carefully removed from the casting plates using a scalpel. 
After their preparation, the films were characterised using a variety of techniques. 
The influence of the three pre-determined drying conditions, drug substance 
solubility and drug substance concentration on film characteristics was determined. 
The film manufacturing process and in-vivo application of the films produced was 
assessed following characterisation. 
8.2.2.1 Film weight 
Films cast were weighed using an analytical balance (Mettler AT400, UK). The 
weight of each film and the associated mean weights of each of the three films 
were determined.  
8.2.2.2 Film thickness 
The individual thicknesses of films cast were measured using a calibrated 
micrometer (Mitutoyo, Japan). The thickness of each film and the associated mean 
thicknesses of each of the three films were determined. 
8.2.2.3 Disintegration of films 
Disintegration testing of films cast was performed according to the methods of 
Chen (2006) using a 50mL beaker and purified water. Twenty five mL of purified 
water was placed into the beaker and the beaker placed into a water bath heated at 
37 °C. Once the contents of the 50 mL reach 37°C a film is placed into the beaker 
and the contents of the beaker swirled every ten seconds. The disintegration time 
was determined when the film began to break or disintegrate. The time taken for 
the film to fully dissolve was also recorded.  
8.2.2.4 SEM analysis of films 
SEM images of placebo and films containing paracetamol and ranitidine were 
obtained as detailed in Section 2.3.1. SEM images of dried films were obtained using 
a Hitachi S-4700 at 50k magnification. 
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8.2.2.5 Dissolution and Assay of Films 
Different types of dissolution methodology were introduced in Section 2.2.4.  
The process of dissolution is described by the Noyes-Whitney equation (Eq 8.1): 
 cck
t
w
s 


  (Equation 8.1) 
Noyes-Whitney describes dissolution as the rate of increase of material in solution 
dissolving from a solid 






t
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
 (where w is bulk concentration and t is time) being 
equal to the product of rate constant of dissolution (k) and the difference in 
concentration between the saturation solubility of the dissolving material and the 
concentration of that material in the bulk media (cs-c). The rate constant of 
dissolution (k) per unit time is determined as (Eq 8.2): 

DA
k 
   (Equation 8.2) 
Where D is the diffusion coefficient of the dissolved solute, A is the area of the 
solvate particles exposed to the solvent and δ is the thickness of the diffusion layer. 
The dissolution rate of films cast from 5 % HPC EXF solutions containing 
paracetamol at 5 mg/g 10 mg/g and 15 mg/g concentration were determined using 
USP II paddle apparatus (ref.USP<711>) on a Distek 2100C Dissolution Bath. Nine 
hundred mL of purified water was used as a media and a paddle speed of 50rpm 
used. Films were placed in the dissolution vessel whilst still within the casting 
plates. The casting plate was dropped into the heated media prior to starting the 
paddles. Care was taken to ensure that the casting plates were orientated with the 
film uppermost and in the centre of the vessel prior to starting the paddles. The 
casting plates acted as sinkers to prevent the films from floating.  
Water was selected to investigate dissolution performance of the films cast. 
Samples were obtained using an automated software program (IDISis v3.01.00B2, 
UK) and a pump (Icalis Data Systems PCP490, UK), at 5 10 15, 30, 45 and 60 minute 
intervals. The samples were filtered in-line using a 10μm cartridge filter 
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(Pharmatest, Germany) and the concentration of paracetamol dissolved in the 
samples obtained was determined using UV absorbance.  
UV spectrometry and absorbance is described in Section 2.2.2 of this investigation. 
A UV absorbance of 243 nm was used to measure the quantity of paracetamol 
released at each time point. Summaries of the dissolution method and UV method 
are provided in Tables 8.2 and 8.3.  
For UV spectroscopy a specific absorbance (A1 %1cm) value of 712 is recommended in 
the British Pharmacopeia for assay of paracetamol tablets in 0.1M NaOH. As water 
was used as the dissolution media, the suitability of this A1 %1cm was checked by 
measuring the UV absorbance of 15 mg of Paracetamol in 100mL NaOH and 15 mg 
of Paracetamol in 100mL of purified water. Using an A1 %1cm of 712, an assay value 
of 100.1 % was obtained for the NaOH Paracetamol Solution and an assay value of 
93.6 % was obtained for the aqueous paracetamol solution. Based on this data an 
A1 %1cm of 712 was considered appropriate for the online analysis associated with 
the dissolution testing of the films and solid state paracetamol. 
Table 8.2  Summary of dissolution method parameters 
Dissolution Parameters Value 
Apparatus USP <711> Apparatus 2 (paddles) 
Dissolution Media Purified Water 
Dissolution Medium Volume 900ml (± 9ml) 
Dissolution Temperature 37.0°C (± 0.5 °C) 
Rotation Speed 50rpm (± 2rpm) 
Sampling Time 0, 5 10 15, 30, 45 and 60 mins 
Filter 10μm, polypropylene 
Pump Speed 75rpm 
 
Table 8.3  Summary of on-line UV analysis 
UV Analysis Parameters Value 
Wavelength 243 nm 
Cell Pathlength 2mm 
A1 %1cm 712 
 
Film dissolution data were compared to the dissolution of solid state paracetamol. 
15 mg of paracetamol powder was dispensed into 3 weighing boats. Using the 
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dissolution parameters shown in Table 8.2 and UV analysis parameters shown in 
Table 8.3, the contents of the weighing boats were transferred to three dissolution 
vessels whilst the paddles were rotating. Dissolution data were obtained as 
previously described for the films. 
The same UV analysis was used to assay paracetamol content of films cast. Five 
films of each drying condition weighed using an analytical balance and each 
individual weight recorded. The films were then placed into 250mL volumetric flasks 
and dissolved using sodium hydroxide according to British Pharmacopeia (BP 2013). 
The solutions were measured using UV absorbance at 257 nm using 715 as the A1:1 
value as provided in BP2013. The quantity of paracetamol present in each film was 
determined as mg of paracetamol per mg of film.  
8.2.2.6 DSC analysis of films 
As described in Section 2.3.5 DSC was used in this investigation to determine if 
there was a glass transition temperature associated with the HPC films or other 
thermal events. Placebo films and films containing paracetamol and ranitidine were 
tested. Testing was performed using a DSC Instrument (DSC Q2000 V24.4 Build 116, 
Country). Samples of each film were prepared by weighing 1 mg (+/- 0.5 mg) of film 
using a scalpel to cut the film. The test film weight for each sample was recorded. 
Each sample was scanned at a heating rate of 10 °C/min up to 250 °C. 
8.2.2.7 TGA analysis of films 
As described in Section 2.3.6, to supplement the DSC testing, TGA was also used. 
Placebo films and films containing paracetamol and ranitidine were also tested. 
Testing was performed using a TGA instrument (TGA Q500 V6.7 Build 203, US). 
Samples of each film were prepared by weighing 1 mg (+/- 0.5 mg) of film using a 
scalpel to cut the film. The test film weight for each sample was recorded. Each 
sample was scanned at a heating rate of 10 °C/min up to 250 °C. 
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8.3 Results and Discussion 
8.3.1 Manufacture of Films 
A 5 % EXF HPC solution containing 15 mg/g paracetamol was used to determine the 
most appropriate film drying conditions. 1mL of 15 mg/g solution was dried to 
constant weight at 40 °C, 60°C and 80°C using a vacuum of 400mBar. Figure 8.2 
shows the weight loss over time during drying. 
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Figure 8.2  Effect of drying time on 15 mg/g paracetamol film samples dried at 
  40°C, 60°C and 80°C. 
These data demonstrate that when drying the films at oven temperatures of 40 °C, 
60°C or 80 °C, a constant weight was achieved after 6, 4 or 2 hrs respectively. The 
constant weight to which the films were dried was approximately consistent with 
the polymer content and paracetamol content mass present in each film. For 
example, a 1g 5 %w/w HPC film containing 15 mg/g of paracetamol contained 50 
mg of HPC EXF Polymer and15 mg of Paracetamol, corresponding to 65 mg of dry 
material. The remaining quantity of purified water per 1g film (935 mg) was 
removed during drying. Drying endpoint was confirmed when films were dried to a 
consistent film weight and may also be verified by comparing this dry weight to the 
theoretical dry film weight calculated based on polymer and drug mass per film.  
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Therefore, these data demonstrate that the drying process employed i.e. either 2 
hrs at 80 °C, 4 hrs at 60°C or 6 hrs at 40°C were effective at removing all purified 
water from the sample enabling a film to be formed. 
During this drying investigation the vacuum applied was also considered and 
400mBar was found to be the most appropriate. In the absence of vacuum a 
significant quantity of condensation formed within the oven and this is likely to 
impact the drying of the films due to the potential for secondary ‘wetting’ of the 
films. A high vacuum of 600mBar resulted in the presence of significant air bubbles 
within the film surface and consequently poor quality films were produced. A 
vacuum of 400mBar was determined as the greatest vacuum possible to decrease 
the drying time without compromising film quality. 
From a commercialisation perspective the fastest drying time achievable without 
compromising film quality would be utilised.  
The effect of drying time and temperatures implemented here and shown in Table 
8.4, on film characteristics will be investigated in this Chapter.  
Table 8.4  Drying conditions employed for HPC film manufacture. 
Drying Temperature  °C Drying Time (Hrs) Vacuum (mBar) 
40 6 400 
60 3 400 
80 2 400 
 
The HPC solutions shown in Table 8.1 were produced and dried according to the 
conditions shown in Table 8.4. Table 8.5 below summarises the potential to form 
films for each polymer solution. 
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Table 8.5  Physical appearance films produced from solutions prepared in  
  Table 8.1  
Polymer 
Grade 
Polymer 
Concentration 
(mg/g) 
Drug 
Drug 
Concentration 
(mg/g) 
Drug:Polymer 
Ratio 
Appearance of 
films produced 
EXF 50 
None None Polymer only 
Intact, clear 
film with no 
cracks 
Paracetamol 
5 1:10 
Intact, clear 
film with no 
cracks 
15 
3:10 
(1:3.3333) 
Intact, clear 
film with no 
cracks 
Ranitidine 
2.5 1:20 
Intact, clear, 
slightly yellow 
film with no 
cracks 
5 1:10 
Intact, opaque, 
pale yellow 
film with no 
cracks 
15 
3:10 
(1:3.3333) 
Intact, opaque, 
pale yellow 
film with no 
cracks 
50 1:1 
White to 
slightly brown 
film with a 
number of 
severe cracks 
around the 
edges. A poor 
brittle film. 
100 1:2 
A brown film 
with a number 
of severe 
cracks around 
the edges. A 
poor brittle 
film. 
Note 
Shaded area indicates solutions for which films could not be successfully prepared. 
 
Table 8.5 shows that HPC solutions containing ranitidine at higher concentrations 
formed very poor films. The films produced from solutions containing 50 mg/g and 
100 mg/g ranitidine were severely cracked and brown in colour. The films had a 
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large hole in the centre and severe cracks around the edges that resembled 
channels. Films produced from solutions containing a lower concentration of 
ranitidine (2.5 mg/g, 5 mg/g and 15 mg/g) were much better but were opaque with 
a slightly uneven distribution of colour and opaqueness. The films were intact 
without any signs of cracking. It was possible to form HPC films from solutions 
containing ranitidine at concentrations up to 15 mg/g. It was not possible to form 
HPC films from solutions containing ranitidine at concentrations of 50 mg/g or 
greater. 
Films prepared from HPC solutions not containing drug substance and solutions 
containing paracetamol at concentrations up to 15 mg/g were clear and fully intact 
with no signs of cracking or fracture. Good quality films may be produced from HPC 
solutions containing no drug substance and those containing paracetamol up 15 
mg/g. These films were fully characterised using a range of characterisation 
techniques.  
Based on the aqueous solubility of ranitidine it was possible to prepare solutions at 
concentrations up to 100 mg. Paracetamol however, has a much lower aqueous 
solubility and therefore the maximum solution concentration that could be 
prepared using paracetamol was 15 mg/g. The visual observations made (Table 8.5) 
suggest that the maximum drug:polymer ratio that enabled good intact films to be 
produced is 3:10, meaning a minimum polymer level of 3 times that of the level of 
drug was required to form good quality films.  
Drug:polymer ratio is critical to determining the visual quality of films produced. 
This requirement is likely to limit the drug loading permissible for this HPC polymer 
film system as high polymer content is likely to have a detrimental impact on other 
film characteristics such as disintegration time and dissolution rate.  
8.3.2 Film Characterisation 
8.3.2.1 Film weight and film thickness 
Upon removing the dried films from the casting plates the films were weighed and 
the film thickness determined for placebo films and those containing 5 mg/g and 15 
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mg/g paracetamol. The impact of drying conditions on film weight and film 
thickness was determined. The data obtained is shown in Table 8.6. 
The weights obtained show that some material was lost to the walls of the casting 
plates for all films and for all drying conditions. Placebo films dried for 2 hrs at 80°C 
had a slightly lower weight and were slightly thinner than all other films prepared.  
 
Table 8.6  The impact of drying conditions on film weight and film thickness  
 
8.3.2.2 Disintegration of films 
Figure 8.3 shows disintegration and complete dissolution times (by visual 
observation) for polymer films prepared without drug substance and polymer films 
containing 5 mg/g and 15 mg/g paracetamol.  
Formulation Drying Conditions Film Weight (mg) Film Thickness (μm)
28.35 60
20.62 57
24.18 61
26.30 60
28.50 59
27.50 61
17.00 38
22.50 38
20.00 37
24.40 64
22.40 57
17.40 67
22.60 68
31.20 63
19.00 63
23.90 51
33.03 70
25.40 51
31.83 62
27.37 79
29.80 65
38.40 86
36.30 88
37.70 84
28.94 80
31.81 69
36.60 81
5% EF HPC Placebo 
Solution 
2 hours @ 80°C
5% EF HPC Solution 
containing 5mg/g 
Paracetamol
6 hours @ 40°C
5% EF HPC Solution 
containing 15mg/g 
Paracetamol
2 hours @ 80°C
3 hours @ 60°C
6 hours @ 40°C
3 hours @ 60°C
6 hours @ 40°C
3 hours @ 60°C
2 hours @ 80°C
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Figure 8.3  Film disintegration time and time to dissolve for HPC films without 
  drug substance and HPC films containing 5 mg/g and 15 mg/g  
  paracetamol 
The disintegration data for HPC films containing paracetamol exhibited slightly 
slower times than films containing no drug substance (‘placebo’). However, placebo 
films dried for an extended period at a lower temperature (6 hrs at 40 °C) 
disintegrated more slowly compared with similar films dried for a shorter period at 
a higher temperature. The disintegration time for placebo films dried for 6 hrs at 
40°C is similar to the disintegration times for films containing paracetamol. The 
drying conditions did not affect the disintegration times for films containing 
paracetamol. An increase in paracetamol concentration increased the disintegration 
times of the films produced. 
Times to completely dissolve showed that all films completely dissolved in 5 to 12 
minutes (300 to 720 s). Films containing 5 mg/g paracetamol took longer to dissolve 
than placebo films; and films containing 15 mg/g paracetamol took longer to 
dissolve than films containing 5 mg/g paracetamol. Thus an increase in drug content 
increased the time taken for the film to fully dissolve.  
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Drying conditions appeared to influence the time taken for the entire film to 
dissolve. For placebo films, those dried for 6 hrs at 40°C took the longest to dissolve 
whereas for films containing 5 mg/g and 15 mg/g paracetamol, films dried for 3 hrs 
at 60°C dissolved the quickest.  
The method used to determine disintegration was previously used by Chen (2006) 
to compare various marketed films and films prepared using different polymers but 
was very subjective. Disintegration time is determined by the time taken for the film 
to initially break or disintegrate. The sample is manually agitated during testing by 
moving the beaker every 10 seconds. The degree of agitation is therefore not 
controlled and may contribute to differences observed in disintegration times 
between films. A pharmacopeial test for film disintegration does not currently exist. 
Standard pharmacopeial tablet disintegration apparatus was considered (BP2013) 
but the films adhered to the walls of the chambers during reciprocation. An 
improved disintegration method is required to provide more qualitative assessment 
of film disintegration.  
Placebo films dried for 6 hrs at 40°C exhibited a longer disintegration time than 
placebo films dried for 2 hrs at 80°C or 3 hrs at 60 °C. Data shown in Figure 6.2 in 
Section 6.3.3 shows the impact of temperature on HPC solution viscosity. The data 
indicate that above the cloud point temperature (60°C and 80°C) the viscosity of the 
polymer solution is likely to be very low due to significant dehydration and 
disentanglement of the HPC molecules during drying. Due to the dehydration and 
disentanglement of the HPC molecules the polymer film may also be more brittle 
and prone to faster disintegration upon rehydration. This is also likely to result in 
more brittle films being formed. Conversely, at (or just below) the cloud point (40 
°C) the HPC solution exists in an anisotropic phase and the HPC will only be partly 
dehydrated. Upon introduction to an aqueous media complete rehydration will be 
slower due to partial hydration and entanglement. Disintegration times associated 
with films dried at 40°C may therefore be longer than for films dried at 60°C or 80 
°C.  
Data presented in Chapter 7 indicate that the inclusion of paracetamol in the HPC 
polymer solution reduced the cloud point temperature of the solution and 
increased the viscosity of the solution. The difference in drying temperature 
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therefore had much less of an impact on polymer film disintegration due to each 
drying temperature used being above the cloud point for HPC solutions containing 
paracetamol (33 °C) as it does for placebo films. However, due to the presence of 
paracetamol in the solution, the HPC molecules may be unable to disentangle as 
readily during drying and consequently are possibly not able to dehydrate to the 
same extent as HPC molecules in placebo films. Films prepared from HPC solutions 
containing 5 mg/g and 15 mg/g paracetamol disintegrate and dissolve similarly to 
placebo films dried for 6 hrs at 40°C due to similarities in the extent of dehydration 
and disentanglement in these films during drying. 
8.3.2.3 SEM analysis of Films 
 
Figure 8.4 SEM images of placebo and 15 mg/g paracetamol film surface 
SEM images in Figure 8.4 show a smoother film surface for the film prepared from 
HPC solution containing 15 mg/g paracetamol than the film prepared from the 
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placebo sample. This may be due to the influence of paracetamol reducing the 
viscosity of the film solution and enabling a smoother surface to form during drying. 
 
8.3.2.4 Dissolution of paracetamol from HPC films 
Dissolution testing of films containing 5 mg/g and 15 mg/g of paracetamol and dried 
at 40 °C, 60°C and 80°C was performed according to the method described in 
8.2.2.5. Dissolution results are shown in Figures 8.6 and 8.7.  
The dissolution profiles obtained for films prepared from HPC solutions containing 5 
mg/g and 15 mg/g paracetamol demonstrate that drug release is slower from the 
films than for drug substance alone. This indicates that the HPC polymer film 
imparts a delay in the dissolution of the drug substance. The dissolution of the drug 
substance is likely to be determined by the dissolution of the film i.e. the dissolution 
of the polymer film is rate limiting. The drug substance is dissolved in the film and 
therefore as the polymer films dissolves the drug substance will remain dissolved in 
the dissolution media. The dissolution of the drug substance in the dissolution 
media is therefore likely to be independent of the solubility of the drug substance 
as long as it is solubilised within the polymer film. In other words, once dissolved in 
the HPC aqueous polymer solution the dissolution of the drug substance should be 
independent of the concentration or absolute solubility in the dissolution media. 
However, if the absolute solubility of the drug substance is poor in the dissolution 
media, precipitation of the drug substance may eventually occur.  
This is supported by the dissolution profiles obtained for paracetamol drug 
substance. The time taken to reach 90 % drug release (T90) for 5 mg of paracetamol 
was 5 mins. The T90 for 15 mg of paracetamol was 10 mins. The T90 for films 
prepared from HPC solutions containing 5 mg/g and 15 mg/g was the same, 30 
mins. The paracetamol drug substance samples follow the Noyes Whitney equation 
(refer to 5.2.2.1), whereby the particle size, concentration and solubility of the drug 
substance drive the dissolution rate of the drug substance. As the particle  
 
124 
 
Figure 8.5  Mean (n=3) paracetamol release from 5 mg/g films dried at various 
  conditions and compared to 5 mg paracetamol (Powder) in purified 
  water  
 
Figure 8.6  Mean (n=3) paracetamol release from 15 mg/g films dried at  
  various conditions and compared to 15 mg paracetamol (powder) in 
  purified water  
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size and solubility is constant the dissolution will be affected by the concentration 
of the sample i.e. 5 mg v 15 mg. 15 mg of paracetamol will take slightly longer than 
5 mg of paracetamol to reach 90 % release due to the difference in concentration 
gradient between the two films. In the film samples the paracetamol dissolution is 
rate limited by the dissolution of the film itself. 
Based on these dissolution profiles, the use of HPC polymer films offers significant 
advantages for oral drug delivery. Drug dissolution from the films is independent of 
drug substance solubility and concentration if the drug substance is dissolved in the 
polymer film. The dissolution of the drug in the film is similar to that may occur 
from an oral solution. This dosage form could therefore help enable linear 
pharmacokinetics of the drug substance across a range of doses. This has particular 
advantages for paediatric medicines as this dosage form not only offers dose 
flexibility based on the size of the dosage unit, but also the potential to predict 
pharmacokinetics and pharmacodynamics performance when dose titrating by 
weight or body mass.  
Such dissolution performance may also enable HPC films to be used to deliver a 
combination of drugs with similar dissolution profiles. This would not typically be 
achievable using other solid oral dosage formulations such as tablets as the 
dissolution performance of the drug substances would be dependent on the 
physicochemical properties of the individual active substances which are likely to be 
different.  
Furthermore, the slight delay in drug release imparted by the polymer film may also 
provide taste masking particularly for highly soluble drug substances with a low 
concentration taste threshold. For the drug substance to reach the taste 
concentration threshold sufficient polymer film has to have dissolved and the drug 
substance concentration threshold be maintained in the mouth cavity (Wise 2013). 
If the rate of drug release is slower than the rate at which the drug is cleared from 
the mouth cavity the taste concentration threshold will not be reached.  
In addition the drug released from the polymer film is presented to the oral cavity in 
the solubilised state and therefore there is the potential for drug absorption from 
the oral cavity. 
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Buccal absorption avoids first pass metabolism and therefore HPC polymer films 
may be particularly useful for the oral delivery of drugs requiring avoidance of first 
pass metabolism.  
Drug substance dissolution rate is therefore controlled by the dissolution rate of the 
polymer film in the dissolution media. Therefore, dissolution rate may be influenced 
by polymer concentration, film thickness and polymer solubility in the dissolution 
medium. 
The dissolution data shown here also indicate that paracetamol release from films 
prepared from HPC solution containing 5 mg/g and 15 mg/g paracetamol is 
independent of the drying conditions used to cast the films. It may therefore be 
possible to dry the polymer films at a high drying temperature for a short period of 
time without influencing the dissolution rate of the HPC films produced. Further 
work may consider the potential application of microwave drying to decrease the 
drying time. This may offer advantages for scale up and commercialisation. The use 
of a solvent instead of water would also decrease the drying time but may offer 
more complications for commercialisation and is not as environmentally friendly as 
an aqueous based system. 
Compared to other films prepared using polymers such as hypromellose (Chen 
2006, and Garsuch and Breitkrutz 2010) HPC aqueous films have similar 
disintegration times. Complete dissolution times recorded here are significantly 
slower than observed for films produced using other polymer solvent systems but 
this investigation demonstrates that this has no impact on drug substance 
dissolution and may positively impact patient adherence. This slow dissolution may 
help provide taste masking of poorly tasting drug substances. These films are ideally 
suited for paediatric patients as once administered polymer film hydration occurs 
rapidly preventing the dosage from being ‘ejected’ by the patient.  
Palatability of the films could be further assessed by performing taste studies in 
human subjects. If required it may be possible to reduce the time to complete 
dissolution by reducing the level of polymer used in the film or by adding a 
surfactant to increase the rate of hydration and subsequent dissolution of the HPC 
polymer upon administration. 
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8.3.2.5 Film assay testing 
Films prepared at 5 mg/g and 15 mg paracetamol were assayed as detailed in 
8.2.2.5.  
Table 8.7  Theoretical composition of 5 mg/g and 15 mg/g paracetamol HPC 
  films. 
Theoretical Quantity per g of Film 
Solution (mg) 
5 mg/g 
Paracetamol 
15 mg/g 
Paracetamol 
HPC (5 %w/w) 50 50 
Paracetamol 5 15 
Total Weight 55 65 
mg of Paracetamol / mg of film 0.0909 0.2308 
 
The assay data obtained is shown in Table 8.8 
Table 8.8  Assay data obtained for films prepared using HPC solutions  
  containing 5 mg/g and 15 mg/g paracetamol 
Formulation 
Drying 
Conditions 
n =5 
Weight 
(mg) 
Assay 
(mg) 
Paracetamol 
Concentration 
(mg) / Film 
(mg) 
 % 
Nominal 
Conc 
15 mg/g 
Paracetamol 
6 hrs @ 40 °C 
Mean 29.556 6.945 0.234 101.395 
±SD 1.859 0.526 0.005 2.196 
%RSD 6.289 7.572 2.166 2.166 
15 mg/g 
Paracetamol 
3 hrs @ 60 °C 
Mean 29.940 7.120 0.234 101.574 
±SD 1.560 0.262 0.007 2.866 
%RSD 5.211 3.683 2.821 2.821 
15 mg/g 
Paracetamol 
2hrs @ 80 °C 
Mean 31.912 7.435 0.230 99.657 
±SD 2.989 0.684 0.017 7.582 
%RSD 9.367 9.195 7.608 7.608 
5 mg/g 
Paracetamol 
6 hrs @ 40 °C 
Mean 26.520 2.571 0.099 108.506 
±SD 0.971 0.094 0.001 1.281 
%RSD 3.660 3.670 1.181 1.181 
5 mg/g 
Paracetamol 
3 hrs @ 60 °C 
Mean 26.400 2.538 0.096 105.883 
±SD 1.317 0.077 0.003 3.191 
%RSD 4.989 3.040 3.014 3.014 
5 mg/g 
Paracetamol 
2 hrs @ 80 °C 
Mean 26.640 2.426 0.097 106.489 
±SD 3.543 0.320 0.001 1.329 
%RSD 13.300 13.195 1.248 1.248 
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These data are presented as mg of paracetamol per mg of film and as % nominal. % 
nominal is calculated based on the actual weight of the film removed from the film 
forming plate. The % nominal mg of paracetamol per mg of film is shown in Table 
8.6. 
Assay values obtained and ±SD (Table 8.7) would meet typical values for other solid 
oral dosage forms (EP 2013). Films dried for 2 hours at 80°C show the greatest 
variation in film weight and assay however, the drying conditions used do not 
appear to influence the data obtained for % nominal concentration. The mean % 
nominal assay data obtained film for the films prepared from HPC solution 
containing 5 mg/g films are slightly higher than those for the films prepared from 
the HPC solutions containing 15 mg/g paracetamol but this may be due to some 
evaporation occurring during the HPC polymer solution manufacture.  
The drying conditions used do not appear to influence the assay data obtained 
enabling a high drying temperature to be used to reduce the drying time for 
commercial manufacture. 
8.3.2.6 Thermal analysis of films 
DSC and TGA analysis were performed for placebo HPC films and HPC films 
containing 5 mg/g and 15 mg/g paracetamol to determine if a glass transition 
temperature was apparent or if any changes in the physical properties could be 
observed.  
The TGA plot in Fig. 8.7 for the placebo film shows a residual moisture content of 
2.402 %. This may be associated with the drying process employed as part of the 
casting or the equilibrium moisture content of the film after drying. The film may 
have reached equilibrium moisture content upon storage after manufacture. 
This DSC heating programme used in Fig. 8.7 was performed to remove the 
moisture from sample (step 1 and 2) and to determine if a glass transition 
temperature Tg was present behind the main moisture peak. No Tg was observed 
for the placebo film using DSC.  
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Figure 8.7  TGA plot for HPC film containing no drug substance 
 
Figure 8.8  DSC plot for HPC film containing no drug substance 
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Figure 8.9  TGA plot for HPC film containing 5 mg/g paracetamol 
 
Figure 8.10  DSC plot for HPC film containing 5 mg/g paracetamol 
1
2 3
4
 
5
 
6
 
131 
The TGA plot in Fig. 8.9 for the HPC film containing 5mg/g paracetamol shows a 
residual moisture content of 2.342 %. This may be associated with the drying 
process employed as part of the casting or the equilibrium moisture content of the 
film after drying. The film may have reached equilibrium moisture content upon 
storage after manufacture. 
Similar to Figure 8.8, the heating programme used in Fig. 8.10 was performed to 
remove the moisture from sample but first additionally explored temperatures 
below ambient to see if a Tg existed at lower temperature ranges (step 1 and 2). No 
Tg was observed for the 5 mg/g HPC film using DSC.  
The TGA plot in Fig 8.11 for a HPC film containing 15mg/g paracetamol shows a 
residual moisture content of 2.876 %. This may be associated with the drying 
process employed as part of the casting or the equilibrium moisture content of the 
film after drying. The film may have reached equilibrium moisture content upon 
storage after manufacture. 
Similar to Figure 8.9, the heating programme in Fig. 8.12 was performed to remove 
the moisture from sample and explore temperatures below ambient to see if a Tg 
existed at lower temperature ranges (step 3 and 4). No Tg was observed for the 15 
mg/g HPC film using DSC.  
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Figure 8.11  TGA plot for HPC film containing 15 mg/g paracetamol 
 
Figure 8.12  DSC plot for HPC film containing 15 mg/g paracetamol 
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These data indicate that no change in the baseline is present indicating an event 
such as the melting of paracetamol or gross degradation of the HPC film. The 
melting point of paracetamol is 169°C to 172°C so if present in the crystalline state 
it is likely that an endotherm would have been observed. These data therefore 
indicate that no crystalline paracetamol was present in the films and that the 
placebo and active HPC films were physically stable. These data also indicated that 
residual moisture of the films was between 2.342 % and 2.876 %. It was not possible 
to determine if this moisture remained following the drying process or if the films 
had reached equilibrium after drying and being stored at ambient conditions. 
These data show that a glass transition temperature does not exist for the HPC 
films.  
8.4  Conclusion 
HPC films are able to retard dissolution rate of paracetamol. Retardation of 
dissolution rate is considered to be associated with the formation of liquid crystals 
as the film undergoes phase transformation prior to fully hydrating and solubilising 
in the dissolution media. HPC films may therefore have application for 
administering drug substance to paediatric or geriatric patients by overcoming 
swallowing difficulties; potentially providing taste masking and aiding oral cavity 
absorption. The drying conditions used to prepare the HPC films has no impact on 
the film characteristics. The presence of drug substance has a slight impacts on 
disintegration time. 
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9 General Discussion 
9.1 Rationale and Aim 
The availability of medicines designed specifically for and clinically evaluated in 
paediatric patients is significantly poor. Developing medicines for paediatric 
patients is challenging and is complicated by a number of factors due to the 
heterogeneous patient population. The paediatric population is made up of 5 sub-
groups defined by ICH guidelines (EMA 2001). As described in Chapter 1, when 
considering the dosage form design for a product intended for use in paediatric 
patients it is important to consider aspects such as the physiological maturity of the 
child including key organs and metabolic pathways, the relative size differences 
between the sub populations, within populations and between geographic 
locations, the relative capabilities of each sub group, the ability for children to 
swallow products designed for oral delivery, adherence issues associated with taste 
and palatability. The correlation of safety data between adults and children must be 
carefully considered together with the potential need for juvenile toxicological 
testing of new chemical entities and excipients prior to administration to children 
(Salunke et al 2013). Consequently, regulatory guidance was recently enforced to 
encourage industry to consider this medically neglected population (FDA 2002 and 
EMA 2006). 
Identifying a suitable oral dosage form that meets the needs of paediatric patients 
is difficult as most of the commonly used adult formulations, e.g., tablets and 
capsules pose issues for dosing to children. The aim of this research was to develop 
an oral dosage form that addresses these challenges whilst ensuring efficacy, safety 
and patient access (Sam et al 2012). 
Based on their diverse application in oral dosage forms and safe toxicological 
profile, hypromellose and hydroxypropycellulose (HPC) were considered as suitable 
polymers for this investigation. To minimise the quantity of functional polymer 
required in the dosage form by potentially enhancing the performance of the 
functional polymer, co-processing by spray-drying hypromellose was evaluated in 
Chapters 4 and 5. The use of HPC to form films containing paracetamol and 
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ranitidine was evaluated in Chapter 8 having explored the impact of temperature on 
aqueous solutions of HPC in Chapters 6 and 7. As described in Chapter 2, 
paracetamol and ranitidine were considered as ‘model’ drugs as they have different 
aqueous solubilities and are both listed by the EMA as drug substances for which 
greater research in paediatrics is required (EMEA 2005 and EMEA 2007).  
 
9.2 Co-processing by Spray-Drying 
Whilst spray-drying has been used extensively in the preparation of pharmaceutical 
products, spray-drying of hypromellose has not been significantly researched. In 
Chapter 4 spray-drying of hypromellose was evaluated.  
Hypromellose was successfully spray-dried and though the process significantly 
changed the physical structure of the material, there was no change in the function 
of the polymer as determined by viscosity measurements. The spherical shape and 
reduced particle size of spray-dried hypromellose may offer processing advantages 
over non spray-dried hypromellose, for instance in modified release matrix tablets 
whereby spray-dried hypromellose may exhibit better flow characteristics and also 
improve gel layer formation based on its reduced size and spherical shape. 
Though hypromellose was successfully spray-dried, the investigation also 
highlighted difficulties associated with spray-drying hypromellose which are mainly 
due to the high viscosity of its aqueous solutions. An increase in polymer content 
and molecular weight results in an increase in viscosity of the aqueous spray-drying 
solution. Only low molecular weight polymers at a maximum concentration of 5 
%w/w could be spray-dried. Such low solids content results in significantly long 
processing times which are likely to render this process commercially unviable. 
Modification to the polymer viscosity is required to enable higher polymer 
concentrations to be processed.  
Attempts were made to reduce the viscosity of polymer solutions by heating at 40°C 
and 60 °C. As temperature increased, solution viscosity began to decrease before 
eventually the gelation temperature was reached. Careful temperature control of 
the polymer solution during spray-drying may even enable higher polymer 
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concentrations or higher molecular weight polymers to be spray-dried by reducing 
the viscosity of the polymer solution. However, although temperature may be used 
to reduce solution viscosity, significant engineering controls such as temperature-
controlled transfer pipework from the stock solution to spray nozzle would be 
required to ensure that the solution temperature is carefully controlled up to the 
point of atomisation. 
Having successfully spray-dried hypromellose, co-processing hypromellose with 
paracetamol using spray-drying was investigated in Chapter 5. The intention was to 
determine the properties and functionality of spray-dried hypromellose and 
paracetamol. Chapter 5 investigated the effect of adding 15 % w/w paracetamol to 
5 %w/w E5LV hypromellose solution. The addition of paracetamol to hypromellose 
solution resulted in significant flocculation at 40°C and 60 °C, and also to an increase 
in polymer solution viscosity at ambient temperature. Such an increase in polymer 
solution viscosity at ambient temperature following the addition of 15 % w/w 
paracetamol will reduce the achievable flow rate for spray-drying. It was not 
possible to spray dry aqueous hypromellose solutions containing 15 % w/w 
paracetamol due to the increase in viscosity at ambient temperature. Flocculation, 
caused by heating the hypromellose solutions containing 15 % w/w paracetamol, 
prevented spray-drying of these solutions.  
Though aqueous hypromellose solutions may be spray-dried with the potential to 
use heat to reduce solution viscosity, hypromellose solutions containing 
paracetamol have a higher viscosity than solutions without paracetamol and require 
formulation optimisation if heating is to be used in the same way.  
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9.3 Investigating the Influence of Temperature on Aqueous 
Solutions of HPC 
Having determined the effect of temperature on aqueous hypromellose solutions 
and aqueous hypromellose solutions containing paracetamol, the effect of 
temperature on aqueous solutions of HPC was determined in Chapter 6.  
An increase in HPC polymer content and molecular weight results in an increase in 
viscosity of the aqueous polymer solutions (Chapter 6) similar to hypromellose 
(Chapters 4 and 5). Only low molecular weight grade (≤370,000 Daltons) of HPC at 
low concentrations (≤10 %w/w) could be considered for spray-drying. However, 
unlike hypromellose, HPC solutions did not exhibit a gelation temperature and 
increased heating to 60°C resulted in a continued decrease in polymer viscosity. 
When heated to temperatures ≥40°C HPC solutions also became cloudy. The impact 
of temperature on aqueous HPC solutions was further investigated. 
HPC solutions changed from clear to cloudy at a reduced temperature when the 
polymer concentration was increased. Polymer molecular weight appeared to have 
no impact on the onset temperature of this physical change. These observations 
supported the theory that the physical change was associated with polymer 
precipitation and the formation of liquid crystals that may be caused by polymer 
dehydration.  
Viscosity testing of aqueous HPC solutions demonstrated that three phases of 
change were apparent when plotting viscosity versus temperature, illustrated by a 
sigmoid shape curve. The change in viscosity appears to occur in 3 phases; i) initially 
a linear reduction in viscosity ii) at 40°C the rate of change in viscosity is more 
significant and at phase iii) at 50°C the rate of change reaches a minimum and 
minimum viscosity is reached. Higher concentrations of aqueous HPC solutions 
exhibited the greatest decrease in viscosity with increase in temperature.  
Data in Chapter 6 suggest that the change in per cent UV transmission is linked with 
a change in viscosity of aqueous HPC solutions. At the cloud-point , the viscosity of 
the HPC solution is significantly decreased. These changes are likely to be associated 
with the formation of liquid crystals as described by Werbowj and Gray (1980) and 
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Wang (1997). These changes may be described using the phase diagram proposed 
by Werbowyj (1980) and Guido (1995) and these data enable the phase diagram to 
be extended to include solutions of a lower HPC concentration (≤10 %w/w).  
The impact of paracetamol and ranitidine on the properties of aqueous solutions of 
HPC was also investigated in Chapter 7. HPC solutions containing drug substance 
exhibit similar shape curves to solutions containing no drug substance. HPC 
solutions containing ranitidine reach ‘phase ii’ of the curve at a slightly higher 
temperature than solutions containing no drug substance, whilst solutions 
containing paracetamol reach ‘phase ii’ of the curve at a slightly lower temperature, 
which correlates well with the data obtained using UV transmission. Increased 
concentrations of the poorly soluble paracetamol further reduced the onset 
temperature whilst solutions containing the relatively higher soluble ranitidine had 
a slightly higher onset temperature than solutions containing HPC alone.  
The physical changes, observed in Chapters 6 and 7, upon heating aqueous 
solutions of HPC may be caused by the HPC molecules dehydrating following 
heating and hydrogen bonds between the HPC molecules and water molecule 
breaking resulting in the formation of liquid crystals. The formation of liquid crystals 
causes the aqueous HPC solutions to go cloudy and the viscosity of the solutions to 
decrease. These data also indicate that the presence of drug influences the cloud-
point temperature of aqueous HPC solutions. Paracetamol reduced the cloud-point 
temperature and ranitidine increased the cloud-point temperature of aqueous HPC 
solutions. These changes may be caused by the salting in effect of the hydrochloride 
salt of the ranitidine molecule or the poor solubility of the paracetamol. Further 
investigation is required to understand the impact of drug properties on the cloud-
point of aqueous HPC solutions.  
Aqueous solutions of HPC form liquid crystals at increased temperature so 
temperature could not be used to reduce the viscosity of aqueous HPC solutions to 
enable spray-drying. Spray-drying of aqueous solutions of HPC was therefore not 
considered.  
Data obtained in Chapters 6 and 7 indicated that changes in viscosity of aqueous 
HPC solutions occurred at temperatures in the range of 35°C to 40°C which is close 
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to human body temperature (37 °C). Therefore the applications of these findings for 
a paediatric dosage form platform were examined. A HPC-based film was 
developed. Polymer films intended for oral administration may provide many 
benefits to the paediatric patient including ease of swallowing due to disintegration 
of the dosage form in the mouth cavity and dose flexibility based on unit film size. 
 
9.4 HPC Film Preparation and Characterisation  
As described in Chapter 8, films could be formed by drying aqueous solutions of 5 
%w/w EXF HPC. The drying temperature used to form the films had no impact on 
the film characteristics measured. Films could be prepared to a consistent weight 
and thickness and disintegrated in water in <30 sec and fully dissolved in 350 
seconds to 540 sec. Following the successful preparation of films from HPC solution, 
the inclusion of paracetamol and ranitidine in the HPC films was investigated.  
Successful film formation with paracetamol and ranitidine was dependent upon the 
drug:polymer ratio within the solution. Films prepared containing 50 mg/g and 100 
mg/g ranitidine were discoloured and contained cracks after drying. Films could be 
prepared from aqueous solutions containing paracetamol and ranitidine at 
concentrations ≤ 15 mg/g. A minimum polymer content of 3 times that of the drug 
substance was required to cast a fully integral film without damage observed 
around the edges of the film during drying. Films could be prepared to a consistent 
weight and thickness. 
The presence of paracetamol in the film increased the disintegration time of the 
film in water slightly to <45 secs. Dissolution testing of paracetamol contained in a 
film showed a slower dissolution rate than that of paracetamol powder. This 
difference in dissolution of paracetamol from HPC films may be explained by the 
formation of liquid crystals with an increase in temperature, slowing the dissolution 
of paracetamol prior to the film fully hydrating and solubilising in the dissolution 
media. These dissolution data suggested that the films produced may provide some 
taste masking potential if the dissolution of paracetamol can be sufficiently delayed 
by the time taken for the film to fully dissolve in the oral cavity. 
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Uniformity of film weight and paracetamol assay data suggest that maximum dose 
flexibility could be provided by enabling the patient or caregiver to cut the required 
size of film as drug content can be expressed by weight of film or by surface area of 
film. Thermal analysis of the HPC films using DSC and TGA illustrated that the dried 
films had a residual moisture content of <3 % and that they do not exhibit a glass 
transition temperature. 
The assessment of films produced from aqueous solutions of HPC containing 
paracetamol indicates that the dosage form may be a suitable for pharmaceutical 
application in paediatric patients.  
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10 General Conclusions and Recommendations 
for Further Work 
10.1 General Conclusions 
This investigation demonstrated that spray-drying of hypromellose is feasible. 
However, the viscosity of its solutions generally restricts the aqueous concentration 
of hypromellose and the hypromellose grade that may be spray-dried. An aqueous 
solution of 5 %w/w hypromellose E5LV was spray-dried but its viscosity significantly 
restricted the maximum achievable flow rate during spray-drying. Increasing the 
temperature may be used to reduce the viscosity of hypromellose solutions but 
requires careful control to avoid reaching the gelation temperature of the solutions 
whereby viscosity significantly increases. 
Spray-dried hypromellose particles are much more spherical and uniform in size 
than non-spray-dried particles, and may offer improved flow and uniform gel 
formation due to their increased surface area. Polymer solutions prepared from 
spray-dried hypromellose have similar viscosity to those prepared from non-spray-
dried hypromellose indicating that the functionality of the spray-dried material is 
unchanged.  
The inclusion of 15 %w/w paracetamol in aqueous solutions of 5 %w/w E5LV 
hypromellose increased solution viscosity. Temperature could not be used to 
decrease the viscosity of this solution as flocculation of the suspension occurred. 
Co-processing hypromellose and paracetamol by spray-drying could not be achieved 
in this work.  
Investigating the impact of temperature on aqueous HPC solutions showed that 
heating causes a reduction in solubility of HPC in water which results in its 
precipitation and the formation of liquid crystals. As a consequence of this 
precipitation, the aqueous HPC solutions appear ‘cloudy’ and their viscosity 
decreases. The temperature at which these changes occur is referred to as the 
‘cloud-point’. Based on the viscosity of aqueous solutions of HPC and the impact of 
temperature of these solutions, spray-drying of HPC was not investigated.  
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The effect of temperature on aqueous HPC solutions containing ranitidine and 
paracetamol was determined. Paracetamol decreased the temperatures of 
dehydration and onset of precipitation and ranitidine increased the temperatures of 
dehydration and precipitation. This is probably associated with a salting in effect. 
The effect of temperature on aqueous HPC solutions containing drug is dependent 
on the properties of the drug.  
HPC was used to form films which are able to retard dissolution rate of 
paracetamol. Integral films may be formed which meet the pharmacopoeial content 
uniformity criteria typically applied to oral dosage forms. HPC films may therefore 
have application for administering drugs to paediatric or geriatric patients by 
disintegrating in the mouth and so overcoming swallowing difficulties; potentially 
providing taste masking and aiding absorption across the oral cavity.  
HPC films offer significant benefits to the paediatric population. The manufacturing 
process is simple and transportation is easy as secondary packs are likely to be less 
bulky than currently used for tablets. The films may also be suitable for 
administering combinations of drugs in the same dosage form by layering or by 
combining the drugs at the HPC solution stage. For these reasons the HPC films may 
have particular application for diseases in the developing world and meet many 
requirements associated with WHO and other global regulatory guidelines. 
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10.2 Recommendations for further work 
 Advantages of spray-dried hypromellose over non spray-dried hypromellose 
could be further assessed. Spray-dried material is more spherical, uniform 
and with a higher surface area than non spray-dried hypromellose and 
therefore it should hydrate more rapidly and form a stronger gel barrier 
more quickly.  
 To understand the effect of drug properties on the formation of liquid 
crystals in aqueous HPC solution, drugs with different functional groups 
could also be assessed. Additionally different salts of the same drug could be 
considered to determine the impacts of the counter ion.  
 Alternative manufacturing processes, such as microwave drying, could be 
considered for film formation to determine if film drying time may be 
reduced to support scale-up and commercialisation of the film formation. 
 The development of an appropriate standardized disintegration test for films 
is required. 
 A taste study in humans would determine if the delay observed in 
dissolution rate was sufficient to improve the taste of poorly tasting drug 
substances with a low taste concentration threshold. This test would also 
enable the palatability of HPC films to be determined.  
 The impact of polymer loading on film formation, drug dissolution and 
palatability should also be determined so that the films are optimized for 
drug loading and in-vivo performance. 
 To determine the potential for films to be used in drug combination therapy, 
the feasibility of preparing films containing more than one drug could be 
assessed.  
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